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In the last two decades, much progress has been made to understand skeletal 
biology. A growing number of transcription factors, co-factors, chromatin modifiers 
and signalling molecules have been discovered to contribute to the precise control of 
gene regulation that determines osteo-chondrogenic lineage specification and bone 
formation. Not only have these factors been identified, increasing number of genes 
are being placed in genetic pathways that control skeletogenesis. Since these 
diverse molecules work together in a highly interconnected network to tightly regulate 
gene expression, skeletal disorders such as cleidocranial dysplasias can be more 
effectively addressed if the molecular mechanisms behind bone development can be 
mapped onto graphic gene regulatory diagrams. 
 
Researchers in the field have identified several master regulators in the lineage 
restriction of multipotent mesenchymal cells into chondrocytes and osteoblasts and 
of these are Sox9 and Runx2. Sox9 is the key factor driving chondrogenesis while 
Runx2 is the master regulator of osteoblast differentiation. Runx3 is another factor 
found to possibly play redundant roles with Runx2 in chondrocyte maturation. My 
study focuses on elucidating the gene regulatory network governing skeletogenesis 
that is centred on Runx2 and Runx3. 
 
Currently, there are many known regulators and target genes of Runx2. However, the 
regulatory information is limited and it is believed that there are many more 
undiscovered factors controlled by Runx2. The expression profiling of Runx3 in the 
context of skeletal formation has also not been undertaken. By coupling mouse 
transgenic techniques with high throughput genomic studies such as gene 





(ChIP-Seq) for both Runx2 and Runx3, gene expression profiles for Runx2 and 
Runx3 using an enriched pool of Runx2- and/or Runx3-expressing cells isolated from 
fluorescing mouse embryos were generated. Additionally, Runx2-specific binding 
sites were mapped using HA3-tagged mouse embryos and anti-HA antibody to 
identify Runx2 direct targets to complement the expression profiling data.  This study 
is the first to reveal the vast number of factors controlled by both Runx2 and Runx3 
cooperatively, antagonistically and uniquely which were partly validated by published 
data and by RNA section in-situ hybridization. As a result, a preliminary gene 
regulatory network centering Runx2 and Runx3 is established.  
 
Finally, this work serves as a proof of principle that the strategy employed is feasible 
and can be built upon as a common platform to fabricate gene regulatory networks 
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CHAPTER 1 – INTRODUCTION 
 
In any one cell of an organism, the traffic of events occurring is tightly regulated to 
ensure its proper development and survival. Though every cell contains identical 
genetic material, the genes are differentially expressed in each cell or group of cells 
at specific time-points in development. The dynamics of gene expression that occur 
within a group of cells as they change fate can be controlled at various levels – 
transcription, translation and stability of mRNA and/or protein. It involves multiple 
genes, transcription factors, miRNAs and even long non-coding RNAs. A complex 
organism’s final form is thus the result of temporal and spatial control of gene 
expression through the interaction of various factors within complex regulatory 
networks.  
 
In order to capture these dynamic events onto a visual network, many have tried to 
decipher the ‘regulatory code’ encoded within the genetic code, elucidating regulatory 
networks that govern cell fate specifications from pluripotency to tissue-specific 
states. In our case, we are trying to map the regulatory relationships that dictate how 
pluripotent mesenchymal stem cells differentiate into chondrocytes and osteoblasts 
during skeletal development onto a graphic gene regulatory network diagram. This 
enables visualization of the regulatory dynamics during cell fate commitments to gain 
a better understanding of skeletal development. Through that, any alterations in the 
network leading to skeletal diseases may be identified and developed as targets for 
bone regenerative therapy and tissue engineering.  
 
1.1 Gene Regulatory Networks  
The concept of using gene regulatory networks (GRNs) to represent regulatory 





than 40 years ago (Britten and Davidson, 1969; Kauffman, 1969). It has since taken 
on a systems-level approach to depict complex interactions between key regulatory 
genes, typically transcription factors (TFs), and the genes they regulate, known as 
target genes, across biological systems and species. So far, the most extensive 
developmental GRN built is of the endomesoderm development in the sea urchin 
(Davidson et al., 2002). Ongoing efforts are made with increasing accuracy to 
assemble comprehensive GRNs of other systems and species such as vulva 
development in the Caenorhabditis elegans (Inoue et al., 2005; Ririe et al., 2008), 
endomesoderm development in the Xenopus (Koide et al., 2005; Loose and Patient, 
2004), and a variety of developmental systems in the Drosophila (Furlong, 2004; 
Silver et al., 2005; Stathopoulos and Levine, 2005). 
 
Gene regulatory networks are usually depicted as diagrams containing nodes, which 
represent genes, and directional edges connecting the regulator to the target genes. 
The edges represent the functional links between the two connected genes and an 
edge that ends with an arrowhead means the target gene is activated by the TF and 
likewise one which ends with a short perpendicular line represents inhibitory action 
by the TF on the target gene.  
 
There are two main components in a GRN. The first is a causal link between the 
functional state or abundance of the TF and the target gene’s expression. The 
second is the relevant site on the genome which the TF binds to control the spatio-
temporal expression of the target gene. This non-coding DNA sequences bound by 
the TF is often known as the “cis-regulatory module” (CRM) of the target gene 
(Levine and Davidson, 2005). The former is often elucidated by genetic perturbations 
of the TF of interest in an organism coupled with global expression profiling while the 
latter is unravelled by either genome-wide chromatin immunoprecipitation studies or 





shift assay (EMSA) verification experiments. As embryonic development is a dynamic 
process which presents a real challenge to constructing developmental GRNs, one 
also needs to consider a third aspect in the GRN – the spatio-temporal expression of 
the TF of interest (Wilczynski and Furlong, 2010) – in order to build a more accurate 
and comprehensive GRN that represents developmental events in a particular organ. 
 
1.2 The Skeleton and Its Development 
1.2.1 Function of the Skeleton 
The skeleton is a pivotal organ in all vertebrates. Primarily, it serves as a scaffold to 
support the body and protect vital visceral organs as well as to allow sophisticated 
movements. However, this complex and multifunctional organ has roles that are not 
only limited to structural ones. It is also a home to haematopoiesis, a reserve of 
essential minerals (mainly calcium and phosphorus) for homeostatic functions and a 
detoxification site where toxins such as heavy metals are adsorbed (Lefebvre and 
Bhattaram, 2010). Furthermore, it has a more influential role as an endocrine organ, 
regulating phosphate metabolism via the release of fibroblast growth factor 23 
(Fgf23) which acts on kidneys to reduce phosphate re-absorption and more recently 
found to contribute to blood sugar regulation and fat deposition through the secretion 
of a hormone called osteocalcin (Jensen et al., 2010; Lee and Karsenty, 2008). 
 
1.2.2 Cellular Structure of the Skeleton 
The strong and hard yet lightweight skeletal frame comprises two types of tissue – 
the cartilage and the bone – and is composed of three types of cells: chondrocytes in 
the cartilage and osteoblasts and osteoclasts in the bone. While chondrocytes and 
osteoblasts are derived from mesenchymal stem cells, osteoclasts have their origins 
traced back to the monocyte-macrophage cell lineage and have bone resorption 





cartilaginous matrix that is rich in proteoglycans, mainly aggrecans, and type II 
collagen whereas the bone matrix is abundant in type I collagen (a major constituent 
of osteoid), osteocalcin (also known as bone gamma-carboxyglutamic acid-
containing protein, BGLAP) and bone sialoprotein. These bone matrix proteins aid 
the precipitation of the bone mineral hydroxyapatite which is the main component 
that confers hardness to the bone (Lefebvre and Bhattaram, 2010). 
 
1.2.3 Formation of the Skeleton 
Skeletogenesis can be described as two major phases. The first begins with 
migrations of multipotent ectoderm-derived (the neural crest) and mesoderm-derived 
mesenchymal cells to the sites where future bones form. The former give rise to 
craniofacial skeletal structures and the latter are divided into two parts. The lateral 
plate mesoderm gives rise to some craniofacial skeletal elements, the appendicular 
skeleton (limbs) and part of the axial skeleton (sternum) while the paraxial mesoderm 
gives rise to the remaining axial skeleton (vertebrae and ribs) via somitogenesis and 
sclerotome formation. Upon resting at these pre-skeletal sites, the mesenchymal 
cells condense to form skeletal templates of osteochondroprogenitor cells in the 
shape of the eventual skeletal elements. This process of migration and condensation 
is governed by numerous factors expressed in a spatial- and temporal-specific 
manner and is commonly known as skeletal patterning. Thereafter, the next phase, 
bone formation, commences (Karsenty et al., 2009; Lefebvre and Bhattaram, 2010).  
 
1.2.3.1 Endochondral Ossification 
During embryonic development, bone formation occurs by two distinct processes – 
endochondral ossification and intramembranous ossification. The former occurs in 
majority of the bones in the body especially the long bones of the axial and 





mesenchymal cells in the centre first differentiate into early proliferating chondrocytes 
which produce copious amounts of type II collagen (Garofalo et al., 1993) and 
aggrecans – the foundational proteins of the extracellular matrix (ECM), to form a 
cartilage anlage. A thin layer of periphery cells, however, do not differentiate into 
chondrocytes. Instead, they remain as type I collagen-producing mesenchymal cells, 
flatten and aggregate to form a structure called the perichondrium that envelops the 
skeletal template. Upon the right cues, the chondrocytes at the core of the cartilage 
anlage stop proliferating and elongate to transiently form prehypertrophic 
chondrocytes before maturing fully into hypertrophic chondrocytes. The transient 
prehypertrophic chondrocytes continue to produce type II collagen as well as secrete 
a signalling molecule, Indian hedgehog (Ihh), which induces the adjacent 
perichondrial cells to differentiate into osteoblasts forming the periosteum (St-
Jacques et al., 1999). The hypertrophic chondrocytes, on the other hand, exclusively 
synthesize type X collagen which provides an extracellular environment that is 
conducive for mineralization of the ECM. The hypertrophic chondrocytes further 
advance into terminal hypertrophic chondrocytes. The second step of endochondral 
ossification initiates with the apoptosis of the terminal hypertrophic chondrocytes and 
the vascular endothelial growth factor (VEGF)-induced capillary invasion of the 
mineralized cartilage template, concomitantly transporting osteoblast progenitor cells 
from the periosteum to replace the dying chondrocytes (Gerber et al., 1999; Zelzer et 
al., 2004). These osteoblasts along with osteoclasts secrete matrix 
metalloproteinases (Mmp9, 13, 14) to degrade the cartilage matrix (Stickens et al., 
2004; Vu et al., 1998). Simultaneously, the osteoblasts secrete bone sialoprotein and 
type I collagen which contributes to the bone matrix in addition to the type X 
collagen-rich mineralized ECM previously laid down by the hypertrophic 
chondrocytes. This forms the bone shaft in the middle that is flanked by organized 
layers of chondrocytes at different maturation stages known as growth plates. 





promote bone lengthening and subsequent chondrocyte apoptosis, vascularization 
and calcification events at the proximal ends complete the endochondral ossification 
with the progressive replacement of the cartilage by bone (Karsenty and Wagner, 
2002; Kronenberg, 2003; Lefebvre and Bhattaram, 2010). 
 
1.2.3.2 Intramembranous Ossification 
A minority of the skeletal tissue, such as the flat bones of the skull and parts of the 
mandible and clavicle, are formed via the more straightforward process termed 
intramembranous ossification. In the course of intramembranous ossification, the 
condensed mesenchymal cells skip the cartilage intermediary and differentiate 
directly into osteoblasts progenitors. As these osteoprogenitors mature into 
osteoblasts, they secrete osteoid, a non-mineralized matrix made up of ninety 
percent type I collagen, osteocalcin and chondroitin sulphate to build up the initial 
bone scaffold. The osteoblasts subsequently express alkaline phosphatase (Alp) and 
bone sialoprotein (Bsp) to facilitate the mineralization of the osteoid matrix. 
Eventually, the osteoblasts get embedded in the calcified bone and differentiate into 

















Figure 1. Bone Formation 
(a) Intramembranous ossification occurs in the flat bones of the skull and the clavicle. 
Condensed mesenchymal cells differentiate directly into osteoblast progenitors and mature 
into osteoid-producing osteoblasts. (b) Endochondral ossification takes place in long bones. 
Condensed mesenchyme first differentiates into an intermediate cartilaginous template and 
matures into terminal hypertrophic chondrocytes before osteoblasts from the perichondrium 











1.3 Transcriptional Control of Skeletal Formation 
Mesenchymal stem cells (MSCs) are the common precursors to a variety of tissue 
cell types: adipocytes (adipose), myocytes (muscle), chondrocytes (cartilage) and 
osteocytes (bone). Several significant transcription factors have been identified as 
critical regulators that govern each lineage commitment of the multipotent MSCs. For 
example, (1) Pparγ2 promotes adipogenesis; (2) MyoD expression is vital for 
myogenesis; (3) Sox9 is the key factor directing MSC down the chondrogenic path, 
and (4) Runx2 is the master regulator of bone formation. These factors were 
discovered from human diseases and mouse knockout studies and the severe 
relevant phenotype resulting from their absence earned them their key title in the 
respective tissue development pathways. As the thesis is focused on skeletal 
development, I will only expand the discussion on the last two points in the following 
segments. 
 
Bone and cartilage tissue are different in their composition, structure and molecular 
regulation but their developments are highly interconnected and tightly coordinated. 
The discoveries of genetic mutations in several human skeletal diseases have 
sparked mouse genetic manipulation and recent genome wide expression studies 
that propagated our understanding of the transcriptional events that control 
skeletogenesis over the last two decades. 
 
1.3.1 Chondrogenesis 
One of the factors being manifested early in skeletal precursors and being critical for 
initiation of chondrogenesis is Sox9. It is a transcription factor containing a high 
mobility group (HMG)-box DNA-binding domain which bears homology to that of the 
mammalian sex-determining region Y factor, Sry. Sox9 was first discovered when its 





dysplasia, and was later shown to regulate expression of cartilage proteins such as 
type II collagen and aggrecan (Bell et al., 1997; Wagner et al., 1994). Formation of 
the sclerotome, the initial pre-skeletal element, requires the paired-box members, 
Pax1 and Pax9 and the homeobox family members Nkx3.1 and Nkx3.2 (aka Bapx1) 
(Herbrand et al., 2002; Peters et al., 1999) in addition to Sox9 for prechondrogenic 
condensation of the mesenchymal cells and the subsequent chondrogenesis of the 
vertebrae. Both pairs of transcription factors Pax1 and Pax9, and Nkx3.1 and Nkx3.2 
(Bapx1) play synergistic and redundant roles respectively in axial skeleton 
development (Herbrand et al., 2002; Peters et al., 1999). Pax1 and Pax9 activate 
Bapx1 during Sox9-mediated chondrogenesis of the sclerotome (Rodrigo et al., 
2003). Furthermore, the transactivating function of Sox9 is enhanced when bound by 
two other Sox family members that do not have the transactivation domains, Sox5 
and Sox6. All three Sox proteins form the well-known Sox trio complex essential for 
proper differentiation of early proliferating chondrocyte but the exact mechanism of 
the Sox trio complex in chondrocyte differentiation is still not well understood 
(Akiyama et al., 2002; Lefebvre et al., 1998). Hypoxia inducible factor-1 (Hif1α) is 
another factor that supports chondrocyte survival through the up-regulation of Vegf to 
promote vascularisation of the developing bone (Schipani et al., 2001). 
 
The core factors driving chondrocyte maturation into prehypertrophic and 
hypertrophic chondrocytes are runt-domain TFs Runx2 and Runx3 evident from the 
complete blockage of chondrocyte hypertrophy in the Runx2-/-Runx3-/- mouse 
(Yoshida et al., 2004). Additional co-factors such as Grg5 and Hdac4 physically 
interact with Runx2 to enhance and inhibit its activity respectively during chondrocyte 
hypertrophy (Vega et al., 2004; Wang et al., 2004). Dlx5 and Dlx6 are reported to 
work synergistically with Runx2 to positively regulate chondrocyte hypertrophy (Chin 





as AP1 family member, Fra2 are required for chondrocyte maturation (Arnold et al., 
2007; Karreth et al., 2004). 
 
The mechanisms of terminal maturation are not well studied and so far only the basic 
leucine zipper protein cMaf is implicated in this process. cMaf is expressed in late 
hypertrophic chondrocytes and mice deficient in this gene have impaired terminal 
maturation of hypertrophic chondrocytes (MacLean et al., 2003). 
 
1.3.2 Osteoblastogenesis 
Runx2 is the crucial factor for the initial commitment of perichondrial cells and 
condensed mesenchymal anlagen of the intramembranous bones to osteoblast 
lineage cells (Komori et al., 1997; Otto et al., 1997). In endochondral ossification, the 
link between chondrocyte maturation and osteoblast differentiation hinges on Ihh 
signalling. While Runx2 regulates Ihh in the prehypertrophic chondrocytes, Ihh 
induces Runx2 expression in the adjacent perichondrium (Karsenty, 2001). Runx2 
expression, however, is not sufficient for osteoblast differentiation reflected by the 
ectopic maturation of chondrocytes without any defects in osteoblast differentiation in 
transgenic mice constitutively expressing Runx2 (Takeda et al., 2001). Further 
commitment of the Runx2-expressing osteoblast progenitor cells to fully committed 
osteoblasts in both endochondral and intramembranous bones requires a Krüppel-
like zinc finger domain-containing transcription factor Sp7 (aka Osterix) (Nakashima 
et al., 2002). The activity of Osterix is enhanced through interaction with nuclear 
factor of activated T cells (Nfatc1) transcription factor (Koga et al., 2005). 
 
Osteoblast maturation involves activating transcription factor 4 (ATF4), Sp-family of 
Krüppel-like zinc finger protein Sp3 and Fos-related antigen Fra1 (Eferl et al., 2004; 





osteoblast and mice deficient in Atf4 have delayed bone formation while Atf4 activity 
in early osteoblasts is inhibited by co-dimerizing with a nuclear leucine zipper protein, 
Fiat (Yang et al., 2004; Yu et al., 2009). The transactivation ability of Atf4 is 
increased through phosphorylation by Rsk2 kinase and through association with 
Satb2 (Dobreva et al., 2006; Yang et al., 2004). The exact mechanism of Sp3 in 
ossification is not known except that an in vitro study demonstrated that it binds to 
the promoter of receptor activator of nuclear factor kappa B ligand, RANKL, and 
regulates its basal promoter activity in osteoblasts (Liu et al., 2005b). RANKL is 
required for osteoclastogenesis hence Sp3 might be involved in osteoclast activity. 
Lastly, Fra1 up-regulates bone matrix proteins such as osteocalcin, col1a2 and 
matrix Gla protein (Mgp). Ectopic expression of Fra1 leads to increased bone mass 
in the transgenic mice while Fra1Δ/Δ mice lacking functional Fra1 developed 
osteopenia (Eferl et al., 2004). 
 
The skeleton is the core organ in the vertebrate body and tremendous progress has 
been made in the past few decades to increase our knowledge in its development. 
Many crucial factors influencing chondrogenesis or osteoblastogenesis that have 
been linked to human skeletal diseases have been discovered and these diverse 
factors often work together in a highly organized and cooperative network to 
propagate bone formation. Some light has also been shed on the molecular 
mechanisms behind the cell type specification and maintenance. However, the 
spatio-temporal expression and activity of many more factors and the complex 
regulatory mechanisms among the factors cooperating to bring about the complex 
but finely tuned events during bone formation is still a huge piece of information 
missing. Evidently, there is still a lot more to uncover in order to unravel the 







1.4 The Runx Family of Proteins 
 
 
Figure 2. The Structure of Runx Proteins 
Figure from (Blyth et al., 2005). Runx proteins share a highly conserved runt domain and are 
transcribed from two distinct promoters P1 and P2. RHD, runt homology domain; NMTS, 
nuclear-matrix-targeting signal; QA, Glutamine-alanine repeat domain of Runx2. 
 
 
The Runx family of genes encodes for transcription factors that contain the 
characteristic DNA-binding runt domain which derived its name from the Drosophila 
pair-rule gene, runt, owing to the high degree of homology between the two 
sequences (Gergen and Butler, 1988). This highly conserved 128-amino-acid runt 
motif found proximal to the N-terminus has functions in (1) DNA binding, recognizing 
a canonical DNA motif TGPyGGTPy (where Py refers to pyrimidine) (Crute et al., 
1996), (2) protein-protein interactions (Kagoshima et al., 1993) and (3) nuclear import 
that is in addition to the conserved nuclear matrix-targeting signal (NMTS) in the C-
terminus (Kanno et al., 1998). On the other hand, the proline, serine and threonine 
(PST)-rich C-terminal portion of Runx proteins is responsible for transcriptional 
activation and repression, and regulation of DNA-binding affinity of the runt domain 
(Gu et al., 2000; Kim et al., 1999). The final five conserved amino acids VWRPY 





transcriptional co-repressors. The Runx proteins, consisting of only the α-subunit, 
position at DNA binding sites as heterodimers with a non DNA-binding -subunit 
protein, Cbf. This cofactor association at the runt domain enhances the DNA-
binding ability of the Runx proteins (Cohen, 2001; Liu et al., 2006). Another defining 
feature of the Runx gene is the presence of two alternative promoters which give rise 
to multiple protein isoforms with either of the two distinct N-terminal start sequences: 
(1) MASNS from the distal P1 promoter generating what is known as type II isoform 
proteins and (2) MRIPV from the proximal P2 promoter yielding type I isoform 
proteins (Bangsow et al., 2001; Levanon et al., 2001; Park et al., 2001). Alternative 
splicing further augments the diversity of Runx gene products.   
 
The stability and activity of Runx proteins are modulated at the post-translational 
level via phosphorylation and acetylation with the former modification conferring 
activating functions to the protein. The Runx proteins can also engage co-activators 
or co-repressors at enhancer or promoter regions of target genes to initiate or inhibit 
a cascade of transcriptional events during development. Therefore, Runx proteins 
serve as transcriptional coordinators in a complex regulatory network directly and 
indirectly governing the expression of a myriad of genes pertaining to a broad 
spectrum of cellular and molecular functions. 
 
There are three members in the mammalian Runx gene family commonly known as 
Runx1, Runx2 and Runx3 [refer to (van Wijnen et al., 2004) for the alternative 
nomenclature]. Despite the extent of semblance in their sequence and structure, 
each of the three Runx genes has a distinct primary biological role in mammalian 
development elucidated from the overt phenotypes manifested in the respective 
knockout mice. Runx1 is essential in definitive haematopoiesis as Runx1null mice die 





Runx2 is crucial for osteoblast differentiation in bone development as Runx2null mice 
die at birth with a non-ossified skeleton (Komori et al., 1997; Otto et al., 1997). Runx3 
has a primary role in neurogenesis apparent from the display of severe limb ataxia in 
Runx3null mice due to impaired development of proprioceptive neurons in the dorsal 
root ganglia (DRG) (Inoue et al., 2002; Levanon et al., 2002). In another independent 
study (Li et al., 2002), the Runx3null mice died of starvation shortly after birth as a 
result of hyperplasia in the gastric mucosa. This led to the implication of Runx3 as a 
tumour suppressor in gastric cancer cells.  Evidently, each of the Runx genes is a 
critical lineage determinant of blood, skeletal, neuronal cells and gut development 
respectively.  
 
Although the individual Runx genes have distinct primary roles, it is no surprise that 
they also have overlapping functions since all the members of the Runx family can 
bind to the same nucleotide sequence. Particularly, there are two highly conserved, 
in sequence and location, Runx binding sites at the 5’ UTR of all three Runx genes 
(Drissi et al., 2000) which hint at the possible cross regulation amongst the Runx 
proteins. Furthermore, their expression domains often coincide at specific tissues (in 
either the same cells or different cells of the same tissue) and developmental stages, 
with some variations in their expression levels. This suggests that they function 
synergistically, redundantly or even complementarily to specify a population of cells 
into a particular type, with one usually taking on as the major player and the other a 
supportive or redundant role. For example, (1) Runx1 and Runx3 are both expressed 
in the developing DRG and mature T-cells but are expressed in different groups of 
sensory neurons in the DRG and at different stages of T-cell development (Kramer et 
al., 2006; Zhong et al., 2006). Moreover, the requirement of Runx1 in the lymphoid 
system always takes precedence over Runx3 (de Bruijn and Speck, 2004). A study 
by (Brady and Farrell, 2009) probing into the mutually exclusive expression of Runx1 





repressed by the latter in proliferating B-cells. This is one prototype of the Runx 
genes working in complementary to define a subpopulation of cells. (2) Runx1, 
Runx2 and Runx3 expressions are found at variable intensity, extent and tempo in 
skeletal tissues (Levanon et al., 2001; Stein et al., 2004). (a) In a particular study 
(Yoshida et al., 2004), Runx2 and Runx3 expressions were noted to coincide in the 
prehypertrophic and hypertrophic chondrocytes. Runx2-/-Runx3-/- mice were also 
observed to have a more severe skeletal phenotype than Runx2-/- or Runx3-/- mice.  
Notably, the Runx2-/-Runx3-/- mice were devoid of large columnar cells typical of 
hypertrophic chondrocytes in the limbs at E18.5. These observations suggest that 
Runx2 and Runx3 play compensatory roles in chondrocyte maturation during 
endochondral ossification. However, Runx2 plays a bigger role in advancing 
chondrocyte maturation than Runx3 as chondrocyte maturation was more impeded in 
Runx2-/- mice than in Runx3-/- mice (Yoshida et al., 2004). (b) Recently, it was 
reported that Runx1 and Runx2 work together acting via Sox5 and Sox6 during 
sternal development as demonstrated by the absence of a sternum in the mouse 
when both Runx1 (conditionally knocked out by Prx1-Cre transgene) and Runx2 
were abrogated (Kimura et al., 2010). This loss was not observed in either the Prx1-
conditional Runx1-/- or Runx2-/- mice.  
 
While early mouse knockout experiments delineated the major roles of the individual 
Runx members (Ducy et al., 1997; Inoue et al., 2002; Komori et al., 1997; Li et al., 
2002; Okuda et al., 1996; Otto et al., 1997), subsequent studies gradually uncovered 
more merging and cooperative functions of the Runx proteins (de Bruijn and Speck, 
2004; Kimura et al., 2010; Stein et al., 2004; Yoshida et al., 2004). However, the 
mechanisms of these overlapping and compensatory roles have not been fully 
elucidated and the scope of functional redundancy among the Runx proteins remains 






Apart from cell lineage determination during foetal development, Runx genes are 
also implicated in human cancer development because RUNX-CBF complexes 
regulate scores of genes pertinent to cell-fate decisions which are compromised in 
cancer cells; decisions to promote apoptosis or proliferation and differentiation or 
self-renewal. Most genes are easily classified as tumour suppressors or oncogenes 
but both conflicting functions have been associated with Runx genes in cancer cells. 
This dual function is not surprising since RUNX–CBFβ complexes can activate as 
well as repress the expression of vital regulators of cell proliferation and 
differentiation. Hence, deregulation of the normally balanced roles of RUNX is 
associated with acute myeloid leukemia (Runx1) (Song et al., 1999), osteosarcoma 
(Martin et al., 2011) and metastatic bone disease of breast and prostate cancer 
(Runx2) (Pratap et al., 2011) and gastric cancer (Runx3) (Li et al., 2002). Therefore, 
a more comprehensive knowledge of the factors and pathways regulated by the 
RUNX-CBF heterodimeric complex in normal conditions is essential to progress 
applications that will benefit cancer diagnosis and treatments.  
 
The Runx genes are largely conserved in sequence and structure between the Homo 
sapiens and the Mus musculus and human diseases caused by RUNX mutations are 
also recapitulated in the mouse when the respective mouse Runx genes are deleted. 
Hence, the elucidation of the GRN governed by each Runx transcription factors 
during mouse development has the potential to contribute to developing applications 
in human gene therapy and drug development for the treatment of human 
developmental diseases and cancer.    
 
In the next two major sub-chapters, I will give a more detailed introduction of Runx2 
and Runx3 as I have decided to focus on only these two Runx members in my 






The mouse Runx2 gene is found on chromosome 17 and the translated Runx2 
protein contains a short exclusive region of glutamine/alanin (QA) repeats at the N-
terminus that is absent in its co-orthologs. This stretch of QA repeats regulates its 
transactivation and heterodimerization activity (Thirunavukkarasu et al., 1998). Like 
the other Runx members, it has two distinct promoters, P1 and P2 (Bangsow et al., 
2001; Miyoshi et al., 1995; Xiao et al., 1998), which give rise to two major transcript 
variants. In addition to the two unique promoters, alternative splicing of the eight 
protein-coding exons generates at least nine protein isoforms, two of which are 
dominant in skeletal tissues: type II isoform starting with MASNS that is derived from 
the osteoblast-specific P1 promoter (Geoffroy et al., 2002; Ogawa et al., 2000; 
Stewart et al., 1997; Xiao et al., 1999; Xiao et al., 2001) and type I isoform beginning 
with MRIPV that is expressed from the chondrocyte-specific P2 promoter (Takeda et 
al., 2001). The two proteins, which differ only in 19 amino acids at the N-terminus, 
otherwise bear the same functional domains, interact with similar co-factors and are 
capable of transactivating similar target genes in vitro (Banerjee et al., 2001; Harada 
et al., 1999; Javed et al., 2001). However, their expression sites are not identical. 
Type I Runx2 expression is more widespread. It is predominantly expressed in the 
perichondrium and periosteum but low levels of expression can be found in a variety 
of tissues including the thymus, proliferating chondrocytes of the cartilage and suture 
tissue of the calvarium. Type II Runx2 is more restricted to the bone tissues and is 
intensely expressed in the hypertrophic chondrocytes and mature osteoblasts but not 
in the perichondrium (Banerjee et al., 1997; Choi et al., 2002; Enomoto et al., 2000; 
Park et al., 2001; Ueta et al., 2001). The distinct spatiotemporal expressions of the 
two protein isoforms can be attributed to the different cis-regulatory elements situated 
at the P1 and P2 promoter regions which allow different factors to discriminately 





functional capabilities of the two isoforms together with their differentially regulated 
expression at various sites may contribute to a more specific yet robust control of 
skeletal development. As I will not be investigating the differential roles of the two 
Runx2 isoforms, I will refer to both isoforms as Runx2.  
 
1.4.1.1 Spatiotemporal Expression of Runx2 in the Developing Skeleton 
Runx2 expression is first detected in the developing mouse embryo at embryonic day 
10.5 (E10.5) at the mesenchyme anterior of the forelimb bud which prefigures the 
shoulder bones (Stricker et al., 2002). At E11.5, Runx2 is strongly expressed in the 
first and second brachial arches, which will eventually give rise to the maxilla and 
mandible, and the condensed mesenchyme of the ulna (Stricker et al., 2002). At 
E12.5, Runx2 expression can be detected in most of the developing skull, axial and 
appendicular skeleton including the condensed mesenchymal cells of the vertebral 
perichondrium, the chondrocytes of the Meckel’s cartilage and the prechondrogenic 
mesenchyme of the limbs (Kaufman et al., 1992). At this stage, the osteochondro-
progenitor cells have the potential to either differentiate into chondrocytes or 
osteoblasts (Ducy et al., 1997). Ossification begins at E13.0 and Runx2 expression 
progresses to the digits of the limbs by E13.5 (Stricker et al., 2002). The first signs of 
osteoblasts can be detected at E14.5 (Kaufman et al., 1992) and Runx2 is expressed 
transiently in prehypertrophic and hypertrophic chondrocytes (Takeda et al., 2001) as 
well as osteoblasts at that stage. Runx2 expression is abundant in the frontal, nasal, 
baso-occipital, baso-sphenoid and hyoid bones and the mandible but is absent in the 
chondrocytes of the Meckel’s cartilage of the E16.0 mouse embryo (Ducy et al., 
1997; Otto et al., 1997). By E16.5, Runx2 expression in the maturing chondrocytes is 
minimal or absent while its expression remains high in the perichondrium and the 







1.4.1.2 Runx2 Phenotype, Function and Associated Skeletal Diseases 
Runx2 was identified as the earliest master driver of osteoblast differentiation in both 
intramembranous and endochondral ossification through genetic analyses of human 
skeletal dysplasias and studies of genetically modified mouse models (Ducy 1997, 
Komori 1997, 2002, Otto 1997).  In those mouse studies, the Runx2+/- mice appeared 
normal but on closer examination revealed a core defect in intramembranous 
ossification characterized by hypoplastic clavicles and delayed fusion of the cranial 
fontanelles. These abnormalities reflected some of the symptoms in the autosomal 
dominant human skeletal disorder, cleidocranial dysplasia (CCD) (Lee et al., 1997; 
Mundlos et al., 1997; Otto et al., 1997). The Runx2-/- mice died from respiratory 
failure shortly after birth owing to the inability to respire from a non-osseous rib cage. 
The mutant mice were clearly smaller with shorter limbs and a foreshortened snout 
and were virtually devoid of a mineralised skeleton. Histological analysis of all the 
bones showed absence of osteoblasts and a lack of bone-associated marrow 
precursors while chondrocytes were still present. This demonstrated that Runx2 is 
essential for osteoblast differentiation and vascularisation of the bone and has no 
positive regulatory functions in chondrocyte differentiation and proliferation. Although 
Runx2 gene deletion has an impact on both intramembranous and endochondral 
ossification, the former appears more sensitive to Runx2 deficiency. 
 
Apart from the osteoblast-deficient phenotype, there was also a lack of hypertrophic 
chondrocytes in some but not all skeletal tissues of the Runx2-/- mice denoted by a 
drastic reduction in type X collagen expression levels (Inada et al., 1999; Kim et al., 
1999). Skeletal elements such as the tibia, fibula, radius and ulna, where 
hypertrophic chondrocytes expressing type X collagen were still detected, however, 
did not express proteins characteristic of terminal hypertrophic chondrocytes such as 
secreted phosphoprotein 1 (Spp1) and bone sialoprotein (Bsp) (Inada et al., 1999; 





chondrocyte-specific type II collagen promoter augmented type X collagen 
expression and boosted chondrocyte maturation in mice whereas the expression of 
dominant-negative Runx2 under the same promoter reduced type X collagen 
expression in chondrocytes and inhibited chondrocyte maturation (Ueta et al., 2001). 
These studies indicate that Runx2 is involved in chondrocyte maturation. 
 
Similar studies in the osteoblast lineage yielded results that were contrary to 
expectations. Transgenic mice over-expressing Runx2 under the control of 
osteoblast-specific type I collagen promoter exhibited low bone mass (osteopenia) 
with multiple fractures owing to restricted mineralization and heightened 
osteoclastogenic activity which resulted in high bone resorption (Geoffroy et al., 
2002; Kanatani et al., 2006; Liu et al., 2001). The osteoblasts in these mice were 
immature and the number of terminally differentiated osteoblasts and osteocytes 
detected were greatly reduced. Conversely, transgenic mice expressing dominant-
negative Runx2 under the same promoter yielded higher bone mass and were able 
to prevent ovariactomy-induced bone loss in the mice (Maruyama et al., 2007).  
 
Taken together, Runx2 has dual functions – osteoblast differentiation and 
chondrocyte maturation. While an adequate level of Runx2 is required for osteoblast 
differentiation and maintenance, excessive Runx2 activity in the osteoblast 
progenitors increases osteoblast-directed osteoclastogenesis disproportionately. 
Therefore, a tight control of Runx2 expression level is of paramount importance to 
proper skeletal formation and maintenance. Notably, Runx2 exerts opposing control 
on chondrocyte maturation, its secondary role. Its early expression (E12.5) in the 
proliferating chondrocytes propagates Ihh-dependent chondrocyte hypertrophy 
(Yoshida et al., 2004). Conversely, its constitutive expression in the perichondrium, 
coupled with its diminishing expression in the chondrocytes, at later stages impedes 





manner, Runx2 prepares the skeletal elements for subsequent endochondral 
ossification events and thus prevents ectopic bone formation and dwarfism. Hence, 
in addition to a balanced level of Runx2 expression, a precise regulation of its spatio-
temporal expression is vital for proper bone formation. Furthermore, the restricted 
effect of Runx2 deletion on chondrocyte maturation is probably attributed to the 
compensatory actions of Runx3 since genetic studies have shown that Runx3 is also 
important for chondrocyte hypertrophy and mice lacking both Runx2 and Runx3 have 
no hypertrophic chondrocytes or type X collagen expression (Yoshida et al., 2004). 
 
1.4.1.3 Upstream, Downstream and Co-regulators of Runx2 
At the molecular level, Runx2 expression is regulated by a number of different 
molecules at different stages of skeletogenesis. At the onset of Runx2 expression, 
Twist proteins repress Runx2 at the post-transcriptional level to prevent premature 
osteoblast differentiation which accounted for the early expression of Runx2 
preceding the appearance of osteoblasts by 4 days (Bialek et al., 2004). Hdac3 and 
Hdac7 associate physically with Runx2 and act as co-repressors to negatively 
regulate osteoblastogenesis (Jensen et al., 2008; Westendorf, 2006). Stat1 inhibits 
the nuclear translocation of Runx2 while Shn3 mediates the degradation of Runx2 
thereby inhibiting the activity of Runx2 in osteoblast differentiation (Jones et al., 
2006; Kim et al., 2003). At the transcriptional level, Sox8 strongly reduces the 
expression of Runx2 again to avert precocious osteoblast differentiation (Schmidt et 
al., 2005) while Bapx1, upon up-regulation by Sox9, directly represses Runx2 in cells 
that are destined for chondrocytic lineage (Lengner et al., 2005; Yamashita et al., 
2009). On the contrary, Bapx1 was shown to positively regulate Runx2 expression 
exclusively in osteochondrogenic progenitor cells prefiguring the vertebral column 
(Tribioli and Lufkin, 1999). Other transcription factors that likely regulate Runx2 are 
Dlx5 and Msx2 which activate the expression of Runx2 thus promoting osteoblast 





decreasing the activity of Runx2 and inhibiting the maturation of osteoblasts 
(Holleville et al., 2007; Lee et al., 2005; Shirakabe et al., 2001). 
 
Subsequent to the expression of Runx2 in osteoprogenitors, the osteoblast lineage is 
reinforced by the expression of Sp7, also known as Osterix (Nakashima et al., 2002). 
The regulation of Osterix in osteoblasts is both Runx2-dependent and Runx2-
independent via Msx2 (Matsubara et al., 2008) or the recently discovered Osterix 
master, Xbp1 (Tohmonda et al., 2011). In osteoblasts, Runx2 directly up-regulates 
bone matrix protein genes such as Col1a1, Col1a2, Spp1 (aka Opn, Osteopontin), 
Ibsp, Bglap (aka Ocn, Osteocalcin) and Fn1 (Fibronectin1) (Banerjee et al., 1997; 
Ducy et al., 1997; Harada et al., 1999; Jimenez et al., 1999; Kern et al., 2001; Lee et 
al., 2000; Sato et al., 1998). The regulation of osteocalcin expression by Runx2 is 
enhanced by association with Satb2 and Atf4/Creb2 and inhibited by Dlx3 and Msx2 
(Dobreva et al., 2006; Hassan et al., 2004; Xiao et al., 2005). However, in an in vivo 
study by Maruyama et al, 2007, it was observed that osteocalcin expression was not 
affected in a dominant-negative Runx2 transgenic mouse model. Hence, there is a 
need to verify the in vitro interactions at the osteocalcin promoter using an in vivo 
model (Hartmann, 2009). 
 
Apart from osteoblastogenesis, Runx2 also promotes chondrocyte maturation and 
this is indirectly inhibited by the Sox trio (Sox9, Sox5 and Sox6) through the reduction 
of Runx2 transcript levels (Saito et al., 2007). Grg5, a Groucho-family member, 
interacts with Runx2 as a positive co-factor while Dlx5 and Dlx6 interact 
cooperatively with Runx2 to enhance chondrocyte hypertrophy (Chin et al., 2007; 
Roca et al., 2005; Wang et al., 2004). Hdac4 associates with Runx2 and inhibits both 
its activity and its transcription to hinder chondrocyte advancement (Vega et al., 





Runx2 to progress chondrocyte maturation (Arnold et al., 2007; Cobb et al., 2006). 
Runx2 positively regulates the expression of Col10a1 in hypertrophic chondrocytes 
(Drissi et al., 2003; Enomoto et al., 2000; Higashikawa et al., 2009; Zheng et al., 
2003) and Spp1, Ibsp and Mmp13 in terminal chondrocytes (Hess et al., 2001; 
Jimenez et al., 1999; Porte et al., 1999; Selvamurugan et al., 2000). Runx2 works 
synergistically with Ets1 to directly regulate Spp1 (Sato et al., 1998). Runx2 also 
interacts with other activating transcription factors such as Smads, C/EBP, Rb and 
with the transcriptional repressor Tle (Gutierrez et al., 2002; Javed et al., 2000; 
McCarthy et al., 2000; Thomas et al., 2001; Zhang et al., 2000). In addition, Runx2 
up-regulates the expression of Fgf18 in the perichondrium which encodes for a 
secreted molecule that activates Fgfr3 to inhibit chondrocyte hypertrophy (Hinoi et 
al., 2006). 
 
Chondrocyte maturation and osteoblast differentiation are linked by Ihh signalling. Ihh 
secretion by prehypertrophic chondrocytes enhances the expression of Runx2 in the 
perichondrium to promote osteoblast differentiation via the up-regulation of Gli2 
expression (Shimoyama et al., 2007) and the inhibition of the repressor form of Gli3 
which hampers DNA-binding ability of Runx2 (Ohba et al., 2008). In hypertrophic 
chondrocytes, Runx2 was found to directly up-regulate Ihh expression (Yoshida et 
al., 2004) which in turn induces chondrocyte proliferation and inhibits chondrocyte 
maturation through the induction of parathyroid hormone related peptide, Pthrp. Pthrp 
inhibits Runx2 expression through the PKA signalling pathway (Iwamoto et al., 2003; 
Li et al., 2004b; St-Jacques et al., 1999; Vortkamp et al., 1996) thus forming a 
negative feedback loop to prevent premature chondrocyte hypertrophy. Hence, while 
Ihh was found to stimulate osteoblast differentiation in the perichondrium by directly 
up-regulating Runx2 expression, Runx2 was found to directly induce Ihh in the 
growth plate to promote chondrocyte proliferation and delay chondrocyte maturation 






Runx2 is transcriptionally activated by several other signalling molecules such as 
bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), and retinoic 
acid (RA), and inhibited by 1,25(OH)2D3 (vitamin D3) and tumor necrosis factor-α 
(TNF-α) (D'Souza et al., 1999; Drissi et al., 2002; Ducy et al., 1997; Gilbert et al., 
2002; Jimenez et al., 2001). Another pathway linked to Runx2 is Wnt signalling. It 
was first implicated in osteoblastogenesis when Wnt5a, Wnt5b and Wnt4 were found 
to be expressed in the perichondrium, subpopulation of the prehypertrophic 
chondrocytes and cells in the joint of the chicken limb bone respectively (Hartmann 
and Tabin, 2000). It was also later demonstrated that the canonical Wnt/-catenin 
signalling was required to push skeletal precursors towards osteoblast differentiation 
while the lack of -catenin resulted in chondrocyte formation instead (Hill et al., 
2005).  In one study, Runx2 was found to be a direct target of the canonical Wnt/-
catenin signalling pathway and that the promoter of Runx2 was directly stimulated by 
Tcf/Lef complex to promote osteogenesis (Gaur et al., 2005). In another study, 
Runx2 was demonstrated to form a ternary complex with Tcf/Lef at the promoter of 
Fgf18 to induce bone formation (Reinhold and Naski, 2007). Combining the two 
findings, Runx2 may well be transcriptionally activated by the canonical Wnt/-
catenin signalling pathway and subsequently work synergistically with it via Fgf18 to 
trigger bone formation.  
 
Lastly, six Runx binding motifs have been found in its promoter and 5’UTR 
sequences which suggests that Runx2 auto-regulates itself. There are opposing data 
demonstrating that Runx2 positively (Ducy et al., 1999) as well as negatively 
regulates (Drissi et al., 2000) itself during osteoblastogenesis. Perhaps, Runx2 





stage of skeletal development and this remains to be examined in an in vivo model. It 
is also unclear if the Runx proteins cross regulate each other. 
  
1.4.2 RUNX3 
Mammalian Runx3, the smallest member of the Runx family with only 6 exons and 
spanning a small stretch of 67kb, is located on the human and mouse chromosomes 
1p36.1 and 4 respectively (Avraham et al., 1995; Bae et al., 1995; Calabi et al., 1995; 
Levanon and Groner, 2004). Among the Runx members, it has the highest 
occurrence of ancient mammalian-wide interspersed repeats (MIRs) which led to the 
speculation that Runx3 is the most primitive in the mammalian Runx family (Bangsow 
et al., 2001). With no exceptions, Runx3 is translated from two distinct promoters, P1 
(MASNS) and P2 (MRIPV). Similar to Runx2, the two promoter regions harbour a 
different repertoire of DNA binding motifs which enable differential regulation of the 
two major Runx3 isoforms (Bangsow et al., 2001). For instance, the P1 promoter 
contains more T- and B-cell-specific transcription factor binding sites such as Ikaros, 
Ets, CREB/ATF and an E-box while the P2 promoter, being more GC-rich, contains 
binding sites for Sp1 and Egr-1 (Leiden and Thompson, 1994; O'Riordan and 
Grosschedl, 2000).  
 
1.4.2.1 Spatiotemporal Expression of Runx3 in the Developing Skeleton 
Runx3 is abundantly expressed in the haematopoietic system particularly in the 
spleen, thymus and blood of an adult mouse (Bangsow et al., 2001; Le et al., 1999; 
Levanon et al., 1996; Levanon et al., 1994). The first expressions of Runx3 are 
detected at E10.5 in the haematopoietic precursors in the liver, cranial trigeminal 
ganglia and dorsal root ganglia of a developing mouse embryo (Levanon et al., 2001; 
Stricker et al., 2002). At E11.5, Runx3 transcripts start to appear in the mesenchymal 
condensations of the developing mouse limb. Subsequently, its expression 





in the distal phalanges of the mouse digits as well as the vertebrae by E13.5 (Stricker 
et al., 2002; Yoshida et al., 2004). By E15.5, Runx3 is manifested in most 
cartilaginous elements of the appendicular and axial skeleton such as the scapulae, 
limbs, ribs, pelvic bones and the vertebrae (Yoshida et al., 2004). Runx3 expression 
first coincides with that of Runx2 in the limb condensation at E11.5 and in the digits, 
ribs and vertebrae by E13.5. Expression of Runx3 is found primarily in the 
prehypertrophic and hypertrophic chondrocytes and to a smaller extent in the 
perichondrium of the developing mouse endochondral bone (Levanon et al., 2001; 
Stricker et al., 2002; Yoshida et al., 2004). 
 
1.4.2.2 Runx3 Phenotype, Function and Associated Skeletal Diseases 
Runx3 is involved in both neuronal (Inoue et al., 2002; Levanon et al., 2002) and T-
cell development (Taniuchi et al., 2002; Woolf et al., 2003) however the severe limb 
ataxia phenotype of Runx3 knockout mice due to the failure of proprioceptive 
neurons to develop in the dorsal root ganglia suggest that Runx3 plays a primary role 
in neurogenesis. Furthermore, Runx3 was implicated as a tumour suppressor in 
gastric cancer in a separate Runx3 mouse knockout study where it was 
demonstrated that the loss of functional Runx3 resulted in excessive growth of the 
gastric endothelial cells causing the mice to die of starvation shortly after birth (Li et 
al., 2002). 
 
In addition to gastric cancer, Runx3 is often found deleted or inactivated in cancers of 
the colon, lung, bladder, bile duct, pancreas, liver, prostate and breast (Goel et al., 
2004; Ito et al., 2008; Kang et al., 2004; Kim et al., 2005; Lau et al., 2006; Li et al., 
2004a; Wada et al., 2004; Xiao and Liu, 2004). Besides the involvement in 
neurogenesis, thymopoiesis and cancers, Runx3 also cooperates with Runx2 to 
contribute to chondrocyte maturation evident from the complete lack of 





chondrocyte marker, Col10a1, in the skeleton of a Runx2-/-Runx3-/- mouse embryo 
(Soung do et al., 2007; Yoshida et al., 2004).  
 
1.4.2.3 Transcriptional Regulation by Runx3 
Of the three Runx genes, Runx3 is the least studied especially in the context of 
skeletogenesis. In an in vitro study (Otto et al., 2003), Runx3 was found to positively 
regulate Col10a1 and Runx2 transcripts. Runx3 was also observed to regulate Ihh 
indirectly in hypertrophic chondrocytes (Yoshida et al., 2004). In gastric cancers, 
Runx3 associates with Smads to activate p21 expression and up-regulates Bim, an 
apoptotic gene, to propagate Tgf-induced apoptosis and tumour suppression (Chi et 
al., 2005; Yano et al., 2006). There was no previous expression profiling or binding 
sites data of Runx3. The mechanisms underlying cooperative regulation among the 
Runx family members during chondrocyte and osteoblast development are yet to be 
determined. 
 
1.5 Research Aims, Strategy and Significance 
The main research objective of our laboratory is to elucidate the complex spatial-
temporal interactions, amongst regulatory proteins and between transcription factors 
and the genetic material, that occur during the commitment of multipotent 
mesenchymal stem cells (MSCs) towards the osteo-chondrogenic lineage in a 
developing mammalian embryo. By coupling conventional mouse genetics with high-
throughput genomic technologies such as microarray and chromatin 
immunoprecipitation-sequencing (ChIP-Seq), we pursue the grand goal of building 
gene regulatory networks (GRNs) that govern embryonic skeletal development.  
 
In our research, we mainly employ the use of mice as they are ideal mammalian 





and (4) the ease of handling them. Furthermore, the availability of mouse embryonic 
stem cells (ESCs) and well-established gene-targeting protocols in the mouse make 
them an excellent species for genetic studies. And in our case, human skeletal 
diseases are often recapitulated in the relevant gene knockout mice; insights and 
knowledge gleaned from mouse studies are thus applicable and beneficial in 
developing drugs and genetic therapies for human skeletal disorders.   
 
From the literature review in this introduction chapter, it is noted that there has been 
much progress in our understanding of the molecular events that take place during 
embryonic bone formation and already an extensive number of transcription factors, 
signalling molecules and hormones have been identified to be implicated in the 
process. However, there is still a huge chunk of information missing to date such as 
the regulatory relationships among these identified factors and the yet numerous 
more undiscovered factors involved in skeletal lineage specification. Therefore, my 
specific aim is to unravel a part of the gene regulatory network controlling embryonic 
skeletogenesis by focusing on two Runx family genes – Runx2 and Runx3. The 
former is a key factor driving osteoblastogenesis while both have functions in 
chondrocyte maturation. I chose to work with only these two Runx genes because 
they play a bigger role in skeletogenesis.  
 
The strategy I have undertaken to elucidate a portion of the GRN is two-prong. The 
first is gene expression profiling of Runx2 and Runx3 (comparing knockout against 
wild-type profiles) to uncover their individual downstream targets. The second is 
ChIP-Seq to differentiate the direct targets from the indirect targets that are identified 
through the microarray analyses.  Ultimately, by means of bioinformatics to make 
sense of the massive amount of complex microarray and ChIP-Seq data generated, I 





1. What other undiscovered factors are under the influence of Runx2 and Runx3 
during skeletogenesis?  
2. Which of those are the primary targets of Runx2 and Runx3?  
3. What is the molecular mechanism behind the possible compensatory roles of 
Runx2 and Runx3? 
 
Finally, if we can map out these regulatory relationships onto graphic skeletal GRN 
diagrams, it will enable us to visualize the regulatory dynamics that can be 
interrogated, not only to gain insight into bone development but also to understand 
human skeletal diseases as a consequence of network perturbations and in turn 
allow identification of targets for therapeutic intervention, regenerative therapy and 





















CHAPTER 2 – MATERIALS AND METHODS 
 
2.1 BAC Modification and Subcloning 
Mouse bacterial artificial chromosomes (BACs) containing a partial or the entire 
genomic locus of Runx2 and Runx3 (purchased from BACPAC Resource Centre, 
CHORI) were used for modification using the Gene Bridges Quick and Easy BAC 
Modification kit via the Red/ET recombineering technology according to the 
manufacturer’s protocol. Appropriate 50 bp homology arms were added to both ends 
of the insertion cassette (EGFP-loxP-PGKgb2-Neo-loxP, F2A-EGFP-Frt-PGKgb2-
Neo-Frt or HA3-TGA-loxP-PGKgb2-Neo-loxP) via PCR. DH10B E.coli strain hosting 
the appropriate BAC was first transformed with pRed/ET and selected with 
chloramphenicol (12.5 μg/mL) and tetracycline (3 μg/mL) antibiotics before a second 
transformation of the insertion cassette flanked with 50 bp homology arms into the 
pRed/ET-containing BAC clones for homologous recombination (Fig. 3). The positive 
recombinants were selected with chloramphenicol and kanamycin antibiotics and 
screened by colony PCR.  
 






Upon successful BAC modification, the region-of-interest was amplified by PCR and 
verified by double-stranded sequencing to ensure that there were no errors in the 
modification. Mutation-free modified BAC clones were subcloned into a minimal 
vector using the Gene Bridges Quick and Easy BAC Subcloning kit. Grabbing arms 
(50 bp) complementary to the regions to be subcloned were attached to the minimal 
vector by PCR. Similarly, the pRed/ET was first transformed into the modified BAC 
host followed by a second transformation of the minimal vector flanked by 50 bp 
homology arms into the pRed/ET-containing modified BAC clones for subcloning by 
homologous recombineering (Fig. 4). The positive recombinants were selected with 
kanamycin (20 μg/mL) and ampicilin (100 μg/mL) antibiotics and screened by colony 
PCR. The subcloned plasmids were designed to contain the modified region flanked 
by short and long homology arms with a combined length of at least 10 kb. 
Subcloned plasmids were verified again by double-stranded sequencing to ensure no 
mutations had occurred within the modified region during subcloning. Subsequently, 
these subclones were linearized with Acl or XmnI restriction enzymes which cut only 
within the minimal vector and electroporated into the mouse ESCs for gene-targeting. 
 
 
Figure 4. BAC Subcloning by Recombineering Technology 





2.2 Homologous Recombination in Mouse ES Cells 
 
 2.2.1 ES Cell Culture  
 
The hybrid (C57BL/6 x 129) mouse ES cell line V6.4 was used for all gene targeting 
experiments as these hybrid ESCs were shown to remain robust after extended 
periods of in-vitro culture and gene-targeting procedures, producing a good number 
of viable cloned mice derived entirely from these cells (Eggan et al., 2001). Culture 
dishes were gelatinized with 0.1% gelatine and cells were grown on a feeder layer of 
irradiated mouse primary embryonic fibroblasts (PEF) and maintained in ES media 
(ESM) containing DMEM supplemented with 15% heat-inactivated ES grade fetal 
bovine serum (FBS) (Gibco, Invitrogen), 0.1 mM β-mercaptoethanol, 4 mM L-
glutamine, 1 mM sodium pyruvate, 40 μg/mL gentamicin, and 500 U/mL LIF 
(ESGRO, Chemicon) at 37°C in 5% CO2. Media was refreshed daily, and cells were 
trypsinized with 0.05% trypsin (Gibco, Invitrogen) every 3-4 days. 
 
 2.2.2 Electroporation of ES Cells 
 
A day prior to electroporation, V6.4 ES cells were passaged. Cells were again 
trypsinized just before electroporation and counted on a haemocytometer. 10 x 106 
cells were resuspended in 400 μL of ESM, mixed with 10-20 μg of linearized 
targeting vector, then placed in an electroporation cuvette (Biorad, 1 mm gap) and 
pulsed at 125 μFarads, 0.4 kVolts. A no vector control was also electroporated in 
parallel. After 5 minutes at room temperature, the cells were divided into 6 DR4 
(multi-drug resistant) feeder-layered 10 cm culture dishes and allowed to recover 









2.2.3 ES Cell Colony Picking 
Putative positive recombinants were selected for with G418 antibiotics over 8-10 
days. No ES cell colonies survived in the control plates. Surviving colonies ranging in 
the hundreds from the vector-electroporated plates were picked into 96-well plates 
containing 0.05% trypsin – one colony per well. Selection media was first replaced 
with warm PBS before each colony was picked under the light microscope in the 
laminar flow hood with a 20 µL pipette set at 15 µL. Upon picking a row of colonies, 
they were broken up immediately with a multi-channel pipette and divided into 2 sets 
of 96-well PEF-layered plates. After a week of culture, one of the duplicates was 
expanded to 24-well plates for genomic DNA extraction and subsequent screening by 
PCR and Southern blot while the other was further replicated and frozen ‘in-situ’ as 
96-well plate duplicates.  
 
2.2.4 ES Cell Freezing  
Freezing media comprising 70% DMEM, 20% FBS and 10% DMSO was prepared 
fresh and sterile filtered each time. When one well of any plate was 80% confluent, 
the entire plate was added freezing media (100 or 200 µL/well in 96- or 24-well 
plate), sealed with cling wrap and aluminium foil, placed in a Styrofoam box and 
slowly frozen in a -80°C freezer. Putative positive cells were thawed from plates, 
expanded, trypsinized, resuspended in freezing media (500 µL/vial) and frozen in 
cryo-vials in a special freezing container (Invitrogen; 1°C drop per minute) at -80°C. 










2.3 ES Cell Clone Screening and Genotyping 
2.3.1 Genomic DNA Extraction 
 ES Cells and Mouse Tail Tips 
ES cells and mouse tail tips were subjected to Proteinase K (Sigma; final 
concentration: cells 0.2 mg/mL, tails 0.5 mg/mL) digestion overnight at 37⁰C and 
57⁰C with agitation respectively. For high quality and yield, genomic DNA was 
extracted using MaXtract High Density tubes (Qiagen; Cat.#129046) by adding an 
equal volume of phenol: chloroform: isoamyl alcohol (pH7.9) to the digested material 
and vortexed for 30 seconds before spinning down at maximum speed for 5 minutes 
to separate the phases. The DNA-containing aqueous layer was decanted into a 
fresh 1.5 ml tube and DNA was precipitated with twice the volume of 100% ethanol 
and washed with 70% ethanol. DNA pellet was air-dried and re-dissolved in sterile 
water or elution buffer (Qiagen). 
 
PK Digestion Buffer (PKDB): 
50 mM  TRIS, pH 7.0-8.0 
5 mM   EDTA 
1%   SDS 
0.2 M  NaCl 
 
 
2.3.2 Southern Blotting 
 DIG Probe Design and Synthesis 
Restriction sites that would differentiate modified alleles from the wild-type based on 
their restricted lengths were identified and any significant repeats found in 40kb of 
genomic sequences flanking the modified region were masked using the 
RepeatMasker (www.repeatmasker.org). Probes spanning from 400 bp to 1 kb in 
size were designed to sit within the restriction sites but either outside of the homology 
arms termed as ‘external probes’ or within the modified region including the 





sequences were combined for enhanced DNA band detection. The external probes 
distinguished ES cell clones that have undergone homologous recombination at the 
targeted locus from those that have simply assumed random genomic integration. 
The internal probes further investigated these clones if random integrations on top of 
homologous recombination have occurred. DNA hybridization probes were PCR-
labelled with non-radioactive digoxygenin (DIG) by incorporating DIG-dUTP into the 
nucleotide sequence using the PCR DIG Probe Synthesis kit (Roche, Cat #1636090). 
These PCR-labelled products are either column purified with Zymo DNA Clean & 
Concentrator kit and eluted in sterile water or used directly in the hybridization buffer. 
Probe quality and yield were assessed by gel electrophoresis and stored at -20°C 
until use.  
 
 DNA Transfer 
Genomic DNA (10-15µg) was digested for 8-16 hours with appropriate restriction 
enzymes and ran on 0.75% TAE agarose gels without ethidium bromide at a 
constant voltage ranging from 20-30 V for 12-24 hours or until DNA bands are well 
separated. Gels were stained with ethidium bromide, imaged under UV light for DNA 
quality, depurinated with 0.25 M HCl (necessary for DNA bands > 5 kb) for 10 
minutes then denatured in 0.5 M NaOH with gentle agitation for 2 x 30 minutes. The 
gel was subsequently laid on a DNA transfer assembly consisting of a positively 
charged nylon membrane (Roche, Cat #1417240) resting on sheets of Whatman 
3MM filter paper and a stack of C-fold towels as illustrated below (Fig. 5). DNA was 
transferred in 0.5 M NaOH onto the membrane by downward capillary movement. 
The gel was drizzled with transfer buffer 3-4 times every hour before the entire 






Figure 5. Southern Blot DNA Transfer Assembly 
 
 Hybridisation and Washing 
The membrane was washed briefly in 5X SSC and placed in a roller bottle containing 
pre-warmed DIG Easy Hyb buffer (Roche, Cat #1603558; 10 mL/100 cm2) for pre-
hybridization at 42°C for 1-4 hours to block non-specific sites. Thereafter, DIG-
labelled probes were denatured at 99°C for 5 minutes, quick-chilled on ice before 
added to fresh pre-hybridization solution at 20-50 ng/mL probe concentration and the 
membrane was incubated in this hybridization buffer overnight at 42°C in a rotating 
oven. After overnight hybridization, the hybridization buffer was stored at -20°C and 
re-used over several hybridisations upon warming at 68°C for 10 minutes and the 
membrane was washed twice at room temperature for 5 minutes (2X SSC, 0.1% 
SDS), then twice for 15 minutes at a higher temperature (60-68°C) in a pre-heated 
higher stringency wash buffer (0.5X SSC, 0.1% SDS) followed by a brief rinse in 1X 
MABT. 
 
 Blocking and Detection 
Blocking of the washed membrane was done with 1% Blocking buffer (Roche 
Blocking Reagent, Catalog #11096176001; 1g/100mL of 1X MAB) for 30 minutes and 
then incubated with alkaline-phosphatase (AP)-conjugated anti-DIG antibody (Roche, 
Catalog #11093274910) at a 1:10,000 dilution in 1% Blocking buffer for another 30 





1X MABT for 15 minutes twice at room temperature. The blot was rinsed briefly in 
detection buffer and CSPD chemiluminescent AP substrate was added (1mL/100 
cm2). After incubation at room temperature for 5 minutes, the blot was warmed at 
37°C for 10 minutes to enhance enzymatic activity of the substrate before signal 
detection on an X-ray film. The film generally has to be exposed for 3-6 hours before 
a reasonable signal is detected.  
 
 Stripping and Re-probing 
Membranes can be stripped by washing with 0.2 M NaCl /0.1%SDS for 2X15mins 
after a brief rinse in double-distilled water. Next, the membrane is washed with 2X 
SSC prior to pre-hybridization and hybridisation with another probe. 
 
 
Maleic Acid Buffer (10X MAB)  
0.2 M Maleic Acid 
0.3 M NaCl  





1X  MAB  
0.3% Tween 20 
 
Detection Buffer 
0.1 M Tris-HCl, pH 9.5   















2.4 Generation of Transgenic Mice 
2.4.1 Microinjection of ES Cells 
Successfully targeted ES cell clones were thawed out, cultured for 3-4 days and 
passaged a day prior to microinjection. On the morning of microinjection, cells were 
trypsinized, washed with PBS and resuspended in M2 medium. Approximately 8-10 
ES cells were microinjected into each of the 2 to 8-cell stage embryos (Kraus et al, 
2010) harvested  from C57BL/6J mice and re-implanted into the oviducts of CD-1 
pseudopregnant mice (6-10 microinjected embryos per oviduct) on the same day. 
This method of microinjection generated many high-percentage, germline 
transmitting chimeras.  
 
2.4.2 Breeding and Genotyping of Transgenic Mice 
Heterozygous transgenic mice were obtained by crossing male chimeras to female 
C57BL/6J mice and homozygous mice, if viable, were obtained by intermating 
heterozygous mice. Mice were weaned and ear-tagged 3 weeks after birth. The 
genotype of the mice were determined by PCR, with primers flanking the modified 
region, on genomic DNA extracted from the tail tips cut during ear-tagging.  
 
2.5 Fluorescence – Activated Cell Sorting (FACS) 
 2.5.1 Dissociation of Mouse Skeletal Tissue into Single Cells 
Mouse embryos expressing enhanced green fluorescent protein (EGFP) under the 
control of endogenous Runx2 and/or Runx3 promoters were harvested and critically 
staged based on M.H. Kaufmann, Theiler morphological criteria.  Skeletal tissues that 
showed green fluorescence i.e. the limbs, ribs, vertebral column, maxilla and 
mandible were dissected out from either E13.5 or E14.5 mouse embryos. Yolk sacs 
of each embryo were retained to verify the genotype of the embryos. Dissociation 





collagenase I and II (Sigma, 150 U/mL), DNase (Sigma, 50 U/mL)  and 0.05% 
trypsin, was freshly made and sterile filtered (Millipore, 0.2 µm filter disc) each time 
right after the embryos were removed from the uterine horns. Dissected mouse 
tissues were placed in a single well of a 24-well plate containing 1 mL of dissociation 
buffer and broken down by mechanically pipetting up and down initially with a wide 
bore then a narrow bore 1000 µL pipette tip. An equal volume of 20% FBS in 
Leibovitz medium (sterile filtered) was added to stop the dissociation activity. The cell 
suspension was then filtered through a 100 µm strainer basket and again through a 
40 µm strainer basket into a 50 mL Falcon tube to remove small bits of tissue. The 
first filtrate was placed on ice while the dissociation and filtration steps were repeated 
several times with the bits of tissue left on the strainer baskets after each filtration 
until there was no more tissue bits visible on the strainer baskets. These subsequent 
filtrates were combined to give the second filtrate. The second and subsequent 
dissociation steps incorporated a 5-minute incubation at 37°C before the mechanical 
pipetting step to enhance the breaking down of the tougher tissues such as cartilage 
and bone retained by the strainer baskets. Prior to centrifugation, 10 µL of cell 
suspension was pipetted into a haemocytometer for cell counting and Trypan Blue 
was used to assay for cell viability. Single cells in filtrates 1 and 2 were then pelleted 
at 2000 rpm for 5 minutes in a 4°C centrifuge and resuspended in 5% FBS/ 50% 
AccumaxTM/ 2.5 µM EDTA (sterile filtered) to give a desired concentration of 3 million 
cells/ mL for cell sorting. A wild-type CD-1 embryo at the same embyonic stage was 
dissociated in parallel and used as a control for gating the GFP detection threshold. 
Cells were sorted into 1.5 mL centrifuge tubes containing 500 µL of 20% FBS. Sorted 
cells were spun down in a 4°C tabletop centrifuge at 1,400 rcf and 20% FBS was 







2.6 Microarray  
 2.6.1 RNA Extraction  
Total RNA extraction was carried out with the hybrid method coupling the use of 
Trizol and the Qiagen RNeasy Micro kit. Sorted cells stored frozen in Trizol were 
thawed, homogenized by repetitive pipetting and incubated at room temperature for 5 
minutes. The lysed samples were transfered to 2 mL MaXtract High Density tubes 
(Qiagen; Cat. #129046). Chloroform (0.2 mL per mL of Trizol) was added to the 
samples and shaken vigorously by hand for 15 seconds before further incubation at 
room termperature for 3 minutes. Samples were centrifugated at maximum speed for 
15 minutes at 4°C. The aqueous layers at the top were transferred to RNase-free 
microcentrifuge tubes and precipitated with an equal volume (about 60% of the initial 
sample in Trizol) of 70% ethanol (made fresh). Well-mixed samples were loaded onto 
the RNeasy MinElute columns (Qiagen) each seated in a 2 mL collection tube and 
spun at > 10,000 rpm at room temperature for 30 seconds. The flowthroughs were 
discarded and the columns were washed with 350 µL wash buffer RW1. On-column 
DNase treatment was done using  80 µL of 1U/L DNaseI in buffer for 15 minutes at 
room temperature after which the columns were washed with 350 µL buffer RW1, 
500 µL RPE and 500 µL 80% ethanol (made fresh). The columns were spun dry at 
full speed for 5 minutes in a new collection tube. Purified RNA samples were eluted 
in 14 µL of RNase-free water into fresh 1.5 mL centrifuge tubes by a full speed spin 
for a minute. Elution was accompanied by a 3-minute incubation each time prior to 
centrifugation. A second elution was performed by returning the eluate to the column 
for incubation and centrifugation to recover more yield. RNA samples were quantified 
using Quanti-iT™ Ribogreen® RNA Reagent kit according to the manufacturer’s 
protocol. The integrity of the RNA samples were assessed with the Agilent RNA Pico 
Chip (#5067-1513) and Agilent 2100 Bioanalyzer software according to the 





 2.6.2 RNA Amplification and Biotin Labeling 
Isolated RNA was amplified using the NuGEN Ovation™ RNA Amplification V2 kit 
and biotin-labeled with NuGEN Encore™ BiotinIL Module kit according to the 
manufacturer’s protocol. In brief, the first cDNA strand was synthesized from 1 ng of 
total RNA samples using a mix of reverse transcriptase and SPIA™ DNA/RNA 
chimeric primers complementary to the 5’ region of the polyA sequence. The second 
cDNA strand was synthesized with DNA polymerase, SPIA™ DNA/RNA chimeric 
primers and RNaseH to fragment the chimeric primer to create a priming site for the 
DNA polymerase. As a result, double-stranded cDNA with unique DNA/RNA 
heteroduplex at one end was synthesized. Finally, linear isothermal DNA 
amplification of the double-stranded cDNA was carried out using a master mix of 
SPIA™ DNA/RNA chimeric primers, DNA polymerase and RNaseH. The amplified 
cDNA was purified using the Zymo Research DNA Clean and Concentrator™-25 kit 
(Cat. D4005) according to the manufacturer’s protocol prior to biotin-labeling.  
 
Three micrograms of purified and amplified cDNA was brought to a final volume of 25 
µL with nuclease-free water. Five microliters of UNG enzyme (1U/L) in 5 L of UNG 
buffer (10 mM K2HPO4.3H2O, 4 mM MgCL2) was added to the cDNA samples, 
incubated at 50°C for 30 minutes in a thermal cycler and placed on ice. Next, 5 L of 
ARP [N-aminooxyacetly)-N’-(D-biotinoyl)hydrazine, trifluoroacetic acid salt] solution 
(Molecular Probes, 11.3 mg/mL ARP  in 22.4 mM phosphate buffer) and 5 µL of 
labeling buffer (0.952 M acetic acid, 28 mM MgCl2) were added and incubated at 
50°C for another 60 minutes. Biotin-labeled cDNA was purified with Zymo Research 








2.6.3 Hybridization on Illumina Mouse WG-6 BeadChip  
Reagents from Illumina MouseWG-6 Expression BeadChip kit were used for the 
microarray. The hybridization oven and the water bath were first preheated to 48°C 
and 58°C respectively and 1.5 g of each biotin-labeled cDNA sample was 
resuspended in 10 L of nuclease-free water and incubated at room temperature for 
10 minutes. Twenty microliters of GEX-HYB (prewarmed to 58°C and cooled to 
dissolve any precipitation) was added to each cDNA sample and heated at 65°C for 
5 minutes. Meanwhile, 200 L of GEX-HCB was added to the humidifying buffer 
reservoirs of the hybridization chambers. The warmed cDNA was briefly vortexed, 
centrifugated at full speed for a minute and cooled to room temperature before all 
30 L of biotin-labeled cDNA was loaded onto the array. There were at least 4 
biological replicates per genotype assessed and the biological replicates of the same 
genotype were randomized on the BeadChip arrays. The loaded BeadChips were 
placed horizontally and sealed within the hybridization chamber. The whole chamber 
was placed in the hybridization oven and incubated for 18 hours at 48°C. The 
hybridization temperature was reduced to compensate the less stable cDNA/DNA 
pairs compared to the cRNA/DNA pairs. The 1X High-Temp wash buffer (500 mL) 
was prewarmed overnight at 55°C in a waterbath-insert-heatblock.  
 
Coverseals of the hybridized BeadChips were removed in Wash E1BC solutions 
(3 mL of E1BC in 1 L of RNase-free water) the next day and incubated in the 1X High 
Temp wash buffer at 58°C for 10 minutes. Every incubation and wash required the 
BeadChips to be completely submerged in solution. Thereafter, the BeadChips were 
washed in E1BC solution for 5 minutes, 100% ethanol for 10 minutes and back in 
E1BC solution for 2 minutes. Next, the BeadChips were blocked with Block E1 buffer 
(prewarmed to room temperature; 4 mL per chip) for 10 minutes in a provided wash 





containing 2 µL of Streptavidin-Cy3 in 2 mL of Block E1 buffer, covered and left to 
incubate in the dark on the rocker for another 10 minutes. A final 5-minute wash was 
done with the Wash E1BC solution before the BeadChips, placed in a chip rack, were 
spun dry at 275 rcf for 4 minutes. BeadChips were scanned with the Illumina® 
BeadArray Reader on the same day. 
 
2.6.4 Gene Expression Analysis using GeneSpring GX 11.0 
Raw image data was interpreted with the Illumina® BeadStudio software and 
exported as GeneSpring compatible gene expression output data with background 
subtraction and no normalization. The sample probe profiles in text file format were 
imported into GeneSpring GX 11.0 for gene expression analysis. Entities with 
detection p-value > 0.8 were flagged  as “Present”, those with detection p-value < 0.6 
were flagged as “Absent” and anything in between were flagged as “Marginal”. 
Negative raw values were shifted to a minimum threshold of 1.0 and a percentile shift 
to 75% with a baseline to median normalization algorithm was applied. Averaging 
among biological replicates was not applied. All entities were first filtered by flags 
retaining entities with “Present” or “Marginal” flags in at least 1 out of the total  
number of samples. The filtered entities were further filtered by retaining entities with 
raw expression data that fell between 20-100th percentile in at least 1 out of the total 
number of samples. Statistical analysis such as the ANOVA for a three-way 
comparison of Runx2+/+ vs. Runx2+/- vs. Runx2-/-  and the unpaired Student’s t-test for 
pair-wise comparisons of Runx3+/- vs. Runx3-/-, Runx2-/-Runx3-/- vs. Runx2-/- and 
Runx2-/-Runx3-/- vs. Runx3-/- were employed and asymptotic p-values were subjected 
to the Benjamini Hochberg False Discovery Rate (B-H FDR) multiple testing 
correction to identify significant differentially expressed entities. Significance was 






2.7 Chromatin Immunoprecipitation – Sequencing (ChIP-Seq) 
 2.7.1 Tissue Harvesting and Cross-linking 
E13.5 mouse embryos were harvested from the mouse uterine horns and critically 
staged based on M.H. Kaufmann, Theiler morphological criteria. Embryonic tissues 
of interest were dissected from E13.5 mouse embryos on ice into chilled Leibovitz 
medium. Tissues were spun at 1,100 g for 5 minutes at 4˚C and resuspended in 
10 mL of fresh Leibovitz medium. Resuspended tissues were homogenized on ice 
with a 15 mL Douncer. Minced tissues were pelleted at 1,100 g for 5 minutes at 4˚C, 
weighed and resuspended in 10X the tissue pellet volume of room termperature 1X 
PBS. Cross-linking buffer (11% Formaldehyde) was added at one tenth the volume of 
PBS and tissues were cross-linked for 10 minutes on a nutator. Cross-linking was 
quenched for 5 minutes with 2.5 M Glycine added at one-tenth of the volume. 
Tissues were spun down at 1,100 g for 5 minutes at 4˚C, resuspended in 10 mL of 
chilled 1X PBS and homogenized on ice again with the Douncer until there were no 
more visible clumps. Cross-linked cells were washed with chilled PBS, pelleted, 
weighed, snap frozen in liquid nitrogen and stored at -80˚C. 
11% Formaldehyde Solution (Cross-linking Buffer):  
50 mM   Hepes-KOH (pH 7.5) 
100 mM NaCl  
1 mM  EDTA (pH 8.0) 
0.5 mM EGTA (pH 8.0) 
11%  Formaldehyde 
 
 
2.7.2  Binding of Antibodies to Magnetic Beads 
Magnetic Dynabeads Protein G (Invitrogen; Cat. 100.04D) (100 L per IP) were 
placed in 1.5 mL centrifuge tubes, washed 3 times with 1 mL of blocking solution 
(0.5% BSA) using a magnetic stand and incubated with 5 g of rabbit IgG or 10 g of 
rabbit anti-HA antibody overnight or for at least 6 hours in 250 L blocking solution at 





the same blocking solution the next day and resuspended in 100 L of blocking 
solution to be added to the sonicated chromatin. IgG bound to magnetic beads were 
used for preclearing the chromatin. 
 
2.7.3  Cell Lysis, Sonication and Chromatin Immunoprecipitation 
Frozen cell pellets were thawed, resuspended in lysis buffer 1 (LB1) at 10 times the 
volume/weight of the pellet, nutated for 10 minutes at 4˚C, spun down at 1,350 g for 5 
minutes at 4˚C and resuspended in lysis buffer 2 (LB2) at the same volume as LB1. 
The cell lysates in LB2 were nutated at room temperature for 10 minutes and spun 
down at 1,350 g for 5 minutes at 4˚C to pellet the nuclei. The nuclei pellets were 
weighed and the nuclear lysis buffer 3 (LB3) was added at 10 times the 
volume/weight of the pellet. The nuclear lysates (2 - 3 mL) were transferred to 15 mL 
bacterial culture tubes containing 1 mL of glass beads (BioSpec Products; 
#11079105) and kept on ice prior to sonication.  
Lysis Buffer 1 (LB1):  
50 mM   Hepes-KOH (pH 7.5) 
140 mM NaCl  
1 mM  EDTA (pH 8.0) 
10%  Glycerol 
0.5%   Igepal CA360 
0.25%  Triton X-100 
 
Lysis Buffer 2 (LB2):  
10 mM   Tris-HCl (pH 8.0) 
200 mM NaCl  
1 mM  EDTA (pH 8.0) 
0.5 mM EGTA (pH 8.0) 
 
Lysis Buffer 3 (LB3) (made with chilled water):  
10 mM   Tris-HCl (pH 8.0) 
100 mM NaCl  
1 mM  EDTA (pH 8.0) 
0.5 mM EGTA (pH 8.0) 
0.5 mM Na-Deoxcholate 
0.5%   Sodium Dodecyl Sulfate (SDS) 






Sonication was performed with the Branson Digital Sonifier® in the cold room. 
Chromatin sonication was previously optimized at 12 minutes (15-cycles of “ON” and 
“OFF” sonication for 20 seconds each time at 40% amplitude and 30 seconds rest in 
between) to shear the chromatin to a recommended size range of 100-500bp using 
E13.5 CD-1 wild-type embryonic tissues (Fig. 6). The sonicator probe was placed 
into the nuclear lysate in LB3 until it was just touching the glass beads. Sonication 
was done using the above optimized parameters in a beaker of ice water to prevent 
overheating of the nuclear lysates. The sonicated chromatin was transferred to a 
2 mL centrifuge tube and 1% Triton X-100 was added. The sonicated chromatin was 
centrifugated to remove any debris from sonication and quantitated with the 
Nanodrop spectrophotometer (Thermo Scientific). The average concentration range 
obtained was 1.0 – 1.4 g/L. Two milligrams of sheared chromatin were used with 
10 g of antibody for each immunoprecipitation (IP). The volume of nuclear lysates 
containing 2 mg of chromatin was brought to a total volume of 1.8 mL with 1% Triton 
X-100 in LB3. The sheared chromatin was pre-cleared with bead-conjugated IgG for 
an hour at 4˚C on a 360° rotating platform before overnight chromatin 
immunoprecipitation with the anti-HA antibody (Abcam 9110) at 4˚C on a 360° rotating 
platform. Preclearing and IP were done in 2 mL centrifuge tubes sealed with parafilm. 
 
Figure 6. Optimizing Chromatin Sonication  
Chromatin sonication was optimized using tissues collected from E13.5 CD-1 wild-type 
embryos. The recommended sheared chromatin size range of 100-500 bp was attained with 
12 minutes of “ON” and “OFF” sonication for 20secs each time at 40% amplitude with 30 secs 







2.7.4  Wash, Elution and Reverse Cross-link 
The immunoprecipitated chromatin was washed with 1 mL of chilled 1X RIPA buffer 
(Upstate; Cat# 20-188) added with protease inhibitor the next day. Each wash 
included a 5-minute 360° rotation at 4°C before recovering the immunoprecipitated 
chromatin with a magnetic stand and discarding the wash buffer. A total of 6 washes 
were performed. Thereafter, the immunoprecipitated chromatin was washed once 
with 1 mL of TE buffer (10 mM Tris, pH 8.0; 1mM EDTA; 50 mM NaCl) and the 
immunocomplex was eluted off the beads at 65°C in 210 L of Elution buffer (50 mM 
Tris, pH 8.0; 10 mM EDTA; 1% SDS) for 30 minutes with shaking at 1,400 rpm in a 
heat block. The magnetic beads were removed with the magnetic stand and the 
supernatants were transferred to a clean 1.5 mL centrifuge tube for reverse cross-
linking by incubating at 65°C overnight.   
 
2.7.5  ChIP DNA Clean Up 
The reverse crosslinked samples were transferred to MaXtract High Density tubes 
(Qiagen; Cat.#129046), added with 200 L TE buffer and incubated with 0.2 g/mL 
RNaseA at 37°C for 2 hours to remove excessive RNA that might interfere with the 
subsequent DNA purification. Proteins were removed next with 0.2 g/mL of 
Proteinase K at 55°C for another 2 hours. An equal amount of phenol-chloroform-
isoamyl alcohol (Ambion; Cat# AM9732) was added to each sample and vortexed for 
30 seconds. The phases were separated by centrifugation at full speed for 3 minutes 
and the aqueous layer was transferred to a new 1.5 mL tube containing 30 g of 
glycogen in 16 L of 5M NaCl. The samples were precipitated with 800 L of 
absolute ethanol and incubation at -80°C for 30 minutes after which the DNA was 
pelleted at full speed for 10 minutes at 4°C. The DNA was then washed with 80% 





8.0. The DNA was quantified with the Nanodrop spectrophotometer and stored at -
80°C until further use. 
 
2.7.6  ChIP-Seq DNA Library Prep 
The purified ChIP DNA was end-repaired, added with ‘A’ bases at the 3’ ends, ligated 
with universal adaptors, amplified and size selected (200-400 bp) using the 
NEBNext® ChIP-Seq Sample Prep Reagent kit (#E6200S) according to the 
manufacturer’s protocol. The DNA libraries were eventually sequenced with the 
Illumina Solexa Sequencer. 
 
2.8 Western Blotting 
ChIP samples eluted from the magnetic beads were added with 4X loading buffer 
and 10X sample reducing agents (Invitrogen; Cat# NP0004), boiled at 80°C for 10 
minutes to denature the proteins and ran on a 10-well NuPAGE® 4%-12% Bis-Tris 
precast gel (Invitrogen) at 120 V for 2 hours or until the blue front ran out. A 
polyvinylidene difluoride (PVDF) membrane (Bio-Rad Immun-Blot™) and 2 extra 
thick filter papers (Biorad) were soaked in 0.2% methanol in Tris-Glycine transfer 
buffer (1st Base #BUF-2020-10X1L) just before the gel run ended. The Western gel 
was taken out of the covers, placed on the PVDF membrane, sandwiched between 
the soaked filter papers and placed on the transfer plate of the Bio-Rad Trans-Blot® 
Semi-Dry Transfer Cell. The protein bands were transferred onto the membrane at 
25 V for 30 minutes. Next, the membrane was blocked with 3% skim milk (BD Difco) 
in TBST (1X TBS and 0.05% Tween20; Bio-Rad) for 1 hour at room temperature, 
rinsed briefly with TBST and probed with HRP-conjugated anti-HA goat primary 
antibody (Bethyl; Cat# A190-107P; 1:20,000) diluted in 3% BSA (Sigma; A3059) for 1 
hour at room temperature and washed with TBST 4 x 15 minutes. Protein bands 





Reagents (Thermo Scientific) and exposed onto Amersham Hyperfilm™ X-ray films 
(GE Healthcare; #28906844). 
 
2.9 Embryo Processing for Histology 
Mouse embryos were fixed in 4% paraformaldehyde (PFA) in PBS overnight at 4°C, 
washed in PBS for 5 minutes and dehydrated through 50% and 70% ethanol/PBS for 
20 minutes each the next day. Dehydrated mouse embryos were processed in an 
automated tissue processor machine (Leica TP 1020), embedded in paraffin and 
sectioned at 10 microns with the microtome (Leica RM 2165).  
 
2.10 Section In-Situ Hybridization (SISH) 
 RNA Probe Synthesis 
cDNA clones purchased from Open BioSystems were used as templates for in vitro 
transcription synthesis of antisense DIG-labelled RNA probes using the DIG RNA 
labelling kit (Roche, Cat.#11 175 025 910) according to the manufacturer’s 
instructions. In vitro transcription reaction was stopped with 0.2 M EDTA. Small 
nucleotides were removed with the RNA Spin Columns (Roche; Cat# 11274015001) 
and the DIG-labelled RNA probes were precipitated with 5 µL of 3M NaOAc, pH 5.5 
and 2.5 X100% ethanol with incubations at -20°C for 30 minutes. RNA probes were 
pelleted at full speed for 10 minutes at 4°C, washed twice with 70% ethanol, air-dried 
and resuspended in DEPC water. Probe concentrations were measured by Nanodrop 










 Section Pre-treatment, Pre-hybridization and Hybridization 
Mouse embryo sections on polysine-coated histology slides were de-waxed in Histo-
Clear™ (a non-toxic substitute for xylene), rehydrated through 100%, 90%, 70% and 
30% ethanol for 5 minutes each, post-fixed in 4% PFA for 20 minutes, digested with 
10 g/mL Proteinase K in 0.1 M Tris, pH 7.5 for 10 minutes and post-fixed a second 
time with 4% PFA for 10 minutes. Sections were then pre-hybridized at 67°C for 2-3 
hours and hybridized overnight at the same temperature with antisense DIG-labeled 
RNA probes at 600-1200 ng/mL concentration in pre-hybrization solution. 
 
Pre-hybridization Solution:  
50%   Formamide (Roche; Cat#11814310001) 
5X   SSC (1st Base) 
1X  Denhardt’s  
(5 g Ficoll, 5 g BSA and 5 g Polyvinylpyrrolidine in  
500 mL DEPC water) 
0.1%  Tween20 
0.1 mg/mL  Yeast tRNA (Ambion; Cat#AM7118) 
0.05 mg/mL Heparin 
 
 
 Post-hybridization Washes and Probing with anti-DIG Antibody 
The hybridized mouse sections were washed the next day with pre-warmed 
Solution I at 67°C for 3x30 minutes, TNT for 3x5 minutes, TNT:Solution II (1:1) for 5 
minutes, pre-warmed Solution II at 63°C for 3x30 minutes and MABT for 3x5 minutes 
before blocking with 2% blocking solution (Roche Blocking Reagent dissolved in 
MAB) for 2-3 hours. Thereafter, the sections were probed with alkaline phosphatase 











Solution I:  
50%   Formamide (Roche) 
5X   SSC (1st Base) 
1%   SDS 
 
TNT:  
10 mM   Tris-HCl, pH 7.5 
0.5 M   NaCl  
0.1%  Tween20 
 
Solution II:  
50%   Formamide (Roche) 
2X   SSC (1st Base) 




 Post-Antibody Washes and Colour Development 
Mouse sections probed with anti-DIG antibody were briefly washed with MABT for 
3x10 minutes before the hourly washes with MABT for 3-4 hours. Sections were 
conditioned in NTMT for 3x10 minutes before NBT/BCIP (Roche; Cat#11681451001) 
substrate (200 L diluted in 10 mL of 0.1 M Tris-HCl, pH9.5 and 0.1 M NaCl) was 
added to the sections for colour development. Hybridization cover slips were placed 
over the sections and the slides were left at 4°C in the dark for slow colour 
development over several days to reduce the background levels. Cover slips were 
removed in PBS when colour development was complete and washed in PBS for 2x5 
minutes prior to mounting with glycerol-gelatin and glass cover slips. 
 
NTMT:  
100 mM Tris-HCl, pH 9.5 
100 mM  NaCl 
50 mM  MgCl2 







All solutions used for SISH were kept RNase-free by using Diethyl Pyrocarbonate 
(DEPC)-treated PBS or water in the solution preparations and the washes. All SISH 
sections were imaged with Zeiss Axio Imager Z1. 
 
2.11 Immunohistochemistry (IHC) 
Mouse sections on slides were baked on a slide warmer at 54°C for 10 minutes to 
remove any trapped moisture. Sections were de-waxed in Histo-Clear™ for 20 
minutes and rehydrated through 100%, 95%, 90%, 70% ethanol each for 5 minutes 
prior to steaming in 0.01 M sodium citrate  buffer, pH 6.0, in a water bath steamer at 
121°C for 15 minutes to retrieve the antigens on the proteins. The slides were left in 
the buffer to cool for 2-3 hours. The slides were then washed with PBS for 3x5 
minutes, incubated with 0.6% hydrogen peroxide for 20 minutes in the dark, washed 
with 0.2% Tween20 in PBS for 2x5 minutes and blocked with horse serum provided 
by the Vectastain® ABC kit (Vector Laboratories) for 30 minutes and another 30 
minutes with blocking solution (2% BSA, 5% sheep serum in PBS) at room 
temperature before overnight incubation with the primary antibody (rabbit anti-Runx2: 
Abcam 23981, 10 g/mL; rabbit anti-Runx3: Abcam 68938, 1:700; rabbit anti-HA: 
Acris Antibodies, AP09230PU-N, 1:400) diluted in blocking buffer at 4°C. 
 
Incubation with the primary antibody was continued at room temperature for an hour 
the next day. The slides were washed with 0.1% Tween20 in PBS for 3x5 minutes 
and incubated with either biotin-conjugated or HRP-conjugated secondary anti-rabbit 
antibody diluted in PBS for 2 hours at room temperature. The secondary antibody 
was washed off with 0.1% Tween20 for 3x5 mins, PBS for 10 minutes, TBS for 10 
minutes prior to colour development using BD Biosciences Pharmingen™ DAB 
substrate kit. Reaction was stopped with water when colour development reached 





slides were mounted with glycerol-gelatin. For biotin-conjugated secondary antibody, 
an extra 1-hour incubation step with the Avidin DH: Biotinylated Horseradish 
Peroxidase H complex in PBS before the 10-minute PBS wash was necessary. The 
complex-forming reagents A and B from the Vectastain® ABC kit were previously 
incubated at 1:1:100 (Reagent A: Reagent B: PBS) proportions for an hour at 4°C 
prior to application on the sections. The Vectastain® ABC kit gave less background 
and better signals when used with the anti-Runx2 and anti-Runx3 primary antibodies. 























CHAPTER 3 – RESULTS AND DISCUSSIONS 
3.1 Gene Expression Profiling of Runx2 and Runx3   
 3.1.1 Generation of Wild-type and Knockout Fluorescing Mice 
In this post-genomic era, the use of increasingly affordable high-throughput 
technologies such as microarray and RNA-sequencing has greatly propelled us 
forward in the field of functional genomics. The possibility of analysing global 
transcriptome patterns during events of differentiation (embryonic development), 
transformation (cancer) or comparing differences between two or more gene 
expression profiles (normal vs. gene mutation) permits discovery of novel links 
between genes and functions.  
 
For any causal link between a transcription factor and its targets within a network to 
be established there must be some form of loss of function experiments. More 
importantly, in order to draw an accurate relationship between the investigated factor 
and the downstream targets interpreted from the gene expression studies, sufficient 
cellular resolution of the gene activity is vital. Therefore, my initial step was to 
generate knockout gene-targeting constructs of Runx2 and Runx3 using BACs 
harboring either a relevant segment or the entire Runx2 or Runx3 gene for 
homologous recombination in mouse ESCs (v6.4). By replacing a small portion (30 
amino acids) of Runx2 and Runx3 with enhanced green fluorescence protein (EGFP) 
whereby the EGFP is driven by the endogenous Runx2 or Runx3 promoter, cells with 
disrupted Runx2 or Runx3 gene activity can be isolated and enriched for gene 
expression profiling by fluorescence-activated cell sorting (FACS).  
 
BACs containing the 5’ region of the genomic locus of Runx2 (RP24-217E4) and the 
entire genomic locus of Runx3 (RP24-118B14) were used for BAC modification using 





Neo-loxP insertion cassette was inserted in frame six amino acids after the second 
ATG at the P2 promoter of Runx2 or Runx3 in exon 3 or exon 2 respectively, deleting 
90bp of DNA sequences simultaneously (Figs. 7, 8 & 9). This enabled both major 


























Figure 7. Runx2 and Runx3 Gene Knock-out Strategy   
The EGFP followed by a loxP-flanking neomycin resistance marker (Neo) expressed under 
the control of a dual eukaryotic-prokaryotic (PGK-gb2) promoter were inserted in frame 6 
amino acids after the P2 promoter in (A) the 3
rd
 exon of the Runx2 gene and (B) the 2
nd
 exon 
of the Runx3 gene, deleting a stretch of 90 bp DNA sequences concomitantly. The insertions 
capture the two major isoforms of Runx2 and Runx3 proteins. The flanking loxP sites enable 






Figure 8. Runx2 Protein Isoforms and Illustration of Runx2 Modifications 
The EGFP-loxP-PGKgb2-Neo-loxP cassette was inserted 6 a.a. after the ATG at the P2 
promoter (MRIPV). Thirty amino acids after the insertion were deleted to ensure complete 
abrogation of the gene. 
Runt Domain 
QA Repeats 
Insertion of EGFP-loxP-PKGgb2-Neo-loxP cassette 







Figure 9. Runx3 Protein Isoforms and Illustration of Runx3 Modifications 
The EGFP-loxP-PGKgb2-Neo-loxP cassette was inserted 6 a.a. after the ATG at the P2 
promoter (MRIPV) of the Runx3 gene. Thirty amino acids after the insertion were deleted to 
ensure complete abrogation of the gene. 
 
Since Runx3 haplo-sufficient mice are normal, viable and fertile, the Runx3+/EGFP mice 
could be taken as wild-type for transcriptomic comparison against the Runx3EGFP/EGFP 
knock-out mice. However, the Runx2 haplo-sufficient mice present a skeletal 
phenotype that recapitulates the human cleidocranial dysplasia. Therefore, I had to 
establish a wild-type mouse line that expresses EGFP in the Runx2-expressing 
domains so that Runx2-expressing cells can be isolated by FACS for microarray 
comparing gene expression profiles of the wild-type, Runx2 haplo-sufficient and 
Runx2 homozygous knockout mice.  
 
In order to co-express Runx2 and EGFP as two functional discrete proteins, the 2A-
peptide (also termed as cis-acting hydrolase elements “CHYSEL”) co-expression 
strategy was employed. This co-expression approach was chosen over the internal 
ribosome entry site (IRES) method to avoid the possible reduced expression of the 
downstream gene, which is a widely-known caveat linked to the use of IRES in 
multicistronic gene expression (de Felipe, 2002; Hellen and Sarnow, 2001; Licursi et 
Runt Domain 
30 amino acids deleted 





al., 2011). The 2A-peptide sequences function in a way that prevents the peptide 
bond formation between glycine and proline at the C-terminus of the 2A-peptide (de 
Felipe et al., 2003). Hence, when placed between two genes, the ribosome appears 
to skip at the glycine-proline junction before translating the downstream gene thus 
producing two discrete proteins that are expressed under the control of the same 
promoter. The compact 23-amino-acid 2A-oligopeptide sequences derived from the 
foot-and-mouth disease virus (FMDV) (F2A) were placed upstream of the EGFP-Frt-
PGKgb2-Neo-Frt cassette. In addition, a furine protease recognition site (RAKR) 
followed by a Gly-Ser-Gly (GSG) spacer were added immediately upstream of the 
F2A sequences. The RAKR site served to trim the residual 2A peptide from the 
upstream Runx2 protein and the GSG spacer was included to enhance the ribosomal 
“skipping”. The entire RAKR-GSG-F2A-EGFP-Frt-PGKgb2-Neo-Frt cassette was 
inserted in frame at the C-terminus of Runx2 just before the stop codon using BAC 
containing the 3’ region of Runx2 genomic locus (RP23-7C18) (Fig. 10).  
 
 
Figure 10. Targeting Strategy to Generate Wild-type Mice Expressing EGFP in Runx2-
expressing Tissues  
The RAKR-GSG-F2A-EGFP-Frt-PGKgb2-Neo-Frt cassette was inserted at the C-terminus of 
Runx2 just before the stop codon. In this manner, both the Runx2 and EGFP genes, 
concatenated by the F2A-peptide sequences can be expressed as discrete proteins under the 






The targeting constructs were introduced into mouse v6.4 ESCs (129/SvJ x 
C57BL/6J). Putative positive recombinants were selected for with G418 antibiotics 
over 8-10 days and these clones were further screened by Southern blotting with 
probes external to the homology arms to identify the authentic clones that have 
undergone homologous recombination in the correct locus (Figs. 11, 12 & 13).  
 
 
Figure 11. Southern Blot Screen for Runx2
+/EGFP-Neo
 Positive Recombinant ES Cell 
Clones  
Genomic DNA extracted from ES cell colonies resistant to G418 were digested with EcoRI 
restriction enzyme and probed with a C-terminal Probe 1 (2C’Probe1; 416 bp; 50 ng/ml) just 
outside the short homology arm. True homologous recombinant ES cell clones will present an 
11.2 kb wild-type and a 3.2 kb mutant band (A; lanes 1, 3 & 4) while a false positive clone will 
only show the wild-type band (A; lane 2). These clones were confirmed by digesting with 
another restriction enzyme, DrdI and probed with N-terminal probes 1 and 2 (2N’Probe1 & 2; 
400 bp & 450 bp; 6 ng/ml each). True clones will give a 19.4 kb wild-type and a 14 kb mutant 
band (B; lanes 1, 3 & 4) and the false positive clone will show only the wild-type band (B; lane 














Figure 12. Southern Blot Screen for Runx3
+/EGFP-Neo
 Positive Recombinant ES Cell 
Clones  
Genomic DNA extracted from ES cell colonies resistant to G418 were digested with EcoRI (A) 
or KpnI (B) restriction enzyme and probed with an N-terminal Probe 1 (3N’Probe1; 801 bp; 25 
ng/ml) just outside the long homology arm. True homologous recombinant ES cell clones will 
give a 30.2 kb wild-type and an 11.1 kb mutant band (A; lanes 1, 2 & 3) when cut with EcoRI 
or a 12.7 kb mutant and a 10.9 kb wild-type band (B; lanes 1, 2 & 3) when cut with KpnI. A 
false positive clone will only show the wild-type band (A; lane 4 and B; lane 4). LHA, long 








Figure 13. Southern Blot Screen for Runx2
+/F2A-EGFP-Neo
 Positive Recombinant ES Cell 
Clones  
Genomic DNA extracted from ES cell colonies resistant to G418 were digested with StuI (A) 
or XbaI (B) restriction enzyme and probed with a C-terminal Probe 2 (2C’Probe2; 590 bp; 30 
ng/ml) just outside the short homology arm. True homologous recombinant ES cell clones will 
give a 14.5 kb wild-type and a 5.5 kb mutant band (A; lanes 1 & 2) when cut with StuI or a 6.1 
kb wild-type and a 4.6 kb mutant band (B; lanes 1 & 2) when cut with XbaI. LHA, long 
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Gene-targeting frequencies at the Runx2 and Runx3 locus. Independent ESC clones derived 
from the same targeting constructs gave identical fluorescence pattern in the F1 mouse 
embryos of the chimeric mice generated. Only one mouse line was used to pursue 








Positive ESC clones identified from the Southern blot screen were expanded for 
microinjections into 2- to 8-cell stage C57BL/6J mouse embryos (Kraus et al., 2010) 
to generate high percentage germ-line transmitting chimeras (Fig.14). The F1 
offspring of the male chimeras when mated to C57BL/6J wild-type female mice were 
heterozygous for the mutant allele. These normal Neo+ F1 mice were further mated 
to homozygous Zp3Cre or Rosa26RFlpe mice to flox out the Neo gene. For crosses 
with Zp3Cre mice, only female F2 mice heterozygous for mutant Runx2 or Runx3 and 
Zp3-Cre alleles were mated to C57BL/6J wild-type male mice to obtain Neo- and Cre- 
mutant F3 Runx2+/EGFP or Runx3+/EGFP mice. The Neo- and Cre-/Flpe- mutant mice 
were maintained by inter-crosses with C57BL/6J wild-type mice. 
 
 
Figure 14. High-percentage Runx2
+/EGFP-Neo
 Chimeras generated by ES Cell 
Microinjection 
The mice were arranged in decreasing percentage of mutant ESC contribution from left to 
right. As the agouti allele from the 129/SvJ is dominant over the allele for black coat in the 
C57BL/6J, the hybrid v6.4 ESC lines microinjected into C57BL/6J mouse embryos would give 
rise to agouti-coated mice. These mice above (four on the left) are commonly referred to as 







Tail tips from 3-week old mice or yolk sacs of embryos harvested for experiments 
were taken for genotyping by PCR. The following primers were used to determine the 
genotype: 
Table 2. Primers for Genotyping 



















809 bp 519bp 633 bp 
Mutant 
PCR band 




  A                                        B         C 
 
 
Figure 15. Mouse Genotype by PCR 
(A) Runx2WT-EGFP; wild-type allele: 809 bp, mutant allele: 1.7 kb (B) Runx2KO-EGFP; wild-
type allele: 519 bp, mutant allele: 1.3 kb (C) Runx3KO-EGFP; wild-type allele: 633 bp, mutant 
allele: 1.3 kb. Runx2
F2A-EGFP/F2A-EGFP 





The homozygous Runx2WT-F2A-EGFP mice generated were normal, viable and 
fertile even when mated to a null background (i.e. Runx2KO-EGFP) and the 
genotypes of inter-heterozygous Runx2WT-F2A-EGFP mouse crosses were 
distributed according to the expected Mendelian ratio. Heterozygous Runx2KO-
EGFP and Runx3KO-EGFP mice were viable and fertile. While homozygous 
Runx2KO-EGFP and Runx3KO-EGFP embryos up to 18.5 days post coitus (dpc) 





weaning age were identified by PCR genotyping. This was congruent with published 
literature reporting that Runx2null mice died at birth due to respiratory failure and 
Runx3null mice did not survive past a day after birth due to starvation (Komori et al., 
1997; Li et al., 2002).  
 
Mouse embryos of the various genotypes were harvested at different embryonic 
stages to assess the EGFP expression (Figs. 16-19). The fluorescence observed in 
all three mouse lines generated matched reported expression domains of Runx2 or 
Runx3 analyzed by RNA in-situ hybridizations respectively (Stricker et al., 2002). The 
expected outcome of the mouse crosses and the relevant fluorescence profiles 
indicated that the gene modifications carried out were correct and the desired wild-
type and knockout mouse lines with fluorescence in the appropriate tissues were 
successfully created. Notably, the fluorescence of the Runx2-F2A-EGFP mouse 
embryos was much brighter than that of the Runx2KO-EGFP mouse embryos 
despite the same copy number of EGFP. This discrepancy in the fluorescence 
intensity between the two mouse lines could be attributed to the 21 amino acids 
fused at the N-terminus of EGFP that is derived from the P1 promoter (MASNS) in 
the Runx2KO-EGFP mice (refer to Fig. 8), thereby possibly preventing proper folding 
of EGFP and compromising its fluorescence. However, to determine the cause of the 
difference in fluorescence, it requires further experimentation that compares the 
transcript levels between the two mouse lines. Nevertheless, the weak fluorescence 












) Wild-type Embryos  
(A) E10.5 – E14.5 Runx2
FE/FE
 mouse embryos taken under white light (top row) and ultraviolet 
light viewed through a GFP filter (bottom row) (B) E10.5 – E14.5 Runx2
FE/FE
 mouse embryos 
at higher magnification (x80 to x120 magnification). EGFP expression mirrored the 
endogenous expression of Runx2 in the mouse (Stricker et al., 2002). BA, branchial arch; FL, 
forelimb; HL, hindlimb; Pfv, primordium of follicle of vibrissae; P, phalanges; R, radius; U, 








Figure 17. Green Fluorescence of E10.5 – E13.5 Runx2
EGFP/EGFP
 Mutant Embryos 
(A) E10.5 – E13.5 Runx2
EGFP/EGFP
 mouse embryos taken under white light (top row) and 
ultraviolet light viewed through a GFP filter (bottom row). EGFP expression mirrored the 
endogenous expression of Runx2 in the mouse (Stricker et al., 2002) but at a much lower 
level. BA, branchial arch; FL, forelimb; Pfv, primordium of follicle of vibrissae; R, radius; U, 






















 mutant embryos at embryonic stages E13.5 
(A) and E14.5 (B). Pfv, primordium of follicle of vibrissae; H, humerus; R, radius; U, ulna; T, 








Figure 19. Green Fluorescence of Runx3KO-EGFP-Neo Mutant Embryos  
Fluorescence of heterozygous and homozygous Runx3KO-EGFP-Neo mutant embryos at 
embryonic stages (A) E13.5 and (B) E14.5. Fluorescence detected recapitulated the 
endogenous expression of Runx3 in the mouse (Stricker et al., 2002). Pfv, primordium of 
follicle of vibrissae; P, Phalanges; Mc, metacarpals; R, radius; U, ulna; T, tibia; F, fibula; Mt, 






3.1.2 Enrichment of Rare Population of Runx2- and/or Runx3-
expressing Cells by FACS. 
 
Ossification begins at E13.0, first osteoblasts emerge at E14.5 and bone 
mineralization commences at E15.5 in the mouse embryos. Initially, I wanted to 
unravel genes that were controlled by Runx2 and Runx3 at the onset of 
osteoblastogenesis and bone formation. In order to isolate cells that were embedded 
in the bone matrix for FACS, I tried to optimize the embryo dissociation protocol to 
break down the bone matrix of E15.5 mouse embryos into single cells by increasing 
the concentration of the collagenases and trypsin in the dissociation cocktail, adding 
varying amounts of EGTA, a calcium-chelating agent, into the dissociation buffer and 
incorporating 37°C incubation steps of varying durations. Unfortunately, the 
additional dissociation buffer components and 37°C incubations together with 
repeated manual pipetting were still inadequate to extricate the osteoblasts from the 
bone matrix of an E15.5 mouse embryo quick enough for FACS. Ultimately, 
harvesting osteoblasts from a late stage mouse embryo required manual pipetting 
and repeated incubations at 37°C for hours which were not feasible for my 
experiments.   
 
I decided to work with E14.5 embryos for both Runx2 and Runx3 gene expression 
profiles since dissociation of E14.5 embryos with the buffer optimized in the 
laboratory was still achievable.  As the Runx3 mutant mouse line was the first to be 
established, I started sorting EGFP+ and EGFP- cells from heterozygous and 
homozygous E14.5 Runx3 mutant mouse embryos. Isolation of EGFP+ cells from 
E14.5 Runx3 mutant mouse embryos was relatively easy and I could obtain sufficient 
cells for enough RNA to be put on the Illumina beadchip microarray. However, I could 
not obtain enough EGFP+ cells from heterozygous E14.5 Runx2 mutant mouse 





osteoblasts at E14.5 and these cells are more tightly adhered in the bone matrix 
whereas Runx3 is mainly expressed in the chondrocytes which are more easily 
dissociated than bone hence the Runx3 mutant mouse embryos yielded more EGFP+ 
cells after sorting. In view of that, I had to work with E13.5 Runx2 mutant embryos 
instead. 
 
Relevant skeletal tissues expressing EGFP (jaw, limbs, ribs and vertebral column) 
from E13.5 Runx2+/FE, Runx2FE/FE, Runx2+/EGFP and Runx2EGFP/EGFP mouse embryos 
as well as E14.5 Runx3+/EGFP and Runx3EGFP/EGFP mouse embryos were dissected out 
prior to dissociation and sorting with the fluorescence-activated cell sorter (FACSAria 
II). CD-1 wild-type embryos at the same developmental stage were dissected and 
dissociated in the same manner as the fluorescent embryos and used for gating the 
fluorescence. The genotype of each embryo was verified by PCR using the yolk 
sacs. The tissues were dissociated into single cells by manually pipetting up and 
down in the dissociation buffer and filtered through the 100 µm and 40 µm filter 
baskets to yield the first filtrate. Bits of hard bony tissue retained by the filter baskets 
were retrieved and subjected to repeated dissociation and filtration resulting in the 
subsequent filtrates. Figure 20 shows the FACS profiles and percentage of EGFP+ 
cells corresponding to the different genotypes. As expected, there was a higher 
percentage of EGFP+ cells found in the later filtrates compared to the first filtrate 
because Runx2- and Runx3-expressing cells were likely to be embeded in the bony 
tissues retained in the filter baskets. A much higher percentage of EGFP+ cells were 
also found in Runx2+/FE and Runx2FE/FE mouse embryos  (ranging from 6.3% - 14.7%) 
compared to Runx2+/EGFP and Runx2EGFP/EGFP mouse embryos (ranging from <0.1% - 
2.4%) (Fig. 20). It was not surprising as the fluorescence in the Runx2+/FE and 
Runx2FE/FE mouse embryos were clearly higher than that in the Runx2+/EGFP and 
Runx2EGFP/EGFP mouse embryos (Figs. 16-18). Cells collected in 20% FBS/Leibovitz 









Figure 20. FACS Profiles of Runx2 and Runx3 Wild-type and Mutant Embryos  
CD-1 wild-type mouse embryos were used to gate the fluorescence. Percentage of GFP
+
 




3.1.3 Low RNA input amplification alternatives: Comparing two 
RNA amplification kits  
One major challenge in exploiting microarray technology to compare transcriptomes 
is the large amount (1.5 g) of labeled antisense RNA (aRNA) or cDNA required for 
hybridization on the high-density arrays. To overcome the obstacle of getting 
sufficient RNA material for hybridization, there is an assortment of RNA amplification 
kits requiring different amounts of starting RNA as input (ranging from 500 pg to 
50 ng) commercially available to boost the amount of RNA obtained. These kits 
generally amplify RNA in a linear and 3’-initiated manner utilizing polyA primers. 
Considering that typical mammalian cells yield an average of 1 pg of total RNA per 





with the standard Illumina® TotalPrep RNA amplification kit that requires 50 ng of 
starting RNA as input. This would translate to 200,000 EGFP+ cells to be collected for 
4 biological replicates per genotype. With only 200 to 3,000 cells collected in an hour 
from each Runx2+/EGFP or Runx3+/EGFP mouse embryo, it would take me too long to 
acquire enough EGFP+ cells for microarray. Therefore, I needed to find low RNA 
input amplification alternatives. As a pilot study, I compared two low input RNA 
amplification kits – TargetAmpTM 2-round Biotin-aRNA Amplification kit 3.0 and 
NuGEN® Ovation RNA Amplification System V2, using 1 ng of RNA extracted from 
EGFP+ and EGFP- cells isolated from E13.5 Runx2+/EGFP mouse embryos as starting 
material for both kits (Table 3).  
 
Table 3. Comparison of Two RNA Amplification Kits 
 TargetAmp
TM
  2-round Biotin-
aRNA Amplification kit 3.0 
NuGen
®
 Ovation RNA 
Amplification System V2 
Starting Amount 50-500pg of RNA (Max. 1ng) 5-50ng of RNA. (Min. 1ng) 




Biotin Labeling  RNA amplified and labeled 
simultaneously to improve RNA 
yield. 
Amplified cDNA labeled in 2 




2 days 0.5 days 
 
 
Gene expression analysis was performed using the GeneSpring GX™ 11.0 software 
comparing EGFP+ vs. EGFP- cells to find enrichment of relevant genes in the EGFP+ 
fraction. Figure 21 clearly showed that there were more genes identified to be 
differentially expressed between the EGFP+ and EGFP- fractions with the NuGEN® 
RNA amplification kit (9,830 genes) contrasted with the TargetAmp™ RNA 





sensitive and is more able to amplify transcripts that are present at very low levels. 
More importantly, the Runx2 transcript was found to be 39-fold enriched in the 
EGFP+ compared to the EGFP- fraction when the NuGEN® RNA amplification kit was 
used (data not shown). However, Runx2 transcript was not found to be enriched at all 
in the EGFP+ fraction when the TargetAmp™ RNA amplification kit was used to 
amplify the same starting material.  
 
The genes enriched in both the EGFP+ fractions were further analyzed using an 
online functional annotation tool, DAVID Bioinformatics Resources 6.7 (NIAID/NIH) 
(Huang da et al., 2009a; Huang da et al., 2009b). GO terms were plotted against the 
enrichment scores for each GO annotation cluster derived from performing functional 
annotation clustering of the genes with DAVID (Figs. 21B & C). GO terms that were 
given enrichment scores higher than 1.3 (indicated by the red dotted line Fig. 21B & 
C) were considered significantly enriched. Genes enriched in the EGFP+ fraction 
amplified by the NuGEN® kit were clustered as more precise skeletal annotations 
such as “bone and cartilage development” and “endochondral ossification” with 
enrichment scores of 2.15 and 1.51 respectively while those amplified by the 
TargetAmp™ were clustered as “bone development, osteoblast differentiation and 
ossification” with an enrichment score of only 1.51 (Figs. 21B & C). Although both the 
kits were able to amplify the starting RNA in a way that essentially preserves the 
original expression profile indicated by the relevant functional annotation clusters 
being above the significant threshold, the results presented in Figure 21 on the whole 
suggest that NuGEN® is more sensitive, produce less data noise and is less tedious 
to perform as the entire amplification and labeling procedure requires only 0.5 day 
compared to 2 days for TargetAmp™. For these reasons, I used the NuGEN® RNA 
amplification kits for all the subsequent RNA amplifications performed prior to the 
microarray studies. The results showing a 39-fold enrichment of Runx2 transcripts as 





compared to the EGFP- cells also demonstrated that the rare population of Runx2-




   Figure 21. Comparing Results Produced by NuGEN® and TargetAmp™                        
RNA Amplification Kits 





 cells yielded by either the NuGEN
®
 or the TargetAmp™ RNA amplification kits. (B and 
C) Each GO term associated with the genes enriched in the EGFP
+
 cells was plotted against 
the enrichment score derived from performing functional annotation clustering of the genes on 
DAVID. The red dotted lines indicate the recommended cut-off point of 1.3. GO terms with 
enrichment scores above 1.3 indicate that genes with these functions are significantly 








After determining the RNA amplification kit to use and establishing that the FACS 
was able to achieve a good level of enrichment for the cell population of interest, total 
RNA was extracted, using the Trizol/Chloroform extraction method followed by a 
cleanup with the Qiagen® RNEasy® micro kit, from all the EGFP+ cells isolated from 
Runx2+/FE, Runx2+/EGFP, Runx2EGFP/EGFP, Runx3+/EGFP and Runx3EGFP/EGFP mouse 
embryos. This was followed by quantification with Ribogreen QuantItTM fluorescent 
assay. RNA integrity was assessed using Agilent RNA 6000 Pico kit and analyzed 
with Agilent Bioanalyzer.  Figures 22 & 23 contain the images of microcapillary 
electrophoretic separation of total RNA, extracted from EGFP+ cells isolated from  
Runx2+/FE, Runx2+/EGFP, Runx2EGFP/EGFP, Runx3+/EGFP and Runx3EGFP/EGFP mouse 
embryos, with the accompanying electropherograms on the right. The two prominent 
bands and peaks on the gel image and the electropherogram respectively represent 
the 28S and 18S ribosomal RNA (rRNA) and the Agilent Bioanalyzer uses the ratio of 
28S:18S bands to assign a RNA integrity number (RIN) to each of the RNA samples. 
The RIN value of 10 indicates perfectly intact RNA while a value of 1 indicates 
completely degraded RNA (Schroeder et al., 2006). The RIN of the RNA samples 
were generally above 8 except for some which were below 5 as shown in Figures 22 
& 23 and as summarized in Table 4. Currently, there is no consensus on what is an 
acceptable range for the various RNA applications. Even though the RNA extracted 
from the EGFP+ cells of the Runx2+/EGFP samples had rather low RIN values and the 
RNA gel electrophoresis image did not match the standard ones, these samples 
were still used for microarray as it was extremely difficult to obtain sufficient EGFP+ 
cells from this genotype due to the low fluorescence level of the embryos as evident 
in Figure 18. Besides, the NuGEN® Ovation RNA Amplification System V2 kit claimed 
to be able to amplify poor quality and partially degraded RNA. 
 
Therefore, cDNA synthesis and amplification were performed with 1 ng of total RNA 





Three micrograms of the amplified cDNA were biotin-labeled and 1.5 g of the 
labeled cDNA was applied onto the Illumina WG-6 Mouse Expression Beadchips for 
overnight hybridization. The beadchips were washed, blocked and hybridization 
signals were detected with Cy3-conjugated strepavidin (SA-Cy3) and scanned with 
























Figure 22. RNA Profiles of Runx2-EGFP Cells on Agilent Bioanalyzer Pico RNA Chip   
Total RNA extracted from EGFP
+





   and (C) Runx2
EGFP/EGFP
 mouse embryos were ran on a RNA Pico Chip using an 
Agilent Bioanalyzer. RNA from EGFP
-
 cells of Runx2
+/EGFP
 were also checked for its RNA 
integrity. Left panel: Gel electrophoresis RNA profile. Right panel: Electropherogram with 
calculated RNA integrity number (RIN) to indicate the integrity of the RNA. The two prominent 






Figure 23. RNA Profiles of Runx3-EGFP Cells on Agilent Bioanalyzer Pico RNA Chip   
Total RNA extracted from EGFP
+
 cells sorted out from (A) Runx3
+/EGFP
 and (B) Runx3
EGFP/EGFP
 
mouse embryos were ran on a RNA Pico Chip using an Agilent Bioanalyzer. Left panel: Gel 
electrophoresis RNA profile. Right panel: Electropherogram with calculated RNA integrity 
number (RIN) to indicate the integrity of the RNA. The two prominent bands and peaks are 



























     Table 4. Quantity and Quality of RNA extracted from EGFP
+














# 1 59,050 30.30 9.0 
# 2 55,746 29.33 9.3 
# 3 49,412 16.82 8.2 




# 1 5,398 2.67 2.5 
# 2 5,344 0.82 2.4 
# 3 5,629 2.69 2.5 
# 4 5,435 1.45 2.5 




# 1 28,298 14.45 8.8 
# 2 23,425 13.77 8.9 
# 3 26,189 17.59 8.7 
# 4 30,507 24.34 8.4 




# 1 20,536 6.92 9.8 
# 2 1,394 3.43 5.8 
# 3 1,345 1.06 1.8 




# 1 35,207 30.60 9.6 
# 2 10,999 8.46 9.0 
# 3 13,075 17.30 9.3 
# 4 13,610 10.60 9.6 














3.1.4 Runx2 and Runx3 Microarray Data Analysis 
 
 
Figure 24. A Schematic Diagram of the Genotypes and the Number of Biological 
Replicates used for Microarray  
Amplified and biotin-labelled RNA extracted from EGFP
+
 cells of the various genotypes was 
loaded onto the Illumina Mouse WG-6 Beadarray chips. Although not clearly represented in 
this diagram, the biological replicates were randomized on the chips to overcome possible 
batch effects of the beadchips. 
 
 
Raw image data files obtained from the Illumina® BeadArray™ Reader were 
downloaded into BeadStudio software to extract the probe lists coupled with the raw 
hybridization intensity values which were then exported as GeneSpring GX™ format 
files. Gene expression analyses were accomplished using the GeneSpring GX™ 11.0 
software. Statistical tests such as the Analysis of Variance (ANOVA) and the 
unpaired Student’s t-test for comparing Runx2+/FE(Runx2+/+) vs. Runx2+/EGFP(Runx2+/-) 
vs. Runx2EGFP/EGFP(Runx2-/-) and Runx3+/EGFP(Runx3+/-) vs. Runx3EGFP/EGFP(Runx3-/-) 
respectively were used to identify differentially expressing genes. All data were put 
through Benjamini-Hochberg FDR multiple testing corrections. Asymptotic p-values 
were computed and the significance threshold was set at p-value < 0.05 and fold 
change > 1.5. Figure 25 shows the number of genes differentially expressed in the 





significant Runx3 target genes identified when comparing Runx3+/- vs. Runx3-/-. It has 
been observed in the laboratory that there is a strong correlation between overt 
phenotypes and large changes in gene expressions when a gene-of-interest is 
deleted. Hence, the small Runx3 target gene list could be due to the fact that there is 
a lack of an overt skeletal phenotype in Runx3-/-. In all three Runx2 genotype 
comparisons, there were more down-regulated genes in the genotype that had more 
Runx2 allele knocked out. This could suggest that Runx2 acts as an activator more 
than a suppressor. In contrast, there were more up-regulated genes in Runx3-/- 
compared to Runx3+/- which likely implied that Runx3 serves as a suppressor more 
than an activator. This implication is supported by earlier reports that Runx3 has 
tumour suppressor roles in several cancers such as breast and gastric cancers (Li et 
al., 2002).  
 
 
Figure 25. Number of Differentially Expressed Runx2 and Runx3 Target Genes 
Bar charts summarizing the number of differentially expressed genes identified in the 
respective comparisons. Data were analyzed with GeneSpring GX™ 11.0 applying ANOVA 
test and unpaired Student’s t-test for Runx2 and Runx3 comparisons respectively with a fold-
change cut-off at >1.5 and p-value < 0.05. Down-regulated and up-regulated genes are genes 







The up- and down-regulated Runx2 putative target genes identified were analyzed 
with DAVID to investigate if they were relevant. Figures 26-28 reveal that genes 
giving rise to extracellular matrix proteins of the skeleton such as glycoproteins, 
collagens and fibronectins were highly enriched mainly in the down-regulated gene 
lists (3- to 22-fold enrichment in the Runx2 knockout). Genes coding for proteins 
related to calcium-binding, glycosaminoglycan-binding, calmodulin-binding and 
collagen catabolic process were also significantly enriched in the down-regulated 
gene lists. Molecules involved in the Wnt signaling pathway were slightly enriched in 
the up-regulated gene list of Runx2+/- vs. Runx2-/- (Fig. 28). Genes particularly 
associated with skeletal and bone development, ossification, embryonic limb 
development, osteoblast differentiation, digit morphogenesis and bone mineralization 
were also enriched significantly (1.3 < enrichment score < 5.44) in both the up- and 
down-regulated gene lists. The observation that genes encoding skeletal extracellular 
matrix proteins were more highly enriched than genes specific to skeletal 
development could either indicate that Runx2 directly regulate these numerous 
structural genes leading to skeletal formation or the effect of knocking out Runx2 by 
this developmental stage has mostly shifted to these secondary targets since Runx2 
expression had already begun several days before the embryos were harvested at 
E13.5 for microarray. The answer to this would require elucidation of Runx2 binding 














Functional annotation clusters associated with the Runx2 target genes that were generated 
by DAVID were ranked according to their given enrichment scores. (A) Down-regulated and 
(B) Up-regulated genes in Runx2
-/-
 compared to Runx2
+/+
. The red dotted lines indicate the 
recommended cut-off point of 1.3. GO terms with enrichment scores above 1.3 indicate that 
genes with these functions are significantly enriched. The red boxes highlight relevant skeletal 















Functional annotation clusters associated with the Runx2 target genes that were generated 
by DAVID were ranked according to their given enrichment scores. (A) Down-regulated and 
(B) Up-regulated genes in Runx2
+/-
 compared to Runx2
+/+
. The red dotted lines indicate the 
recommended cut-off point of 1.3. GO terms with enrichment scores above 1.3 indicate that 
genes with these functions are significantly enriched. The red boxes highlight relevant skeletal 














Functional annotation clusters associated with the Runx2 target genes that were generated 
by DAVID were ranked according to their given enrichment scores. (A) Down-regulated and 
(B) Up-regulated genes in Runx2
-/-
 compared to Runx2
+/-
. The red dotted lines indicate the 
recommended cut-off point of 1.3. GO terms with enrichment scores above 1.3 indicate that 
genes with these functions are significantly enriched. The red boxes highlight relevant skeletal 









To further examine how the Runx2 gene lists relate to one another, they were 
compared using a Venn diagram tool, Venny. Figure 29 shows 82.7% (8,020 out of 
9,692 genes) overlap between the Runx2+/+ vs. Runx2-/- and the Runx2+/+ vs. Runx2+/- 
gene lists while 24.5% (2,396 out of 9,765 genes) of the total number of differentially 
expressed genes were found in all three gene lists. When the genes in the core 
overlap were analyzed with DAVID, GO terms specific to embryonic skeletal 
development, ossification and osteoblast differentiation were enriched above the 




Figure 29. A Venn Diagram of Runx2 Target Genes and Enriched GO Terms Associated 
with the Core Overlap 
Left: Lists of significant differentially expressed Runx2 target genes (p-value < 0.05; fold 
change >1.5) were compared using the interactive Venn diagram tool, VENNY. Venn diagram 
was re-drawn to proportions. Right: Functional annotation clusters associated with the core 
overlap of the Runx2 target genes were generated by DAVID and ranked according to the 
given enrichment scores. The red dotted lines indicate the recommended cut-off point of 1.3. 
GO terms with enrichment scores above 1.3 indicate that genes with these functions are 








To ensure that the Runx2 microarray data obtained were congruent with what had 
been reported in the literature, the Runx2 target genes were compared with 
previously published in vivo mouse Runx2 microarray data by (Vaes et al., 2006) and 
(Hecht et al., 2007). Both studies used E14.5 mouse embryos and Affymetrix 
GeneChips. The only differences between the two studies are that Vaes et al (2006) 
compared the forelimbs, hindlimbs and calvariae of wild-type and Runx2-/- mice and 
analyzed both up- and down-regulated target genes in the Runx2-/- while Hecht et al 
(2007) compared only the humeri of wild-type and Runx2-/- mice and identified only 
the positively-regulated targets in the wild-type.  
 
The Venn diagram in Figure 30 shows a good overlap between each of the previous 
independently reported Runx2 microarray studies and my data. This gave me 
confidence in my own data. The genes common in all three studies are mostly genes 
with known skeletal functions and/or are known direct targets of Runx2 (Ibsp and 
Spp1). Interestingly, there was a better overlap between my Runx2 target gene list 
and each of the two independent studies than the two studies had with each other 
even though both groups performed their microarrays with E14.5 mouse embryos 
and with the same Affymetrix GeneChips while my microarray was performed using 
E13.5 mouse embryos and Illumina WG-6 BeadChips. My Runx2 target gene list was 
also more extensive, consisting of 9,765 up- and down-regulated genes while Hecht 
et al (2007) identified only 69 positively-regulated Runx2 targets. Vaes et al (2006) 
originally found 1,277, 606 and 492 differentially modulated transcripts in the 
calvariae, forelimbs and hindlimbs respectively but assessed only the top 500 most 
significant transcripts based on the p-values for each tissue type and reported only 







Common in all 
three studies 
Common in Hecht et al 
(2007) and my study: 
Common in Vaes et al (2006)                                   
and my study: 
Ibsp Smpd3 Apcdd1 Matn4 Tgfbi Cxcl4 
Spp1 Thy1 Phex Col9a1 Tagln2 Gata2 
Satb2 Fabp3 Ptprz1 Runx2 Sox9 Ghr 
Akp2 S100a4 Hpgd Ppp2r5d 2900010M23Rik Lyzs 
Mmp9 Npnt Epha3 Ndufb10 Hbb-y Ptn 
Cfh Tcf7 Mef2c Fdps Mif Abca1 
Hck Ihh Rasa3 Mfap5 Jub Ebf3 
Lox Ccl9 Chst1 Dlk1 Col14a1 Gpm6b 
 
Wnt5a Tmem119 Figf Kitl Ogn 
 
Mmp13 Gpx3 Sdpr Dpt Cxcl12 
 
Atp6v0d2 Capg Cpxm2 Apoe Rhoj 
 
Cdo1 Pthr1 Trim2 Fap Igf1 
 
Cnn2 Gpc1 Abcf1 Mrc1 Ablim1 
 
Ctsk Scd1 Hbb-bh1 Sepp1 Bgn 
  
Anxa1 Matn3 Matn2 Ppap2b 
   
Matn1 Cd36 Pdgfra 
   
2310039H08Rik Dcn Spnb2 
   
Slc16a3 Nova1 D0H4S114 
   
Hba-x Igfbp7 Sparc 
 
Figure 30. Comparison between My Runx2 Target Genes and Two Published Runx2 
Microarray Studies  
Top: A Venn diagram comparing my list of Runx2 target genes and previously published 
Runx2 microarray analysis by Vaes et al (2006) and Hecht et al (2007). Bottom: Lists of 
genes found in the respective overlapping regions. Genes in bold have some form of known 







Not every cell in the entire limb or even humeri expresses Runx2; therefore, the 
effect of knocking out Runx2 might be diluted out by transcripts in the other non 
Runx2-expressing cells within the same organ. As my microarray study utilized a 
pool of cells specifically enriched for Runx2-expressing cells obtained by FACS 
unlike the other two studies which used whole organs, I hypothesized that my data is 
more accurate and that the Runx2 target genes that could not be identified by the 
other two studies would be picked up by my microarray analysis. Hence, it would be 
interesting to examine the list of genes from my Runx2 microarray analysis that were 
not found by Vaes et al (2006) and Hecht et al (2007) to identify novel Runx2 targets 
that have not been previously discovered. In order to ensure that the Runx2 targets 
uncovered were genuine, validation of a few top Runx2 targets were performed by 
RNA section in situ hybridization which will be discussed in the next segment. 
 
Akin to the functional annotation cluster analysis performed with the Runx2 target 
genes using DAVID, the Runx3 target genes were clustered to determine significantly 
enriched GO terms. However, the number of Runx3 target genes was too small and 
the enrichment score was below the significant level (data not shown). Currently, 
there are no Runx3 microarray data performed in the context of skeletal development 
reported for comparison. Thus, all 24 Runx3 target genes found in my microarray can 
be considered as novel Runx3 targets (Table 5). Genes with lower expression in the 
Runx3-/- are listed as down-regulated genes and vice versa. The genes in bold 
indicate that they were also found in the Runx2 target list and of the six Runx3 down-
regulated genes in bold, three (Ifi204, Clec7a and Lgmn) were up-regulated and two 
(Bcl2a1c and Use1) were down-regulated in Runx2-/- and Runx2+/- compared to 
Runx2+/+. Adam15 was found in both up- and down-regulated lists of Runx2. Five out 
of sixteen Runx3 up-regulated genes were also found in the Runx2 target gene lists. 





while Satb2 was regulated in the same direction. Pgm5 was found in both the up- 
and down-regulated lists of Runx2.  
 





Down-regulated Fold Change Up-regulated Fold Change 
Bcl2a1c 26.53 Satb2 126.92 
Ifi204 20.43 B230112C05Rik 42.42 
Adam15 14.99 Myocd 33.58 
Clec7a 13.30 Capn10 27.08 
1700003M02Rik 10.01 E230017H14Rik 20.96 
Lgmn 7.30 Ptpn20 16.40 
Ppfia3 7.00 Lpar2 15.99 
Use1 6.07 Ddr1 15.38 
  Gng5 14.55 
  Cdadc1 13.52 
  Pps 10.04 
  Pgm5 8.81 
  C230064E07Rik 4.80 
  G3bp2 3.01 
  LOC433261 2.04 
  Zfp383 1.88 





. Down-regulated and up-regulated genes were genes with 
lower or higher expression in Runx3
-/-
 respectively compared to Runx3
+/-
. The genes in bold 
were also found in the Runx2 target gene list. 
 
 
Interferon activated gene 204 (Ifi204) protein, also known as p204, associates with 
Runx2 as a co-activator of osteoblast differentiation (Liu et al., 2005a) and pRB was 
found to link Ifi204 and Runx2 in a ternary complex at the promoters of alkaline 
phosphatase and osteocalcin to promote osteogenesis (Luan et al., 2007). The 5’ cis-
regulatory elements of Ifi204 were also found to contain Runx2 and Sox5 binding 
sites. The binding of Runx2 at the promoter of Ifi204 enhanced its expression and as 
a result induced chondrocyte hypertrophy in chondrocytic cell lines while Sox5 
inhibited the expression of Ifi204 (Zhang et al., 2008a). Thus, Ifi204 had been 
demonstrated in literature to cooperate with Runx2 primarily to regulate 





shown. From the microarray data, it appears that Runx3 positively-regulates Ifi204 
and could be up-regulating it in the Runx2-/- to compensate the loss of Runx2. Ifi204 
might be the compensatory link between Runx2 and Runx3 in the skeletal network.  
 
Satb2 was found to be a key node in regulating skeletal development. Satb2-/- mice 
exhibit craniofacial abnormalities resembling a cleft palate condition in humans with a 
translocation in the SATB2 gene (Britanova et al., 2006; Dobreva et al., 2006). Satb2 
was found to repress Hoxa2 to release the inhibition on bone formation and directly 
interacts with and promotes the activity of Runx2 and ATF4 to drive osteoblast 
differentiation (Dobreva et al., 2006). It is not established if either Runx2 or Runx3 
regulates Satb2 as a negative feedback loop. From the microarray data, both Runx2 
and/or Runx3 could be down-regulating Satb2 to prevent an early onset of 
osteoblastogenesis that might lead to ectopic bone formation and limb defects if the 
osteoblast differentiation function of Runx2 were to be turned on too early before 
chondrocyte maturation could take place (Maeno et al., 2011).  
 
Adam15 was suggested to have a homeostatic role in cartilage remodeling (Bohm et 
al., 2005). Adam15 can be inferred to be positively regulated by Runx3 in cartilage 
development. Clec7a, Lgmn, Bcl2a1c, Use1, Lpar2, Ddr1, Zfp383 and Pgm5 have no 
known skeletal functions as yet and could be potential novel targets of Runx3 in 
skeletogenesis and newly discovered factors contributing to skeletal development. 
 
As mentioned earlier, the small Runx3 gene list is likely due to no overt skeletal 
phenotype in the Runx3-/- other than a slight delay in chondrocyte maturation. To 
reiterate, Runx3 is postulated to play a role in chondrocyte maturation during 
endochondral ossification that can be mostly compensated by Runx2 based on the 
study by (Yoshida et al., 2004) who reported that Runx2-/-Runx3-/- mice had a more 





more impeded in Runx2-/- than in Runx3-/-. Therefore, it is not surprising that there 
were not many differentially regulated genes uncovered from comparing Runx3-/- to 
Runx3+/- since the more dominant Runx member in skeletal development, Runx2, 
was likely to regulate most of Runx3 downstream target genes to compensate for the 
loss of Runx3. Henceforward, to elucidate the entire Runx3 targets involved in 
skeletogenesis, the transcriptional profiling of Runx2-/-Runx3-/- had to be performed 
and compared to that of Runx2-/-.  
 
3.1.5 Validation of Runx2 Targets by SISH 
Four top Runx2 targets (Smpd3, Panx3, Ifitm5 and a novel 1200009I06Rik) from the 
Runx2+/+ vs. Runx2-/- list were validated by RNA in situ hybridizations on E13.5 
mouse embryo sections. Figure 31 shows sagittal sections of the face, ribs, hindlimb 
and vertebral column. Smpd3 expressions were seen in the mandible, maxilla and rib 
chondrocytes of the Runx2+/+ and Runx2+/- mouse embryos. Weak signals were also 
detected in the femur and tibia of the Runx2+/+ and Runx2+/- mouse embryos. The 
signals were completely abolished in the jaws, ribs and hindlimb of the Runx2-/- 
mouse embryo. Likewise, Panx3 transcripts were detected in the clavicle, Meckel’s 
cartilage, mandible, maxilla, rib chondrocytes and weakly in the hindlimb of the 
Runx2+/+ and Runx2+/- mouse embryos but the expressions diminished drastically in 
the Runx2-/- embryos. Strong expressions of Ifitm5 were found in the mandible and 
the basisphenoid bone of the Runx2+/+ mouse embryo but not in the Runx2+/- and   
Runx2-/- mouse embryos. No expression of Ifitm5 was found in the vertebral column 
and hindlimbs. Lastly, the expressions of a novel Riken gene 1200009I06Rik were 
detected in the facial muscle, mandible, maxilla, intercostal muscles and rib 
perichondrium and chondrocytes of the Runx2+/+ and Runx2+/- mouse embryos. In the 
hindlimb of the Runx2+/+ and Runx2+/- mouse embryos, 1200009I06Rik was detected 
in the perichondrium and maturing chondrocytes of the tibia, perichondrium of the 





the 1200009I06Rik transcripts were visibly reduced in the facial muscle and the 
intercostal muscles of the Runx2-/- mouse embryos and expressions were obliterated 
in the mandible, maxilla, ribs, and hindlimbs of the Runx2-/- mouse embryos.  
 
 
 Figure 31. Validation of Runx2 Target Genes by RNA Section In Situ Hybridizations 
In situ hybridizations of antisense Smpd3, Panx3, Ifitm5 and a novel Riken gene 







sections. The red arrows highlight the RNA expression or the missing expression in the 
Runx2
-/-






Sphingomyelin phosphodiesterase 3, neutral (Smpd3), also known as Smase2, is a 
member of the phosphodiesterase gene family of three: Smpd1, Smpd2 and Smpd3. 
Smpd3 was originally identified as a brain-specific neutral sphingomyelinase which 
hydrolyzes sphingomyelin to ceramide and phosphorylcholine (Hofmann et al., 2000; 
Marchesini et al., 2003) until the year 2005 when Smpd3 was first discovered to 
cause osteogenesis and dentinogenesis imperfecta in mice upon its deletion (Aubin 
et al., 2005). Two years later, the Smpd3-/- mouse was again characterized as having 
a dwarf and chondrodysplasia phenotype that reflected common human 
achondrodysplasia (Stoffel et al., 2007). Smpd3 was further demonstrated to respond 
positively to Runx2 expression in an in vitro experiment and that Runx2 bound to the 
promoter of Smpd3 in an electrophoretic mobility shift assay (EMSA) suggesting that 
Runx2 might regulate Smpd3 directly during skeletal development (Chae et al., 
2009). Hence, Smpd3 found to be positively regulated by Runx2 in my Runx2 
expression profiling and its expression in the skeletal elements which was obliterated 
in the Runx2-/- mouse embryos as illustrated by the RNA in situ hybridizations 
concurred with previous reports. Smpd3 is likely to have a role in skeletogenesis via 
Runx2 direct regulation although it still has to be shown if Runx2 regulates Smpd3 
directly in vivo. 
 
Panx3, a member of the pannexin family which encodes for a class of gap junction 
proteins, was recently found to be highly expressed in the craniofacial flat bones and 
the long bones of the mouse axial and appendicular skeleton. It was detected 
specifically in the hypertrophic chondrocytes, perichondrium and osteoblasts (Bond 
et al., 2011; Iwamoto et al., 2010). Panx3 was demonstrated to regulate ATP/cAMP 
levels to promote chondrocyte differentiation  in one study (Iwamoto et al., 2010) and 
shown to function as endoplasmic reticulum calcium channels, hemichannels and 
gap junctions to promote osteoblast differentiation in another study (Ishikawa et al., 





Runx2 was able to bind at the promoter of the Panx3 between -275 and -283 bases 
to drive expression of Panx3 thus putting forward the notion that Panx3 is a direct 
target of Runx2 during bone development (Bond et al., 2011). The finding of Panx3 
transcripts greatly reduced in the Runx2-/- mouse embryos as revealed by both the 
microarray and RNA in situ hybridization in my experiments further supports the 
notion that Panx3 might indeed be regulated by Runx2 and whether directly or not, it 
has yet to be determined in vivo.  
 
Interferon-inducible transmembrane protein 5 (Ifitm5), also known as Bril, encodes 
for a small membrane protein that is highly expressed in osteoblasts (Moffatt et al., 
2008). Its peak expression coincides with early bone mineralization during osteoblast 
maturation and knocking out both alleles of Ifitm5 in the mouse resulted in smaller 
long bones. However, the phenotype became less severe in the adult mice possibly 
due to compensatory mechanisms by other factors or members of the interferon-
inducible transmembrane protein family (Hanagata et al., 2010). There are no reports 
linking Runx2 and Ifitm5 in the regulation of bone formation so far. This could be a 
novel target of Runx2 especially in the craniofacial bone development as suggested 
by the RNA in situ hybridization results.  
 
1200009I06Rik is a protein coding gene located on mouse chromosome 12. 
Currently, there is not much information on this gene. The expression of this gene is 
15-fold decreased in the Runx2-/- mouse embryo when compared to the Runx2+/- 
mouse embryo in the Runx2 microarray and its significantly high transcript levels in 
both the muscles and skeletal elements suggest that this novel gene has a role in the 
development of both organs. It is potentially a downstream target of Runx2 and is 
likely to be involved in Runx2-modulated bone development as only its expressions 






3.1.6 Transcriptional Profiling of Runx2-/-Runx3-/- Mouse Embryos 
Runx2+/EGFP (Runx2+/-) and Runx3+/EGFP (Runx3+/-) mice were crossed to produce 
Runx2+/EGFPRunx3+/EGFP (Runx2+/-Runx3+/-) mice, which were grossly normal and 
fertile. These double heterozygotes were subsequently inter-mated to yield 
Runx2EGFP/EGFPRunx3EGFP/EGFP (Runx2-/-Runx3-/-) mouse embryos at the Mendelian 
ratio of 1:16 (Fig. 32). Only the single and the double heterozygote mice survived and 
were normal in appearance. There were no live births of Runx2-/-Runx3+/-, Runx2+/-
Runx3-/- and Runx2-/-Runx3-/- pups but E13.5 Runx2-/-Runx3+/-, Runx2+/-Runx3-/- and 
Runx2-/- Runx3-/- mouse embryos could still be obtained.  
 
 


















 mice that 




 mouse embryos were produced below the 
expected Mendelian inheritance ratio of 1:16. 
 
EGFP+ cells from enriched tissues (jaw, limbs and ribs) of the brightest E13.5 mouse 
embryos produced by inter-mating Runx2+/-Runx3+/- mice were isolated by FACS and 
yolk sacs were kept for PCR genotyping to determine the genotype of the embryos 
dissociated and sorted. After 6 months of sorting, only 2 out of 70 embryos sorted 





double heterozygote crosses (data not shown), the Runx2-/-Runx3-/- mouse embryos 
were observed to be produced at less than the expected Mendelian inheritance ratio 
of 1:16 indicating that many Runx2-/-Runx3-/- mouse embryos die even before E13.5. 
Owing to time constraints, RNA was extracted (Fig. 33), amplified with the NuGEN® 
Ovation RNA Amplification System V2 kit and microarray was proceeded with the two 
Runx2-/-Runx3-/- mouse embryos obtained. Technical replicates of the Runx2-/-  






















# 1 9,110 12.0 9.0 
# 2 19,051 21.7 8.6 
 
Figure 33. Profiles of RNA from EGFP
+




 mouse embryos  
Total RNA extracted from EGFP
+









) mouse embryos were ran on a RNA Pico Chip using an Agilent 
Bioanalyzer. Top left panel: Gel electrophoresis RNA profile. Top right panel: 
Electropherogram with calculated RNA integrity number (RIN) to indicate the integrity of the 
RNA. The two prominent bands and peaks are 28S and 18S rRNA. Bottom: A table showing 
the number of EGFP
+
 cells, quantity and quality of RNA obtained per embryo. 
 
In order to circumvent the problem of not being able to pick out Runx3-regulated 
genes due to the likely compensation by Runx2 during chondrocyte maturation, it 





the Runx2-/- profile, Runx3 targets could be elucidated. Hence, the raw microarray 
profile for Runx2-/-Runx3-/- was extracted using BeadStudio software and exported as 
GeneSpring GX™ format files for differential gene expression analysis by comparing 
Runx2-/-Runx3-/- against the previous Runx2-/- microarray data using GeneSpring 
GX™ 11.0 software. In addition, Runx2-/-Runx3-/- was compared against the previous 
Runx3-/- microarray data to investigate if there were new Runx2 target genes that 
were not identified in the Runx2+/+ vs. Runx2+/- vs. Runx2-/- comparisons owing to 
compensation by Runx3. Unpaired Student’s t-test and a volcano plot with 
significance threshold set at p-value < 0.05 and fold change > 2 was applied. All data 
were put through Benjamini-Hochberg FDR multiple testing corrections.  
 
Figure 34 shows the number of differentially expressed genes identified from 
comparing Runx2-/-Runx3-/- vs. Runx2-/- and Runx2-/-Runx3-/- vs. Runx3-/-. Genes with 
lower expressions in Runx2-/-Runx3-/- were listed as down-regulated genes and vice 
versa in both the comparisons. There were more up-regulated genes in Runx2-/-
Runx3-/- vs. Runx2-/- and more down-regulated genes in Runx2-/-Runx3-/- vs. Runx3-/-. 
In total, there were also more significant differentially modulated genes by Runx2 
(6512) than Runx3 (7141). These observations support what has been established in 
literature that Runx2 plays a more prominent role in skeletal development and 
reiterate the connotation made earlier that Runx3 probably acts more as a repressor 







Figure 34. Number of Exclusively Runx2 or Runx3 Target Genes 













 comparisons. Data was analyzed with 
GeneSpring GX™ 11.0 using unpaired Student’s t-test with a fold-change cut-off at >1.5 and 





 for both comparisons. 
 
The Runx3 targets identified were analyzed with DAVID to examine if they were 
relevant to skeletal development or known Runx3 functions (Fig. 35). Intriguingly, the 
top 2 enriched GO terms associated with genes positively-regulated by Runx3 were 
“transcription” and “transcription repressor activity”. Evidently, Runx3 represses 
genes and activates repressor genes to establish itself as an overall transcription 
repressor. Genes associated with embryonic limb development, skeletal system 
development and axis patterning were significantly enriched between the enrichment 
scores of 1.93 to 2.48. Genes associated specifically with osteoblast differentiation 
and ossification were not enriched at all; suggesting that Runx3 is only involved in 
chondrocyte maturation and has no role in bone ossification. Genes associated with 
other known Runx3 functions such as neural development (Inoue et al., 2002; 
Levanon et al., 2002), lung development (Lee et al., 2010), immune system 
development (Woolf et al., 2003) and various cancers (Xiao and Liu, 2004; Yano et 














Functional annotation clusters associated with the Runx3 target genes that were generated 
by DAVID were ranked according to their given enrichment scores. (A) Down-regulated and 




 compared to Runx2
-/-
. The red dotted lines indicate 
the recommended cut-off point of 1.3. GO terms with enrichment scores above 1.3 indicate 
that genes with these functions are significantly enriched. The red boxes highlight skeletal 
functions. 
 
Likewise, the Runx2 targets identified from Runx2-/-Runx3-/- vs. Runx3-/- comparison 
were analyzed with DAVID to examine if they were relevant to skeletal development 
or known Runx2 functions (Fig. 36). The GO term specifically pertaining to bone 
development and ossification that was associated with the down-regulated gene list 

















Functional annotation clusters associated with the Runx2 target genes that were generated 
by DAVID were ranked according to their given enrichment scores. (A) Down-regulated and 




 compared to Runx3
-/-
. The red dotted lines indicate 
the recommended cut-off point of 1.3. GO terms with enrichment scores above 1.3 indicate 
that genes with these functions are significantly enriched. The red boxes highlight relevant 








Unfortunately, not all the genes originally found to be differentially expressed in the 
Runx3+/- vs. Runx3-/- comparison were differentially expressed in the Runx2-/-Runx3-/- 
vs. Runx2-/- comparison. Of the 24 genes, only 11 were differentially expressed in the 
Runx2-/-Runx3-/- compared to the Runx2-/-.  Out of the 11 gene, only 3 (Lgmn, Ddr1 
and Pps) were regulated in the same direction and the remaining 9 genes (Adam15, 
Satb2, B230112C05Rik, Gng5, Pgm5, G3bp2, LOC433261, Zfp383) were regulated 
in the opposite direction. Ifi204, thought to be the linking gene between the regulatory 
mechanisms of Runx2 and Runx3 was not found to be differentially expressed in the 
Runx2-/-Runx3-/- vs. Runx2-/- comparison. This discrepancy could be due to the fact 
that the earlier Runx3 microarray was performed with E14.5 Runx3+/- and Runx3-/- 
mouse embryos while the Runx2-/-Runx3-/- and the Runx2-/- mouse embryos were 
harvested at E13.5 for microarray. To maintain consistency, only the results obtained 





























3.2 Genome-wide Mapping of Runx2 and Runx3 Binding Sites  
3.2.1 Introduction to Chromatin Immunoprecipitation-Sequencing 
(ChIP-Seq) 
At the core of a transcriptional regulation network is the complex interaction amongst 
multiple transcription factors (TFs), chromatin modifiers and the polymerase complex 
to initiate or repress transcription at the transcriptional start site of target genes 
(MacQuarrie et al., 2011). This interaction is facilitated by the binding of TFs and/or 
chromatin modifiers at nearby or distant cis-regulatory DNA sites to induce proximity 
amongst the core complexes for interaction (Cosma, 2002; Fry and Peterson, 2001). 
Hence, determining where the TFs bind on the DNA to regulate gene expression 
complemented by genome-wide gene expression of these TFs enable the depiction 
of both direct and indirect links between the TFs and their target genes in a more 
comprehensive gene regulatory network. 
 
Chromatin immunoprecipitation followed by hybridization onto DNA arrays (ChIP-
chip) or high-throughput sequencing (ChIP-Seq) are two powerful methods used to 
detail genome-wide distribution of TF binding sites. With the lowering cost of high-
throughput sequencing, ChIP-Seq, however, has become a more popular alternative 
to ChIP-chip to map the genome-wide physical DNA-TF interactions. The latter which 
requires hybridization on an array has inherent hybridization biases and its whole-
genome mapping power and resolution is restricted by a fixed number of probes and 
their predetermined lengths on the array. ChIP-seq, on the other hand, requires less 
input material and can generate more precise binding site information as data is 
presented in short sequence reads (~30 base pairs) (Robertson et al., 2007). As a 
sequencing-based technology, it is also able to capture mutation in binding site 
sequences (Mardis, 2007) and identify novel binding sites that are not limited to an 





in the form of sequencing bias that is yet to be well studied and understood (Mardis, 
2007).  
 
The foremost part of ChIP-seq entails the enrichment of the DNA sequences bound 
by the TF of interest in living cells. Whole mouse embryos or enriched mouse tissue 
parts are first homogenized into single cells with a Douncer. Proteins and their target 
DNA are crosslinked with formaldehyde before the chromatin and the bound proteins 
are lysed from the cells. The chromatin is then sheared to fragments between 100 to 
500 base pairs by sonication. The DNA regions bound by proteins remain intact. An 
antibody specific to the TF of interest is used to exclusively immunoprecipitate the 
TF-bound DNA fragments. The TF-DNA complexes are next purified and reverse-
crosslinked. The retrieved DNA fragments are further purified, ligated with adaptors, 
amplified and size selected (200-400bp) to produce a library of target DNA binding 
sites for the second half of ChIP-Seq and that is parallel sequencing with a high-
throughput Solexa sequencer. Short reads of 30 to 50 bases from either ends of the 
DNA fragments are subsequently mapped back to the genome. The number of reads 
associated with the genomic locus will be proportional to the occupancy of the TF at 
that locus. 
 
3.2.2 Generation of HA3-tagged Mice for ChIP-Seq 
As previously discussed, Runx proteins are highly similar in structure and 
commercially available anti-Runx2 and anti-Runx3 antibodies may not be specific 
enough to discriminate Runx2 or Runx3 from the other Runx members. Therefore, to 
avoid issues of antibody cross-reactivity and antibody promiscuity, C-terminally HA-
tagged Runx2 and Runx3 mice were generated via locus-specific homologous 
recombination for ChIP experiments with HA antibodies.  This would enable the 





experiments prior to sequencing. The tag was intentionally placed at the C-terminal 
end so that all the Runx2 and Runx3 protein isoforms which differ at the N-terminus 
would be tagged. Three HA epitopes were added instead of one to increase the level 
of recognition by the antibody.  
 
A long forward primer containing a 50bp homology arm followed by a triple HA tag 
(HA3), a stop codon (TGA) and a 20bp sequence complementary to the 5’ region of 
the PGK-gb2-Neo fragment together with a 70bp reverse primer (a 50bp homology 
arm and a 20bp complementing the 3’ region of Neo) were used to synthesize the 
HA3-TGA-PGK-gb2-Neo insertion cassette. This cassette with the flanking 50bp 
homology arms was inserted just before the stop codon of Runx2 and Runx3 via 
BAC modifications done with the Gene Bridges Quick and Easy BAC Modification kit 
(Fig. 37). BACs containing the 3’ region of the genomic locus of Runx2 (RP23-7C18) 
and the entire genomic locus of Runx3 (RP24-118B14) were used for the 
modifications. Upon modification, the region-of-interest was amplified by PCR and 
verified by double-stranded sequencing to ensure that there were no errors in the 
modification. Successfully-modified and mutation-free BAC clones were subcloned 
into a minimal vector using the Gene Bridges Quick and Easy BAC Subcloning kit. 
The subcloned plasmids comprised the modified region flanked by short and long 
homology arms whereby the combined homology arms added up to at least 10 kb in 
length. Subsequently, these subclones were linearized with XmnI (for modified 
Runx2) and Acl (for modified Runx3) restriction enzymes which cut only within the 
minimal vector before being electroporated into the mouse ESCs for gene-targeting.  
 
The targeting constructs were introduced into mouse v6.4 ESCs (129/SvJ x 
C57BL/6J) and putative positive recombinants were selected as mentioned and 
screened first by PCR with a forward primer sitting within the insertion cassette and a 





the PCR-positive clones using Southern blotting with probes external to the 




Figure 37. Targeting Strategy to Generate HA3-tagged Mice  
The HA3-TGA-loxP-Neo-loxP cassette was inserted at the C-terminus of (A) Runx2 and (B) 
Runx3 just before the stop codon. The Neo gene is excised by crossing with the Zp3-Cre 








Figure 38. PCR and SB Screen for Runx2
+/HA-Neo
 Positive Recombinant ES Cell Clones  
(A) Correctly targeted ES clones would have a wild-type and a tagged allele as shown. (B) 
PCR screen for positive recombinant clones was carried out with a forward primer 
complementary to the 3’ end of Neo and a reverse primer outside the short homology arm 
yielding a 2.4kb PCR product (primers indicated with black arrows in A). (C) Genomic DNA 
extracted from putative positive ES clones identified by PCR were digested with StuI (top 
panel) or DrdI (bottom panel) restriction enzyme and probed with a C-terminal Probe 2 
(2C’Probe2; 590 bp; 25 ng/ml) just outside the short homology arm. True homologous 
recombinant ES cell clones will give a 16.5 kb wild-type and a 9.6 kb mutant band (top panel; 
lanes 1, 2 & 3) when cut with StuI or a 14.5 kb wild-type and a 5.5 kb mutant band (bottom 
panel; lanes 1, 2 & 3) when cut with DrdI. A false positive clone will only show the wild-type 








Figure 39. PCR and SB Screen for Runx3
+/HA-Neo
 Positive Recombinant ES Cell Clones  
(A) Correctly targeted ES clones would have a wild-type and a tagged allele as shown. (B) 
PCR screen for positive recombinant clones was carried out with a forward primer 
complementary to the 3’ end of Neo and a reverse primer outside the short homology arm 
yielding a 2.4kb PCR product (primers indicated with black arrows in A). (C) Genomic DNA 
extracted from putative positive ES clones identified by PCR were digested with StuI (top 
panel) or DrdI (bottom panel) restriction enzyme and probed with a C-terminal Probe 2 
(2C’Probe2; 590 bp; 25 ng/ml) just outside the short homology arm. True homologous 
recombinant ES cell clones will give a 16.5 kb wild-type and a 9.6 kb mutant band (top panel; 
lanes 1, 2 & 3) when cut with StuI or a 14.5 kb wild-type and a 5.5 kb mutant band (bottom 
panel; lanes 1, 2 & 3) when cut with DrdI. A false positive clone will only show the wild-type 






















































Gene-targeting frequencies at the 3’ region of Runx2 and Runx3 locus. Only one mouse line 
was used to pursue downstream ChIP studies. GLT, germ-line transmitting. 
 
 
Positive ESC clones identified from the Southern blot screen were expanded for 
microinjections into 2- to 8-cell stage C57BL/6J mouse embryos (Kraus et al., 2010) 
to generate high percentage germ-line transmitting chimeras. The F1 offspring of the 
male chimeras when mated to C57BL/6J wild-type female mice were heterozygous 
for the tagged allele. These Runx2+/HA-Neo and Runx3+/HA-Neo mice were normal but 
when they were mated to homozygosity, Runx2HA-Neo/HA-Neo mice were smaller and 
had severe malocclusion while Runx3HA-Neo/HA-Neo pups were absent. The 
malocclusion in Runx2HA-Neo/HA-Neo mice probably prevented proper feeding and in turn 
resulted in the poor growth (Fig. 40). The Runx2HA-Neo/HA-Neo mice were crossed to 
Runx2+/HA-Neo mice but no pups dropped even after several months. The Runx2HA-
Neo/HA-Neo mice were either infertile or were too weak to mate.  
 
The Neo gene was subsequently excised by mating the Runx2+/HA-Neo and the 





inter-mated to homozygosity. Consequently, there were no Runx2HA/HA nor 
Runx3HA/HA mice produced among the littermates. There were two occasions where a 
very small three-week old mouse with a foreshortened snout was genotyped to be 
Runx2HA/HA but the mouse did not survive past a month. Unfortunately, the Neo gene 
was not the cause of the malocclusion in the Runx2HA-Neo/HA-Neo mice and the lethality 
in the Runx3HA-Neo/HA-Neo embryos. On the contrary, removing the Neo appeared to 
aggravate the condition of the tagged mice for unexplained reasons. 
 
Next, I tried to harvest E13.5 Runx2HA/HA and Runx3HA/HA mouse embryos from intra-
heterozygous crosses of Runx2+/HA and Runx3+/HA mice and apparently normal E13.5 
Runx2HA/HA mouse embryos were obtained but Runx3HA/HA embryos were absent 
even as early as E10.5. The phenotype observed in these homozygous tagged 
embryos did not match that of the Runx2 and Runx3 homozygous mouse knockouts 
although the phenomenon seen in the Runx2HA-Neo/HA-Neo mice could be associated 
with impaired skeletal development of the jaw and the occasional Runx2HA/HA mice 








 Mice  
Runx2
+/HA-Neo
 mice were grossly normal and fertile. Runx2
HA-Neo/HA-Neo
 mice were smaller and 






The genotype of mice or embryos was determined by PCR using tail tips from 3-
week old mice or yolk sacs of embryos harvested for experiments. The following 
primers were used to determine the genotype: 
 
Table 7. Primers for Genotyping Runx2-HA3 and Runx3-HA3 mice or embryos 
 Runx2-HA3 Runx3-HA3 
Forward 
Primer 
5’ CCCAGCCACCTTTACCTACA 3’ 5’ GGACCCCAGGATGCACTAC 3’ 
Reverse 
Primer 
5’ CTGCCTCTTGTCCCTTTCTG 3’ 5’ GGGAGGGAGAGAAAGTCCAG 3’ 
Wild-type 
PCR band 
809 bp 782 bp 
Mutant PCR 
band 
944 bp 917 bp 
           
 
 
                         A                                         B          
 
Figure 41. Genotyping Runx2-HA3 and Runx3-HA3 Mice by PCR 
(A) Runx2-HA3; wild-type allele: 809 bp, mutant allele: 944 bp (B) Runx3-HA3; wild-type allele: 
782 bp, mutant allele: 917 bp. 
 
 
In order to find out if the mice were correctly tagged and the HA epitopes were 
exposed for detection by anti-HA antibodies, immunohistochemistry (IHC) was 
performed with IHC-grade anti-HA antibody (AP09230PU-N; Acris Antibodies) on 







Figure 42 details the expression of Runx2-HA3 protein detected by both the anti-HA 
and the anti-Runx2 antibodies in the Meckel’s cartilage of the lower jaw, clavicle and 
the perichondrium of the ribs, humerus and hindlimb digits. Runx2-HA3 protein 
expression was specifically detected by the anti-HA antibody (Fig. 42 top right panel) 
which was not found in the wild-type embryo (Fig. 42 top left panel) and the 
expression recapitulates the endogenous expression of Runx2. (Fig. 42 bottom left 
panel). Anti-Runx2 antibody was also able to detect the Runx2 and the Runx2-HA3 
proteins in the heterozygous tagged embryo in the corresponding expression 
domains (Fig. 42 bottom right panel). 
 
In Figure 43, it is evident that the HA epitope of Runx3-HA3 protein could not be 
detected by the anti-HA antibody. This could be because (1) the HA epitope at the C-
terminus was folded within the Runx3-HA3 protein and could not be recognized, (2) 
the HA3 tag was cleaved off by a protease due to the presence of an unidentified 
protease site at the C-terminus or (3) the C-terminally tagged Runx3-HA3 was prone 
to degradation for some unknown reason (Munro and Pelham, 1987). Although 
signals were present in the Runx3-HA3 embryo sections when probed with the anti-
Runx3 antibody, it could not be verified if the antibody detected both the Runx3 and 
the Runx3-HA3 proteins or just the Runx3 protein in the heterozygous Runx3-HA3 
embryo. Unfortunately, E13.5 homozygous Runx3-HA3 mouse embryos could not be 
obtained for IHC with anti-Runx3 antibody to investigate if the Runx3-HA3 proteins 









Figure 42. Runx2-HA3 Protein Expression Recapitulates Endogenous Runx2 
Expression 
Immunohistochemistry was performed using IHC-grade anti-HA and anti-Runx2 antibodies on 
sagitally sectioned E13.5 wild-type and Runx2
+/HA
 mouse embryos embedded in paraffin. 
Images on the left and right of each quarter panel were taken at x50 and x200 magnifications 








Figure 43. Runx3-HA3 Protein Expression  
Immunohistochemistry was performed using IHC-grade anti-HA and anti-Runx2 antibodies on 
sagitally sectioned E13.5 wild-type and Runx2
+/HA
 mouse embryos embedded in paraffin. 
Images on the left and right of each quarter panel were taken at x50 and x200 magnifications 











In summary, Runx2 was successfully tagged with the HA epitope and the expression 
of the Runx2-HA3 proteins reflected endogenous Runx2 expressions. The HA 
epitope could also be recognized by the anti-HA antibody. The only problem was that 
the Runx2HA/HA mice frequently did not survive and a colony of Runx2HA/HA mice could 
not be maintained. Hence, E13.5 Runx2HA/HA embryos could only be obtained via 
intra-heterozygous crosses for ChIP experiments. The rationale for proceeding to use 
the Runx2HA/HA mouse embryos for ChIP despite the phenotype observed was that 
the E13.5 Runx2HA/HA embryos appeared normal and the tagged protein could be 
recognized by anti-HA antibodies. It was also postulated that the Runx2-HA3 was 
likely to retain its DNA-binding ability. This could be further determined by future 
EMSA experiments with purified Runx2-HA3 protein. 
 
On the other hand, the tagging of Runx3 in the mouse was not successful. The HA 
epitope of the Runx3-HA3 protein in the Runx3
+/HA mouse embryos could not be 
recognized for one of the several possible reasons. Firstly, the tag could have been 
folded within the protein and hidden away from the antibody. Secondly, the tagged 
protein could have undergone post-translational modifications resulting in the HA 
epitope being cleaved off and thirdly, the C-terminal tag could expose the 3’ end 
domains to phosphorylation and subsequent protein degradation. Furthermore, it 
could not be determined if Runx3-HA3 protein was either present but undetectable or 
degraded as Runx3HA/HA mouse embryos could not be obtained for further 
experimentation. The lethality of the Runx3HA/HA mouse embryos exceptionally early 
in developmental stage could not be explained. Although, from the IHC experiments, 
it was anticipated that the Runx3-HA3 proteins could not be immunoprecipitated, HA-
tagged Runx3 mouse embryos were still collected for ChIP-Western blot experiments 
described in the following segment to assess if Runx3-HA3 proteins could be pulled 





acquired, a pool of wild-type and Runx3+/HA embryos were collected from inter-
Runx3+/HA crosses for ChIP experiments. 
 
3.2.3  ChIP-Western blot (ChIP-WB) to Assess Ability to 
Immunoprecipitate Runx2-HA3 and Runx3-HA3 Proteins from 
Tagged mice. 
 
ChIP with an anti-HA antibody (Abcam 9110) followed by Western blot (WB) 
detection of the immunoprecipitated proteins with another WB-grade HRP-
conjugated anti-HA antibody (Bethyl) was first performed using the tagged mouse 
tissue to assess if the anti-HA antibody (Abcam 9110)  was sensitive and specific 
enough for ChIP experiments. It was also done to test if the tagged proteins from the 
mouse tissue could be immunoprecipitated and enriched. A HRP-conjugated primary 
anti-HA antibody (Bethyl) was chosen for WB detection to avoid overwhelming 
background signals from the binding of secondary antibodies to the heavy and light 
chains of the primary antibody used for immunoprecipitation.  
 
E13.5 mouse embryos were harvested from intra-heterozygous mouse crosses of 
Runx2+/HA or Runx3+/HA mice.  Different tissues such as the jaw, the ribs and the limbs 
were dissected from the embryos on ice to enrich for Runx2- or Runx3-expressing 
cells. Similar tissues were also harvested from E13.5 CD-1 wild-type mouse embryos 
as controls for the ChIP experiments with anti-HA antibody. The same tissues from 
all the embryos with the same tagged protein were pooled together. The different 
jaw, rib and limb tissues were kept as separate samples during homogenization, 
cross-linking, lysis, chromatin shearing, immunoprecipitation and WB or sequencing. 
The yolk sacs of each embryo were kept for genotyping. Among the 74 E13.5 
embryos harvested from the Runx2+/HA mouse crosses, there were 15 wild-type, 43 
Runx2+/HA and 16 Runx2HA/HA mouse embryos which corresponded to the Mendelian 





each pool of Runx2-HA3 tissues collected. Correspondingly, out of the 41 E13.5 
embryos collected from the Runx3+/HA mouse crosses, there were 10 wild-type, 31 
Runx3+/HA and no Runx3HA/HA mouse embryos. This would translate to 37.8% of the 
Runx3 proteins being tagged.  
 
Figure 44 made evident that the Runx2-HA3 protein from the tagged mouse tissues 
was successfully immunoprecipitated. This also demonstrated that the anti-HA 
antibody was sufficiently specific and sensitive for ChIP and a good enrichment of the 
DNA-bound TF of interest was attained. As expected, the Runx3-HA3 protein could 
not be pulled down. One can interpret that either the HA tag was hidden, the Runx3-
HA3 protein was absent or that the proportion of tagged proteins was too low to be 
successfully pulled down by the anti-HA antibody since only 37% of the Runx3 
proteins used for ChIP was tagged. Notably, the ChIP-WB experiment results 
corroborated with the IHC results even though a different anti-HA antibody was used. 
As a result, only the Runx2-HA3 tissues were used in the subsequent ChIP-Seq 
experiments. 
 
Figure 44. ChIP-WB of Runx2-HA3 and Runx3-HA3 proteins  
Crossed-linked single cells from CD-1 wild-type, Runx2-HA3 and Runx3-HA3 mouse rib tissue 
were lysed, sonicated and DNA-bound Runx2-HA3 and Runx3-HA3 proteins were 
immunoprecipitated with anti-HA antibody (Abcam 9110; 10ug) overnight and loaded onto a 
Western gel for detection with HRP-conjugated anti-HA antibody (Bethyl; 1:20,000). The red 
box highlighted the Runx2-HA3 protein band that was successfully immunoprecipitated. CD-1 






3.2.4  In Vivo ChIP-Seq of Runx2-specific Binding Sites 
 
After verifying by ChIP-WB that Runx2-HA3 proteins could be pulled down with the 
anti-HA antibody, jaw, rib and limb tissues from Runx2-HA3 and CD-1 wild-type 
mouse embryos went on to be processed separately for ChIP-Seq. DNA libraries of 
Runx2-HA3-bound DNA fragments immunoprecipitated by anti-HA antibodies were 
synthesized using the NEBNext® ChIP-Seq Sample Prep kit. CD-1 wild-type tissue 
samples immunoprecipitated with anti-HA antibody were used as a background 
control for the corresponding Runx2-HA3 tissue samples. The quantity and quality of 
the size-selected DNA ChIP libraries were analyzed using the Agilent DNA chip and 
the Agilent Bioanalyzer before sequencing. Figure 45 illustrates that the DNA 
libraries were indeed between a good range of 200-400 bp and the amount of DNA 
was also sufficient for sequencing with the Illumina Solexa sequencing technology.  
 
 
Figure 45. Runx2-HA3 in Vivo ChIP Libraries Assessed with Agilent DNA BioAnalyzer  
DNA libraries were prepared for each of the immunoprecipitated Runx2-HA3-bound DNA 
fragments as well as the corresponding CD-1 WT tissue samples. Fragment size, quantity 









Short sequence reads were mapped back to the mouse genome (NCBI build 
37/mm9) to determine the genome-wide Runx2-DNA interaction sites. Model-based 
Analysis of ChIP-Seq (MACS) (Zhang et al., 2008b) was applied to the Runx2-HA3 
ChIP-Seq datasets to predict Runx2 binding peaks with high resolution. The peaks 
were analyzed using the Genomic Regions Enrichment of Annotations Tool (GREAT) 
(McLean et al., 2010). GREAT first assigns a regulatory domain to each gene. The 
genomic regions which coincide with the Runx2 binding peaks are next associated 
with all the genes whose regulatory regions overlap with the Runx2 binding peaks. 
The association rule used to identify genes which the Runx2-bound genomic regions 
possibly regulate was “Approach 2: Two Nearest Genes”. 
 
Figure 46. GREAT Association Rule Setting Approach 2: Two Nearest Genes  
Figure from GREAT website. Arrows represent transcription start site. Each gene is assigned 
a regulatory domain that extends in both directions to the nearest gene's TSS but no more 
than a maximum extension in one direction.  
 
Using the association rule mentioned above (Fig. 46), the two nearest genes within 
1kb, 5kb, 10kb, 100kb and 1000kb from either side of the Runx2 binding peaks were 
identified by GREAT for each of the different tissues. The number of genes identified 
was plotted against the distance of the Runx2 binding site from the TSS (Fig. 47). In 
other words, Figure 47 shows the distribution of Runx2 binding sites from the TSS of 
any gene. The most number of genes found associated with the Runx2 binding sites 
were between 10-1000kb away from the TSS of any gene. This implies that Runx2 at 
this stage of development likely regulates most of its target genes directly at a distal 
enhancer rather than at the promoter of target genes. There have been evidences 





mechanism brings these distal enhancers in proximity to the promoter of the target 
gene (Hill and van Heyningen, 2008; Ptashne, 1986; Yoshida et al., 1999). One 
example is the long range enhancer of the Shh gene (Lettice et al., 2003) regulating 
expression in the limb. Hence, it could be postulated that there might be the same 
looping mechanism bringing Runx2 bound at the distal enhancer to the transcription 
machinery at the promoter. 
 
 
Figure 47. Distribution of Runx2 Binding Sites from Jaw, Rib and Limb Tissues   
The number of genes identified within 1 kb, 1 - 5 kb, 5 -10 kb, 10 -100 kb and 100 -1000 kb 
from the significant Runx2 binding peaks was plotted against the distance between the Runx2 
binding sites and the transcription start site (TSS) of the genes.   
 
The genes were next analyzed by DAVID to examine what GO terms associated with 
the genes were significantly enriched. Figure 48A shows significant enrichment 
scores of 4.92 and 2.05 for GO terms such as limb morphogenesis and cartilage 
development respectively for genes found within 1 kb from the Runx2 binding site. In 
fact, the highest ranking GO term that came up in the DAVID analysis was limb 
morphogenesis. The result confers confidence that the ChIP-seq data was reliable 





Hoxa11, Hoxd10, Hoxd11, Hoxd12 and Hoxd13 and those clustered under “cartilage 
development” were Hoxa11, Runx2 and Hoxd11. Interestingly, when the binding sites 
of these genes were examined more closely, most of them identified as within 1 kb 
from Runx2 binding sites were in fact more than 1 kb away. To supplement the 
association rules mentioned above, GREAT utilizes literature-curated regulatory 
domains where it had been shown that a gene is directly regulated by a regulatory 
element that falls outside the basal regulatory domain i.e. the promoter region. 
Hence, GREAT overrides the restricted rules to include curated regulatory domains. 
Genes currently with curated regulatory domains are Shh, Lnp, Evx2, Hoxd10, 
Hox11, Hoxd12 and Hoxd13 which explains why these genes were still associated 
with the Runx2 binding sites even when the 1 kb rule was applied during the 
analysis.  
 
GO terms associated with genes found within 5 kb from the Runx2 binding site were 
still relevant such as limb development and cartilage development albeit the 
enrichment scores were lower (Fig. 48B) and Ptch1 was the only additional skeletal 
gene identified but was not found in any of the Runx2 microarray lists. Table 8 shows 
the relevant skeletal genes identified as within 1 kb or 5 kb from Runx2 binding sites, 
the location of the binding site from the TSS, the tissue which the genes are identified 










Figure 48. GO Terms Associated with Genes Nearest to Runx2 Binding Sites   
Enriched GO terms associated with nearest genes found within (A) 1 kb, (B) 5 kb and (C) 
10 kb from the significant Runx2 binding peaks in all the tissues combined. GO terms with 
enrichment scores above 1.3 are significantly enriched. The red dotted lines indicate the 



















Table 8. Genes Associated within 1 kb and 5 kb of Runx2 Binding Sites and Clustered 
under Relevant Skeletal GO Terms. 
Gene 
Symbol 
Gene Name Binding Sites 
(Distance from TSS) 
Tissue Microarray 
(Regulation by Runx2) 
Genes identified as within 1 kb from binding sites: 
Lnp Limb and neural patterns (+377, 321) Jaw Yes (Negative) 
  (+489,709) Ribs  
  (+2,076) Limbs  
Evx2 Even skipped homeotic 
gene 2 homolog 
(+82,547) Limbs No 
Shh Sonic hedgehog (-417,351) Jaw Yes (Positive and 
negative) 
  (-366,989), (+142,089) Limbs 
Hoxa11 Homeobox A11 (-744) Ribs Yes (Positive) 
Hoxd10 Homeobox D10 (-115,076) Limbs No 
Hoxd11 Homeobox D11 (-105,521) Limbs No 
Hoxd12 Homeobox D12 (-98,158) Limbs No 
Hoxd13 Homeobox D13 (-91,438) Limbs Yes (Positive) 
Runx2 Runt related transcription 
factor 2 
(+616) Ribs Yes (Negative) 
Gene identified as within 5 kb from binding sites: 
Ptch1 Patched homolog 1 (-2674), (+2298) Ribs No 
 
 
When genes found within 10 kb of Runx2 binding sites were assessed, no relevant 
skeletal functions were found. Instead, the GO term “Metallothionein, vertebrate, 
metal binding site” was given a significant enrichment score of 2.29.  
 
Metallothioneins are cysteine-rich metal-binding proteins. Mammals express at least 
four types of metallothioneins – metallothionein-1 to metallothionein-4 (Mt1 to Mt4).  
They bind and regulate the cellular metabolism of physiological metals such as zinc 
and copper. In addition, they have detoxifying functions by binding to toxic metals 
such as cadmium, silver, copper and mercury (Nordberg, 1998). Furthermore, Mt3 is 





astrocytes (Masters et al., 1994; Palmiter et al., 1992). It was suggested to be 
involved in brain repair (Hozumi et al., 1998). However, the full functions and 
functional mechanisms of metallothioneins are not well-understood. The 
metallothionein genes found within 10 kb of Runx2 binding sites were Mt1, Mt3 and 
Mt4 while only Mt1, Mt2 and Mt4 genes were found in the Runx2 microarray gene 
lists. The direction of regulation by Runx2 of these was conflicting; hence, it is not 
possible to determine if Runx2 positively or negatively regulated these 
metallothionein genes. Perhaps Runx2 has a role in the detoxification function of 
bone by regulating the metallothionein genes or that the metallothionein genes have 
yet to be discovered functions in bone development. 
 
Next, the genes whose regulatory domains, set at 100 kb and beyond, overlap with 
Runx2 binding sites were assessed with DAVID and many GO terms related with 
skeletal functions were found significant such as “Extracellular matrix”, “Embryonic 
limb development”, “Wnt signalling”, “Osteoclast differentiation” and “Bone 
development, ossification and osteoblast differentiation” (Fig. 49). As mentioned 
earlier, it is likely that Runx2 directly regulates most of its skeletal target genes at a 
distal enhancer cooperating with other transcription factors bound at the promoter of 







Figure 49. GO Terms Associated with Genes Identified with Distal Runx2 Binding Sites   
Enriched GO terms associated with nearest genes found within (A) 100 kb and (B) 100-
1000 kb from the significant Runx2 binding peaks in all the tissues combined. GO terms with 
enrichment scores above 1.3 are significantly enriched. The red dotted lines indicate the 
recommended cut-off point of 1.3. The red boxes highlight skeletal functions and pathways.  
 
Lastly, I tried to find out how many of the potential Runx2 targets identified from the 
microarray were direct targets. Figure 50 shows two Venn diagrams illustrating the 
number of genes found in both the Runx2 microarray gene list and the Runx2 ChIP-
Seq list of genes with Runx2 binding sites within 1 kb or 1 Mb from the TSS. A list of 
Runx2 targets with Runx2 binding at the promoter region is found in Table 9. In 





genes. Approximately two-thirds of the genes with their promoters or distal 
enhancers bound by Runx2 transcription factor were not differentially regulated. The 
regulation of these genes could require other co-factors to bind to Runx2 or other 
transcription factors to sit along the DNA near the Runx2 binding site in order to 
synergistically regulate the transcription. Hence, the Runx2 transcription factor may 
be situated on these binding sites poised to be activated by other factors at a 
different developmental stage. 
 
 
Figure 50. Putative Runx2 direct targets   
Overlap of potential Runx2 targets from microarray data with genes identified within 1 kb from 
Runx2 binding site (left Venn diagram) and with genes identified within 1 Mb of Runx2 binding 
site (right Venn diagram).  
 
Table 9. List of Runx2 direct targets with Runx2 binding at the promoter region 
No. Runx2 Direct 
Targets 
Microarray  
Runx2+/+ vs. Runx2-/- 
Runx2 Binding Site(s) Tissue 
1 Ptp4a3 8.6-fold ↓ (+146) Jaw 
    (+149223) Ribs 
2 V1rc6 8.6-fold ↓ (-600) Jaw 
3 4930572J05Rik 7.4-fold ↓ (+319) Jaw 
4 Lrrc61 6.7-fold ↓ (-673) Ribs 
5 Zfp316 6.2-fold ↓ (+293) Jaw 
6 Olfr800 4.9-fold ↓ (-674) Ribs 
7 Hoxd13 4.4-fold ↓ (-91438) Limbs 
8 Ptgis 4.0-fold ↓ (-192) Jaw 
9 Tsc22d2 3.9-fold ↓ (-963) Limbs 
10 Eif4a1 3.2-fold ↓ (+900) Ribs 
11 Hoxa11 3.1-fold ↓ (-744) Ribs 
12 Eif3g 2.9-fold ↓ (-95) Limbs 





14 Abcb8 2.6-fold ↓ (+740) Limbs 
15 Mapk7 2.6-fold ↓ (+741) Limbs 
    (-58922) Ribs 
16 Midn 2.3-fold ↓ (+738) Ribs 
17 Ppp1r13b 2.3-fold ↓  (+467) Jaw 
18 Nuak1 2.2-fold ↓ (-387) Ribs 
    (+647780) Limbs 
19 Adamts14 1.7-fold ↓ (-534) Ribs 
20 Scrib 1.6-fold ↓ (-54) Jaw 
21 Parva 1.5-fold ↓  (+200) Ribs 
    (+243614) Jaw 
22 T 4.9-fold ↓ (-45196), (+294), 
(+29544) 
Limbs 
    (+764) Jaw 
    (+7303), (+153857) Ribs 
23 Odz2 4.2-fold ↓ (+552) Limbs 
24 Kti12 2.1-fold ↓ (+101) Ribs 
25 2010001M09Rik 1.9-fold ↓  (+402) Limbs 
26 Smarcd1 1.8-fold ↓ (-13) Limbs 
27 Pip5k1a 1.7-fold ↓ (+837) Jaw 
28 Rwdd1 1.6-fold ↓  (-95) Limbs 
29 Rrm1 1.6-fold ↓ (+561) Ribs 
30 Exosc8 1.6-fold ↓ (+890) Jaw 
31 Mpzl1 3.0-fold ↓ (+54), (+225) Jaw 
  9.7-fold ↑ (+140) Limbs 
32 Lnp 34.8-fold ↑ (+2076) Limbs 
    (+377321) Jaw 
    (+489709) Ribs 
33 Ppp1r13l 8.4-fold ↑  (-101), (+4) Jaw 
    (-14) Limbs 
34 Runx2 8.4-fold ↑ (+616) Ribs 
35 Shh 7.2-fold ↑ (-366989), (+142089) Limbs 
    (-417351) Jaw 
36 Acox2 7.5-fold ↑ (-977) Limbs 
37 Amotl2 5.3-fold ↑ (-133) Ribs 
    (-129) Jaw 
38 Rcn2 4.3-fold ↑ (+210) Ribs 
39 Gabpb1 2.9-fold ↑ (-306), (-69) Ribs 
40 Glcci1 2.8-fold ↑ (-19813), (-142) Jaw 
    (-67312) Ribs 
41 H2afz 2.2-fold ↑ (+643) Jaw 
42 Abcg2 2.1-fold ↑ (-355) Ribs 
    (-360) Jaw 
43 Hdgfrp3 2.0-fold ↑ (-7) Jaw 








Figure 51. Runx2 ChIP-Seq Peaks   
Runx2 ChIP-Seq peaks at promoters of different genes underlined in red. Peaks are 
highlighted with the red boxes. ChIP was performed separately with three different tissue 
types (jaw, ribs and limbs) harvested from the Runx2-HA3 mouse embryos. ChIP-Seq library 
tracks were uploaded to the USCS browser and images were captured on the browser. 
 
It is noted that only 0.5% of all the Runx2 differentially regulated genes have Runx2 
binding sites at its promoter and 17.3% have Runx2 binding within 1 Mb of its TSS. 
This could mean that Runx2 indirectly regulates most of its downstream genes or that 
the ChIP experiment was not able to pick up all the Runx2 binding sites. On the 
whole, the Runx2 ChIP-Seq peaks were not very enriched and there was a lot of 
background noise evident by the small random peaks seen in Figure 51 which 
probably masked out many true peaks. Mouse tissues, unlike cells from tissue 
cultures, consist of a heterogeneous population of cells and the endogenous 
expression of transcription factor Runx2 is relatively low compared to histones which 





insufficient enrichment of the Runx2 protein for immunoprecipitation. Fluorescence-
activated cell sorting of the Runx2F2A-EGFP/HA mouse embryos prior to 
immunoprecipitation was considered, however, the time taken to sort the cells before 
cross-linking would have changed the binding dynamics. Another group in the 
institute attempted to cross-link mouse tissues before sorting for ChIP but that did not 
yield good ChIP-Seq results either. Though a sensitive and specific ChIP-grade 
antibody is tantamount to a successful ChIP experiment, it is also believed that the 
protein of interest needs to be sufficiently enriched for prior to immunoprecipitation to 
reduce the noise level and to enhance the binding peak so as to be detected as 
significant. So far, there are no reports of a successful ChIP-seq to map binding sites 
of a transcription factor using mouse tissue. Though my Runx2 ChIP-Seq result is far 
from ideal, some of the relevant binding sites identified are nonetheless informative 




















CHAPTER 4 – BUILDING THE GENE REGULATORY 
NETWORK 
 
The task of integrating the massive amount of data generated from gene expression 
profiling and ChIP-Seq requires a huge amount of time and bioinformatics expertise. 
Furthermore, a lot more work is required to validate the targets elucidated. As a 
preliminary attempt to map out the gene regulatory network governed by Runx2 and 
Runx3 during skeletogenesis, the top genes from the microarray profiles were 
screened through for relevant skeletal functions or phenotype. Runx2 targets with 
Runx2 binding at the promoter were also given more focus. Figure 52 illustrates a 
plausible gene regulatory network connecting Runx2, Runx3 and novel skeletal 
targets. Novel regulatory relationships between the Runx proteins and known skeletal 
factors are also depicted below.  
 
Figure 52. A GRN Centred on Runx2 and Runx3   
Green arrows depict positive influence while blunted red lines depict inhibitory regulation. 
Solid and dotted lines represent direct and indirect regulation respectively. All regulations by 






Genes with probable connection to skeletal development found to be negatively-
regulated by Runx2 and positively-regulated by Runx3 in my microarray studies were 
Amotl2, Sox9, Zbtb44, Kbtbd8, Etl1 (Smarcad1), Dlx2, Murr2, Satb2, Sox6, Shh and 
Zfp383 while genes regulated vice versa by Runx2 and Runx3 were Hoxd13, T 
(Brachyury), Smpd3 and Arid5a. Angiomotin-like 2, Amotl2, encodes for a protein 
receptor for angiostatin, an angiogenesis inhibitor (Aase et al., 2007). Runx2 and 
Runx3 might be regulating this gene to control vascular invasion of the endochondral 
bone. The gene locus of Kelch repeat and BTB (POZ) domain containing 8, Kbtbd8 
and Zinc finger and BTB domain containing 38, Zbtb38, were recently discovered to 
be strongly associated with short stature in humans (Hong et al., 2011; Kim et al., 
2010; Kim et al., 2011). Furthermore, strong expressions of Kbtbd8 were detected in 
the forelimb bud and facial regions of an E11.5 mouse embryo (MGI database; Table 
10). Although Zbtb38 was not differentially expressed in the Runx2 and Runx3 
expression profile, a close member Zbtb44 was significantly down-regulated (94.6-
fold) in the Runx2-/-Runx3-/- transcriptome compared to that of the Runx2-/- and up-
regulated (8.2-fold) in the Runx2-/- compared to Runx2+/+. Deletion of Etl1 
(Smarcad1), Dlx2 and Satb2 in the mouse presented a relevant skeletal phenotype 
(Dobreva et al., 2006; Harris et al., 2003; Schoor et al., 1999). The expression of Etl1 
was also detected in the forelimb and head mesenchyme of an E12.5 mouse embryo 
(MGI database) and Murr2 is a positive regulator of Wnt signalling pathway (Lui et 
al., 2011) (Table 10). Therefore, these targets were considered interesting and 
germane to bone development. 
 
Apart from the known committed osteoblast marker Sp7, deletion of Evc, Tbx15, 
AI848100 (Opt) in the mouse resulted in impaired bone formation (Ruiz-Perez et al., 
2007; Singh et al., 2005; Sohaskey et al., 2010) (Table 10). Evc is also a positive 
modulator of Ihh signalling (Ruiz-Perez et al., 2007). These genes were found to be 





respectively suggesting that they are possibly activated by Runx2 and Runx3 in a 
synergistic or compensatory manner to regulate chondrocyte maturation and 
ossification. Besides working cooperatively, Runx3 positively regulates Runx2 which 
concurs with the data published (Otto et al., 2003). Runx2 transcripts were 8.4-fold 
up-regulated in the Runx2-/- compared to Runx2+/+ but when both alleles of Runx2 
and Runx3 were disrupted, Runx2 transcripts were down-regulated by 13.9-fold in 
the Runx2-/-Runx3-/- compared to that in the Runx2-/-. It is postulated that when Runx2 
was disrupted, the change in levels of the Runx2 downstream targets triggered 
Runx3 to upregulate Runx2 transcripts in a negative feedback manner and when 
both Runx2 and Runx3 were disrupted, there was no functional Runx3 protein to 
maintain the Runx2 transcript levels resulting in a greatly reduced Runx2 transcript 
level. However, it could not be determined if Runx3 directly regulates Runx2. 
 
Genes that were exclusively regulated by Runx3 and not Runx2 were Pax9, Sox5, 
Hoxc8 and Barx2 of which Barx2 was repressed by Runx3. Pax9, Hoxc8, Sox5 and 
Barx2 all have roles in skeletal development based on their knockout phenotype and 
literature. Pax9 directly activates Bapx1 transcription to induce chondrogenic 
differentiation in the vertebral column (Rodrigo et al., 2003), Sox5 is essential for 
cartilage formation and maintenance of hypertrophic chondrocytes (Smits et al., 
2004; Smits et al., 2001) and Hoxc8 negatively regulates osteoblast differentiation 
(Zheng et al., 2009). Runx3 might be positively regulating Pax9 and Sox5 to promote 
chondrogenesis and chondrocyte maturation while up-regulating Hoxc8 to inhibit 
osteoblast differentiation and induce chondrogenic differentiation of 
osteochondroprogenitors. Barx2 cooperates with the Sox proteins to regulate 
expression of Col2a1 during limb chondrogenesis particularly in the joint and articular 
cartilage of the developing digits (Meech et al., 2005). Runx3 might be inhibiting 
Barx2 to advance chondrocyte hypertrophy in the mesenchymal condensations of the 






Runx2 exclusively activated Ibsp, Panx3, Hoxa11, Ihh, Tcf7, Dlx3, Ifitm5 and 
1200009I06Rik to promote bone formation. Ibsp, Panx3 and Ihh were found to be 
direct targets of Runx2 in in vitro studies conducted by (Bond et al., 2011; Roca et 
al., 2005; Yoshida et al., 2004). It was never demonstrated in vivo that Runx2 directly 
regulates these genes through binding at its promoter. I did not find any Runx2 
bound to the promoter or any distal enhancer sites of Ibsp, Panx3 or Ihh in my in vivo 
ChIP-Seq study. Maybe Runx2 does not directly regulate Ibsp, Panx3 and Ihh at this 
developmental stage or the in vivo ChIP-Seq study performed was not sensitive 
enough to pick up the binding sites. Nevertheless, I cannot rule out the possibility that 
Runx2 might be directly regulating these genes during skeletal development. Hoxa11 
was identified as a direct target of Runx2 in the ribs (Table 9) and is a potential direct 
target of Runx2. My finding of Tcf7 being positively regulated by Runx2 concurred 
with the recent literature reporting that Runx2 regulates chondrocyte maturation 
through Tcf7 (Mikasa et al., 2011). Although Dlx3 was reported to be upstream of 
Runx2 during osteoblastogenesis (Hassan et al., 2006), the elimination of functional 
Runx2 in the mice resulted in down-regulation of Dlx3 transcripts in my microarray 
study indicating that Runx2 is likely to regulate Dlx3 as a form of positive feedback 
loop.  Ifitm5 and 1200009I06Rik are hypothesized to be two novel targets of Runx2 
found in my microarray study. There are no reports of them being linked to Runx2 as 
yet but the RNA in-situ hybridization validation results (Fig. 31) strongly support the 
hypothesis. 
 
Genes found to be exclusively repressed directly by Runx2 were Gabpb1, Hdgfrp3 
and Ppp1r13l. Gabpb1, Hdgfrp3 and Ppp1r13l have no known skeletal roles but their 
promoters were bound by Runx2 in the various tissues and were up-regulated in the 
Runx2-/- compared to Runx2+/+ (Table 9). In order to determine their involvement in 





Table 10. List of targets with relevant skeletal functions 
No. Gene Symbol Gene Name Remarks Reference 
1 Sox9 SRY-box containing 
gene 9 
Sox9 is the master regulator for 
chondrogenesis 
(Wright et al., 1995) 
2 BC038156 
(Zbtb44) 
Zinc finger and BTB 
domain containing 44 
No known skeletal function but a 
close family member Zbtb38 was 
strongly associated with  human 
height 
(Hong et al., 2011) 
(Kim et al., 2011) 
(Kim et al., 2010) 
3 Kbtbd8 Kelch repeat and BTB 
(POZ) domain 
containing 8 
Associated with short stature in 
humans. 
Strong expression in FL bud and 
facial regions of E11.5 mouse 
embryo (MGI database) 






regulator of chromatin, 
subfamily a, containing 
DEAD/H box 1` 
Homozygotes for a targeted null 
mutation exhibit retarded growth, 
impaired fertility, skeletal 
dysplasias, and peri- and postnatal 
lethality. Strong expression in the 
forelimb and head mesenchyme of 
E12.5 mouse embryos (MGI 
database) 
(Schoor et al., 1999) 
5 Dlx2 Distal-less homeobox 2 Homozygous null mutants show 
morphogenetic abnormalities in 
first and second branchial arch-
derived proximal skeletal and soft 
tissue structures. 
(Harris et al., 2003) 
6 Evc Ellis van Creveld gene 
homolog (human)  
Mice homozygous for a null allele 
exhibit some lethality shortly after 
birth and exhibit aphagia, infertile, 
teeth abnormalities, short limbs 
and long bones, delays in 
ossification, and short ribs. Evc is 
a positive mediator of Ihh-
regulated bone growth. 
(Ruiz-Perez et al., 
2007) 
7 Murr2 (Usp34) Ubiquitin specific 
peptidase 34  
Positive regulator of canonical Wnt 
receptor signalling pathway 
(Lui et al., 2011) 
8 AI848100 
(Opt) 
Osteopotentia  Mice homozygous for a mutation in 
this gene display background 
strain dependent neonatal and 
postnatal lethality with impaired 
osteoblast differentiation resulting 
in impaired bone formation, brittle 
bones, and impaired fracture 
repair.  
(Sohaskey et al., 
2010) 
9 Satb2 Special AT-rich 
sequence binding 
protein 2 
SATB2 is a multifunctional 
determinant of craniofacial 
patterning and osteoblast 
differentiation 
(Dobreva et al., 
2006) 
10 Sox6 SRY-box containing 
gene 6 
The transcription factors L-Sox5 
and Sox6 are essential for 
cartilage formation 
(Smits et al., 2001) 
(Smits et al., 2004) 
11 Tbx15 T-box 15 Homozygous mutants have low set 
ears that project laterally, skeletal 
abnormalities and distinctive 
dorsoventral coat color patterning.  
Expression found in 
prehypertrophic chondrocytes. 
(Singh et al., 2005) 
12 Amotl2 Angiomotin-like 2 Runx2 and Runx3 might be 
regulating this gene to control 
vascular invasion of the 
endochondral bone. 





Table 10. Continued… 
No. Gene Symbol Gene Name Remarks Reference 
13 Barx2 BarH-like homeobox 2 Barx2 regulates chondrogenesis 
during limb development 
(Meech et al., 2005) 
14 Hoxc8 Homeobox C8 Mice homozygous for a 
hypomorphic allele exhibit abnormal 
growth and axial skeleton 
morphology. Mice homozygous for 
a knock-out allele exhibit postnatal 
lethality, axial skeletal defects, 
abnormal growth, and abnormal 
gait. 
(Juan et al., 2006) 
(Zheng et al., 2009) 
 
15 Pax9 Paired box gene 9 Mice homozygous for knock-out 
allele exhibit neonatal lethality, 
abnormal cranium morphology, 
arrested tooth development, cleft 
secondary palate, athymia, and 
polydactyly. 
(Peters et al., 1999) 
(Rodrigo et al., 2003) 
 
16 Sox5 SRY-box containing 
gene 5 
Homozygous null mice fail to 
breathe and die at birth exhibiting a 
narrow thoracic cage, irregularly 
mineralized sternum, cleft 
secondary palate, and delayed 
bone mineralization. 
(Smits et al., 2001) 
(Smits et al., 2004) 
17 T  Brachyury Homozygotes exhibit defects in 
notochord differentiation and 
mesoderm formation, lack a trunk 
and tail, and die around 10 dpc. 
Heterozygotes have a shortened tail 
and abnormal sacral vertebrae. 
(Hoffmann et al., 2002) 
(Ghebranious et al., 2008) 
(Wu et al., 2010) 
 
18 Smpd3 Sphingomyelin 
phosphodiesterase 3, 
neutral 
Homozygous null mice exhibit 
dwarfism, delayed sexual and 
gonad maturation, delayed 
ossification of the long bones, and 
reduced serum levels of thyroxine, 
triiodothyronine, cortisol, and 
insulin-like growth factor. 
(Aubin et al., 2005) 
(Stoffel et al., 2007) 
(Chae et al., 2009) 
19 Arid5a AT rich interactive 
domain 5A (MRF1-
like) 
Arid5a cooperates with Sox9 to 
stimulate chondrocyte differentiation 
(Amano et al., 2011) 
20 Hoxd13 Homeobox D13 Homozygotes for targeted and 
spontaneous mutations exhibit 
abnormalities of the axial and 
appendicular skeleton especially the 
limbs. 
(Debeer et al., 2002) 
(Salsi et al., 2008) 
21 Panx3 Pannexin 3 Panx3 promotes chondrocyte and 
osteoblast differentiation. Found to 
be a direct target of Runx2 in 
osteoblasts and mature 
chondrocytes. 
(Iwamoto et al., 2010) 
(Bond et al., 2011) 
(Ishikawa et al., 2011) 
22 Hoxa11 Homeobox A11 Homozygotes for targeted null 
mutations exhibit homeotic 
transformations affecting thoracic 
and sacral vertebrae, and forelimb 
defects. 
(Boulet and Capecchi, 
2004) 
23 Ifitm5 (Bril) Interferon induced 
transmembrane 
protein 5 
A novel osteoblast-specific protein. 
Long bones of homozygous mutant 
mice exhibit reduction in length 
during prenatal development. 
(Moffatt et al., 2008) 
(Hanagata et al., 2010) 
24 Tcf7 Transcription factor 7, 
T-cell specific 
Regulation of Tcf7by Runx2 during 
chondrocyte maturation and 
proliferation 






Table 10. Continued 2… 
No. Gene Symbol Gene Name Remarks Reference 
25 Dlx3 Distal-less homeobox 
3 
Dlx3 together with Dlx5 directly 
activate Runx2 activity in 
osteoblasts 






















CHAPTER 5 – CONCLUSION 
 
By coupling mouse transgenic techniques with high throughput genomic studies such 
as gene expression profiling and ChIP-Seq for the study of two skeletal genes, 
Runx2 and Runx3, I was able to more accurately identify new factors that are 
potentially involved in skeletogenesis directly or indirectly governed by Runx2 and/or 
Runx3 transcription factors. The generation of three fluorescing mouse lines – wild-
type Runx2 tagged with EGFP and mutant Runx2 and Runx3 whereby the genes 
were disrupted by the insertion of EGFP – allowed for the purification of Runx2- or 
Runx3-expressing cells prior to microarray in order to specifically tease out the 
authentic targets of Runx2 and Runx3. The generation of the C-terminally HA-tagged 
Runx2 mouse line also enabled ChIP-seq to be performed with anti-HA antibody that 
was known to work well for ChIP experiments and allowed for the specific 
immunoprecipitation of Runx2 proteins in order to map out Runx2 binding sites 
without concerns of antibody cross-reactivity which may confound the ChIP-seq data. 
Unfortunately, the tagging of Runx3 at the C-terminus was not successful for reasons 
that were explored in chapter 3.2.2. 
 
As validated and discussed in chapter 3.1.5, there were already evidences that my 
microarray data was more accurate. Some genes that were not found in the previous 
two Runx2 microarray studies (Hecht et al., 2007; Vaes et al., 2006) such as Panx3 
and Ifitm5 were recently found to have skeletal functions and Panx3 was even 
demonstrated to be a direct target of Runx2 in an in vitro setting (Bond et al., 2011). 
Unfortunately, my ChIP-seq experiment performed with anti-HA antibody on DNA-
bound Runx2-HA proteins from the HA-tagged mice did not uncover any Runx2 
binding sites within 1 megabase of Panx3 in any of the three tissues (jaw, ribs and 





was not picked up for the reasons discussed in chapter 3.2.4. Ifitm5 has been 
implicated as a novel osteoblast protein and could be a novel target of Runx2 during 
osteoblastogenesis. In addition, a novel gene 1200009I06Rik was discovered to be a 
potential target of Runx2 in the microarray data. Its expression was specifically 
obliterated in the skeletal elements of the Runx2-/- embryos. Other genes specifically 
regulated by Runx2 and not Runx3 were also identified such as Ibsp, Tcf7, Hoxa11, 
Dlx3, Ihh, Gabpb1, Hdgfrp3 and Ppp1r13l. 
 
Runx3 is the least studied of the three Runx members. As mentioned, there is 
currently no gene expression profiling of Runx3 performed in the context of skeletal 
development for comparison. This is the first study undertaken to uncover Runx3 
skeletal targets by comparing the transcriptomes of an enriched pool of Runx3-
expressing cells from the Runx3+/- and Runx3-/- mouse embryos. However, only 24 
factors emerged to be regulated by Runx3. From the skeletal phenotype of the 
Runx2-/- and Runx3-/- mice, it is recognized that Runx2 is the dominant skeletal player 
of the two as it is able to compensate almost fully for the lack of Runx3 resulting in a 
Runx3-/- mouse that has no overt skeletal phenotype. In order to circumvent the 
compensation of Runx3 by Runx2 and to successfully elucidate all the Runx3 
skeletal targets, the transcriptome of enriched populations of Runx2- and Runx3-
expressing cells from Runx2-/-Runx3-/- mouse embryos were profiled and compared 
against that from Runx2-/- mouse embryos. As a result, novel skeletal factors such as 
Zbtb44, Kbtbd8, Etl1 (Smarcad1), Murr2 (Usp34), Zfp383, Evc, Tbx15, AI848100 
(Opt), Arid5a, Smpd3 and Brachyury were discovered to be regulated by both Runx2 
and Runx3. Furthermore, well-established skeletal genes such as Sox9, Satb2, 
Sox6, Dlx2, Hoxd13, Sp7 and Shh were also identified as putative novel targets of 
both Runx2 and Runx3. Genes such as Pax9, Sox5, Hoxc8 and Barx2 were also 
found to be exclusively regulated by Runx3 as they were not found differentially 





unable to compensate at this particular stage to produce a mild delay in chondrocyte 
hypertrophy of the E15.5 Runx3-/- mouse embryos (Yoshida et al., 2004). Genes that 
were thought to be expressed early in development such as Shh, Sox9 and Pax9 
might still be involved in later events of skeletogenesis and be indirectly or directly 
regulated by Runx3 as a positive feedback mechanism to fine tune skeletal events. 
Regrettably, the tagging of Runx3 protein in the mouse was unsuccessful and ChIP-
seq could not be performed with anti-HA antibody to identify Runx3-specific direct 
targets. Alternative tagging strategy might need to be explored with Runx3. Other 
tags such as the V5 or the S-peptide tag might work better with the Runx3 protein. 
The tagging position other than the C-terminus can also be experimented to 
circumvent the problem encountered with the C-terminal HA-tagging of Runx3. 
 
While extensive validation of individual targets and their significance to bone 
formation needs to follow, the strength of this study lies in the vast number of 
potential Runx2 and Runx3 downstream targets that have not been previously 
identified and in the fact that the study was performed entirely in vivo thus accounting 
for the spatio-temporal factors that come into play during actual developmental 
events. Furthermore, sufficient cellular resolution of the specific investigated gene 
activity was achieved prior to transcriptome profiling. The known targets of Runx2 
that emerged in my study also conveyed confidence to the method and technique 
used. With more targets identified to be involved in skeletogenesis, greater insights 
into bone development are gleaned and more of these novel skeletal factors 
potentially serve as targets for preventive and regenerative therapy as well as bone 
tissue engineering. Given the prevailing uncharted transcriptional control of 
chondrocyte hypertrophy, the targets of Runx3 are likely to serve as valuable nodes 
in the pursuit of generating a comprehensive network that represents the complex 






Moving forward, the results serve as a platform to venture into more specific studies 
such as investigating osteoblastogenesis in intramembranous bones and 
chondrocyte maturation in endochondral bones or moving to earlier time-points to 
unravel the first targets of skeletal development. The main challenge facing these 
more specific or earlier time-point studies is the availability of material for microarray. 
However, with the advent of RNA-Seq which requires as little material as RNA from a 
single cell (Tang et al., 2010), the obstacles are overcome. RNA-Seq is not limited to 
probes placed on the microarray and differentially regulated isoforms can also be 
identified. In the same way as ChIP-chip has given way to ChIP-Seq, RNA-Seq is the 
future avenue to expression profiling.  
 
Lastly, the approach in this study to uncover downstream targets of known key 
factors to map out the network controlling skeletogenesis presents a promising 
method that can be applied to unravel downstream targets of known factors in any 
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